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Kinetics and Selectivity of an Isolated Dehydratase 
domain from a Fungal Polyketide Synthase 
Previous work in the field has shown it is possible to isolate catalytic domains from 
polyketide synthases (PKS) which are able to carry out their programmed catalytic 
function independently from the complete PKS enzyme. A number of dehydratase (DH) 
domains have been isolated from modular polyketide synthase (mPKS) systems and 
their substrate selectivity characterised. Until now, there has been no published study of 
a DH domain from an iterative polyketide synthase (iPKS). Previous work within the 
Cox group has shown that it is possible to isolate and characterise the selectivity of the 
enoyl reductase (ER) domain from squalestatin tetraketide synthase (SQTKS). In order 
to further the understanding of the SQTKS enzyme, the isolated DH enzyme was 
produced and tested in vitro with substrates designed to test the stereoselectivity of the 
enzyme.  
The assays developed and carried out for this work utilised LCMS to measure the initial 
rate of the enzyme reaction in order to assess the selectivity of the DH domain. The 
results demonstrated that the DH domain is highly selective and the correct 
stereochemistry of the α and β positions is vital for efficient substrate turnover. A 
second set of assays investigated the potential for non-native substrates to act as 
inhibitors for the DH. None of the non-substrates inhibited the dehydration reaction, 
indicating that the substrates were unable to enter the active site.  
In the absence of a crystal structure, a model of the SQTKS DH domain was produced 
using crystal structures of isolated modular DH enzymes. Docking studies via a 
homologous model were undertaken to rationalise the selectivity of the SQTKS DH. 
Docking of the substrate into the active site of the model showed the programming of 
the DH domain arises from the position of the two catalytic amino acids, H44 and 
D235. The position of these amino acids dictates which substrates are tolerated and 
dehydrated. Through combining the results from the ER and DH assays, it is possible to 
elucidate the stereo selectivity of almost all of the steps of the SQTKS and show that 
these are identical to those of mammalian fatty acid synthase (FAS). The significance of 
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Bor Borrelidin 
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CoA Coenzyme A 
COSY Homonuclear correlation spectroscopy 
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DNA Deoxyribonucleic acid 
E. coli Escherichia coli 
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ER Enoyl reductase 
Ery Erythromycin  
eq Equivalents 
FA Fatty acids 
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 viii 
GMQE Global model quality estimation 
H or (His) Histidine 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
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HPLC High performance liquid chromatography 
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Hz Hertz 
iPKS Iterative polyketide synthase(s) 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
J Coupling constant 
KDa Kilo Dalton 
KR Ketoreductase 
KS Ketosynthase 
LB Luria Bertain media 
LCMS Liquid chromatography/mass spectrometry 
LDA Lithium di-isopropylamide 
LDKS Lovastatin diketide synthase 
LNKS Lovastatin nonaketide synthase 
M Molar 
m Multiplet 
m/z    Mass to charge ratio 
MAT Malonyl-acetyl transferase 
MCAT Malonyl-CoA:ACP 




mp Melting point 
mPKS Modular polyketide synthase(s) 
MPT Malonyl-palmitoyl transacylase  
NADPH Nicotinamide adenine dinucleotide phosphate 
NCBI National Centre for Biotechnology Information 
NR-iPKS Non-reducing iterative polyketides 
NRP Non-ribosomal peptide 
NRPS Non-ribosomal peptide synthase 
OD Optical density 
p Pentet 
PDB Protein data bank 
 ix 
PicTE Picromycin thiolesterase 
Pik Picromycin 
PK Polyketide 
PKS Polyketide synthase(s) 
PT Product template 
q Quartet 
Rif Rifamycin 
RMSD Root mean squared deviation 
RT Room temperature 
s Singlet 
SAM S-adenosyl methionine 
SAT Starter-unit acyl transferase 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
SIM Selected ion monitoring 
SNAC N-acetylcysteamine 
SQTKS Squalestatin tetraketide synthases 




TENS Tenellin synthase 
TIC Total ion current 
TLC Thin layer chromatography 
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Chapter 1 - Introduction 
1.1  Natural products 
Secondary metabolite natural products are a category of compounds which are of great interest 
due to the significant role they play in agrochemical research and drug development. The 
biosynthetic origin dictates the classification of secondary metabolites. The main classifications 
are terpenes, polyketides, peptides and alkaloids (Figure 1).
1
 Terpenes are derived from 5-
carbon isoprene units,
1
  of which paclitaxel (taxol) 1 is a well-known example as it can be used 
to treat a range of cancers such as breast and lung cancer.
2
 Peptides are another class, which are 
made of amino acids and can be produced ribosomally or by a dedicated multifunctional 
enzyme called a non-ribosomal peptide synthetase (NRPS).
1
 Vancomycin 2 is an example of a 
non-ribosomal peptide (NRP), which has antibiotic properties.
3
 Alkaloids as a class of natural 
products vary greatly in structure, but one commonality is the presence of a basic nitrogen 
atom.
1




Figure 1 – Examples of natural products. 
Polyketides (PK) are another class of natural products which possess wide ranging structural 
diversity and biological activities.
5
 Applications of PK include antibiotic (e.g. erythromycin  4,  
Figure 2),
6
 antifungal (e.g. natamycin 5),
7
 immunosuppressant (e.g. sirolimus, also known as 
rapamycin 6),
8
 and anticancer agents (e.g. pederine 7).
9
 Polyketides have been isolated from 
plants, bacteria, fungi and marine organisms. One such example is the fungal derived polyketide 





Figure 2 – Examples of bioactive polyketide natural products. 
Polyketides are comprised of a carbon backbone which is produced by a class of enzymes 
known as polyketide synthases (PKS). Once the backbone has been formed, the polyketide can 
undergo further functionalisation which is carried out by ‘tailoring enzymes’, further increasing 
the structural diversity exhibited. 
PKS are large enzymes known as megasynthases, which usually comprise over 2000 amino 
acids and possess multiple catalytic domains.
5
 Identifying the genes which encode the PKS and 
associated tailoring enzymes is relatively simple, as they tend to be clustered together in the 
genome. The identification of the PKS genes enables the biosynthesis of the polyketide to be 
studied. Gene knock out and heterologous expression in a host organism allows key 
intermediates to be isolated and the biosynthetic pathway to be elucidated.
11
 It is also possible to 
produce isolated PKS proteins using gene expression, thus allowing the biochemical selectivity 
of PKS to be investigated.
12-14
  
Due to their bioactive properties and interesting structures many polyketides have been targets 
for chemical total synthesis, which often involves multiple steps and low overall yields due to 
their chemical complexity. For example the first total synthesis reported for rapamycin 6 
involves 102 synthetic steps.
15
 By investigating and understanding the biosynthesis of 
polyketides, it is possible to create mutant PKS which are able to produce drug compounds 
which are more active and with titres high enough to be suitable for commercial use, for 
example Wang et al. engineered a strain of Streptomyces avermitilis resulting in a 300 fold 




1.2  Fatty acid and polyketide biosynthesis 
Although polyketides have great structural diversity, they all share a common biosynthetic 
origin. Their biosynthesis is closely related to that of fatty acids (FA), the study of which has 
helped to advance the knowledge of PKS greatly.
5, 17
 FA are produced by large megasynthases, 
known as fatty acid synthases (FAS), which link acetate derived malonyl-CoA units in a head to 
tail formation, via enzymatic reactions to produce a fully saturated alkyl product.
18
 
1.2.1  Fatty acid biosynthesis   
FA are formed by the linkage of simple building blocks. Straight chain FA utilise acetyl-CoA as 
a starter unit and malonyl-CoA as an extender unit (Scheme 1).
19, 20
 The acetate building blocks 
are linked head to tail via a Claisen-like condensation (Scheme 3).
5, 18
 The carbon backbone is 
then subsequently acted on by various other enzymatic β-processing domains which tailor the 
backbone. Successive cycles of elongation and β-processing occur until the chain of the 
required length is produced (Scheme 2). Branched FAs are usually formed by the utilisation of a 
branched starter unit, for example isobutyl-CoA, isovaleryl-CoA and 2-methylbutyryl-CoA.
20
 
Malonyl-CoA is still used as the extender unit.  
 
Scheme 1 – Loading of the acetyl-CoA starter unit. 
The biosynthesis of FAs can be broken down into two stages; chain extension and 
β-modification. Chain extension is controlled by three domains: malonyl-acetyl transferase 
(MAT), acyl carrier protein (ACP), and the β-keto acyl ACP synthase (also known as 
ketosynthase KS). The first step in the biosynthetic cycle is the loading of the starter and 
extender units. The MAT binds an acyl Coenzyme A (CoA) starter unit via an ester bond, 
utilising a conserved serine hydroxyl group (Scheme 1).
21
 The MAT then transfers the starter 
unit to the ACP via the formation of a thiolester to the terminal thiol of a pantetheine cofactor. 
The ACP subsequently transfers the starter unit to the KS domain via another thiolester to the 
thiol of a cysteine residue. An extender unit is then loaded in a similar fashion, firstly to AT 




Scheme 2- Fatty acid biosynthetic cycle, malonyl-acetyl transferase (MAT), acyl carrier protein (ACP), ketosynthase (KS), ketoreductase (KR), dehydratase (DH), enoyl reductase 






Scheme 3 – Proposed mechanism for the Claisen-like condensation of starter and extender unit in FAS. 
Once the β-keto thiolester has been formed it then undergoes a number of β-modification steps. 
These catalytic reactions are controlled by the ketoreductase (KR), dehydratase (DH) and enoyl 
reductase (ER) enzymes (Scheme 2). The KR domain catalyses the reduction of the β-keto 
thiolester 9 to a β hydroxyl group using NADPH as a co-factor.
22
 The reductions result in the 
formation of β-hydroxyl-acyl ACP 10.
23
 The alcohol can then be dehydrated by the DH domain 
to give an α,β-unsaturated thiolester 11.
22
 The dehydration reaction occurs via a syn elimination 
mechanism, where the 3-hydroxy and 2-hydrogen are lost from the same face. This results in an 
E alkene, forming crotonyl-ACP 11 (Scheme 4).
24
  
The ER domain reduces the enoyl ACP 11 to give a fully saturated alkyl chain 12, using 
NADPH as a cofactor. The stereochemical course of the enoyl reduction varies from organism 
to organism (Scheme 4). The hydrogens can be added to either the Re or Si face of the alkene. In 
rat FAS the hydrides are added to the α-Si-β-Re faces of the alkene 13.
25
 In E. coli FAS the 
hydrides are added to the α-Re-β-Si faces 14, this is the opposite to the addition observed in 
mammalian FAS.
26
 In plant and insect FAS it was found that the addition of the hydride 
occurred at the α-Re-β-Re faces 15,
27




The fatty acid chain is then ready to undergo another round of chain elongation and β-
processing. The cycle is repeated until the alkyl chain has reached the desired length, then a 













1.2.2  Fatty acid synthase classification 
All FAS contain the same five domains, ACP, KS, KR, ER and DH. Other domains present vary 
between species of FAS. Mammalian contains an embedded thiolesterase (TE) domain as well 
as a malonyl-acetyl transferase (MAT).
21, 29
 Yeast FAS possesses a number of unique features. 
Instead of a MAT, it has an acetyl transferase (AT) which is dedicated to priming the FAS with 
the acetyl-CoA starter unit. The extender units are loaded using a malonyl-palmitoyl 
transacylase (MPT) which also off-loads palmitoyl products.
29
 Yeast FAS also does not contain 
a TE, instead the finished fatty acid is transferred to the MPT, where the fatty acid is transferred 
to CoA and released. 
Although all FAS comprise the same key enzymatic domains, the domain organisation can 
differ, which gives rise to different classifications of FAS (Figure 3). In Type I FAS the 
enzymatic domains are covalently linked and organised into a large multi-functional complex.
30-
32
 Type I FAS are most commonly found in animals and fungi. Type II systems consist of 
individual enzymes and are typically found in bacteria. 
 
Figure 3 – Cartoon of FAS domain organisation, type I the enzymatic domains are covalently link, type II 
the enzymatic domain are discrete proteins. 
Although it is possible to classify FAS by type, their structural organisation can vary 
significantly. For example type I yeast FAS has a different structure to that found in mammalian 
FAS. Type I yeast FAS forms a barrel-like structure which comprises six “reaction chambers”.
29
 
Each reaction chamber contains one complete set of catalytic domains. The barrel is made of 
two dome shaped units, with each unit containing different catalytic domains. The α-unit 
contains four catalytic domains (KS, KR, ACP, and PPT) and two structural units. The β-unit 
comprises four catalytic domains (AT, ER, DH, and MPT) and four structural units. Mammalian 
type I FAS, on the other hand, adopts an X-shape, with a central body with extended arm and 
leg-like structures on the upper and lower ends (Figure 4).
33
  
The X-shape is divided into two units horizontally across the middle. The structure is discussed 
in more detail in Section 1.3. The lower unit contains two catalytic domains (KS, MAT) and no 
additional structural domains. The upper unit comprises three catalytic domains (DH, ER and 
the KR). FAS also contains two additional domains, the ACP and TE domains. Both of these 





 It is thought that the ACP and the TE domains are located on the 
periphery of the upper or lower unit, but this is yet to be confirmed by crystal structure.   
 
Figure 4 - Crystal structure of FAS (PDB: 2VZ8).  
In Type II FAS, each enzymatic domain is expressed as a discrete protein, which can be isolated 
individually. These are typically found in plants, bacteria and algae. 
30-32, 35
 It is thought that 
Type II FAS, although discrete proteins, form a highly organised complex.
36
  
1.2.3  Polyketide biosynthesis 
There is a high degree of chemical and structural homology between FAS and PKS. This 
homology results in the biosynthesis of polyketides being similar to that of fatty acids. As with 
FAS, simple building blocks are condensed together to form the backbone of the molecule. PKS 
are able to utilise a wide range of starter units (Figure 5). 
 
Figure 5 – Starter units which can be utilised during polyketide acid biosynthesis. 
 Type I PKS commonly utilise acetate and propionate derived starter units.
37
 Type I PKS have 
also been known to utilise more novel starter units. For example isovaleryl-CoA 17 is used as 
the initial building block for myxothiaxol,
37
 whereas isobutyryl-CoA 18 and (S)-2-















PKS can also utilise a wide range of extender units (Figure 6). A typical extender unit is  
malonyl-CoA 24,
42
 but branched extender units such as 2-methylmalonyl-CoA 25 and 
2-ethylmalonyl-CoA 26 are also used. Extender units containing halogen atoms, 27, ethers 28, 
hydroxyl groups 29 and amines 30 have also been observed.   
 
Figure 6 - Extender units which can be utilised during polyketide biosynthesis. 
PKS join C2 starter and extender units together to form the backbone of the chain utilising the 
AT, ACP and the KS domains. PKS are then able to tailor the backbone of the chain using the 
same enzymatic domains as the FAS (KR, DH and ER). Some PKS are able to carry out an 
additional tailoring reaction, such as methylation at the α-carbon. Methylation reactions are 
catalysed by a C-methyltransferase (C-MeT) domain, using S-adenosyl methionine (SAM, 31, 
Scheme 5) as a cofactor. Methylation occurs before any of the other tailoring reactions take 
place. While both mFAS and fungal PKS contain a C-MeT domain, in FAS this domain is 
inactive. Many fungal type I PKS on the other hand contain an active form on this domain.  
 
Scheme 5 - C-MeT domain catalyses transfer of a methyl group from S-adenosyl methionine to the β-keto 
thiolester.  
In addition to controlling the number of chain extensions which occur, PKS have additional 
levels of programming.
5
 PKS have the ability to control starter and extender selection. PKS are 
able to control which domains are active in each catalytic cycle, allowing the extent of reduction 
and dehydration in each round of extension to be controlled, this results in a variety of 





Scheme 6 – Polyketide biosynthetic cycle. The methyl group can arise from the incorporation of a methylated starter or extender unit; in fungal systems an active CMet domain 




1.2.4  PKS classification 
PKS are categorised into three broad categories, type I, II and III.
5, 9, 18
 Type I and II 
classifications arise from their similarities to fatty acid biosynthesis. Type I PKS comprise 
multiple catalytic domains covalently linked together to form large multifunctional proteins. 
Type II PKS are formed of discrete proteins which each catalyse a specific reaction. Type II and 




1.2.5  Type I PKS 
Type I PKS are the most complicated and the most versatile of all the PKS catalysts. They are 
further subdivided into two categories, modular and iterative.
9
 Type I Modular Polyketide 
Synthase (mPKS) contain more than one distinct module of enzymatic domains.
9
 There is a 
distinct module for loading and for every subsequent catalytic cycle, with every catalytic 
domain within each module only acting once. The presence or absence of different β-processing 
domains dictates the structure of the final product, such as the ER or DH domain. Typically type 
I mPKS produce reduced compounds. 6-Deoxyerythronolide B Synthase (DEBS) is the type I 
mPKS responsible for producing the macrolide ring precursor of erythromycin 4         (Figure 
7).  
 
Figure 7 - Illustration of programming in DEBS mPKS. The loading module and the first two 
extension/modification modules of erythromycin PKS shown. 
There are three core enzymatic domains required for chain extension AT, KS and ACP. Type I 
mPKS are known to contain two types of AT.
43
 If the AT domain is paired with its own ACP, it 
is referred to as a cis-acting AT (Scheme 7, A). DEBS is an example of a PKS with cis-acting 
AT domains, each module contains an AT and it is paired to an ACP. Trans-acting AT are stand 
alone enzymes which can work iteratively to transfer extender units to one or more of the ACP 
in the PKS assembly line.  The DSZS PKS responsible for the production of dizorazole is of the 






Scheme 7 – The different modes of  cis and trans-acting AT: A, shows the cis-acting AT of DEBS loads the extender unit from its corresponding CoA to the ACP within the same 




Unlike mPKS, Type I iterative PKS (iPKS) consist of a single modular architecture which is 
used repeatedly (Scheme 8).
9
 The single module contains all the domains required to produce 
the compound. Each catalytic domain acts repeatedly to extend and tailor the growing 
polyketide chain. iPKS can produce both reduced and aromatic compounds. The iPKS 
undergoes a defined number of chain extensions in order to produce a polyketide chain of the 
desired length. Norsolorinic acid (NSA) is an example of a  iPKS which contains only a KS, AT 




Scheme 8 - A “minimal” iPKS, which contains the 3 key domains, AT, KS, ACP. 
The type I iPKS found within fungi are further subdivided into non-reducing (NR), partially 
reducing (PR) and highly reducing (HR) types.
9, 44
 This classification arises due to the 
incorporation of certain β-processing catalytic domains, ketoreductase (KR), dehydratase (DH) 
and enoylreductase (ER).  
Non-reducing iterative polyketide synthases (NR iPKS) produce compounds which require no 
reductions during chain extension, for example citrinin 32 (Figure 8). 
5, 9
 The synthase contains 
a minimal number of domains (AT, KS, ACP), but it lacks all β-keto processing domains (KR, 
DH, ER).
5, 9
 NR PKS domains are typically organised as follows; a starter unit loading domain 
(SAT), the KS and an AT for loading extension units. After the AT domain is a conserved 
domain, (PT, which helps control chain length of the product and act as a product template 
domain). The final domain is the ACP, some NR iPKS terminate after the ACP. Many have 
been found to have other domains after the ACP such as C-methyltransferases and reductases 
involved in product release (Figure 8). 
 
Figure 8 – General domain architecture of NR iPKS, PR iPKS and HR iPKS, with example compounds 
produced by the PKS. 
14 
 
Studies of the genes involved in non-reduced polyketide compounds have found that the NR 
iPKS can incorporate advanced starter units, which have been derived from dedicated FAS, 
another PKS or an acyl-CoA. Monocerin 33 and zearalenone 34 are examples of products from 
NR PKS which incorporate advanced starter units  (Figure 9). The structures of these 
compounds suggest high levels of reduction occurs in the early stages of biosynthesis.
5
 The later 
stages of biosynthesis indicate that no reduction reactions occur. Labelling studies have shown 
that the NR PKS responsible for the production of dehydrocurvularin 35 utilises a tetraketide 




Figure 9 – Examples of NR PKS which potentially incorporate advanced starter units (shown in blue). 
Partially reducing (PR) iPKS have a domain structure more closely related to FAS and contain 
some β-keto processing domains.
5
 Typically they possess a KS, AT, DH, KR and an ACP 
domain. In addition they possess a “core domain”, which is located between the DH and KR 
domains. It is thought that the core domain is responsible for controlling the formation of the 
synthase. The core domain forms the motif required for key subunit-subunit interactions.
5
 
Unlike NR iPKS, they do not possess a SAT or PT domain. A well-studied example of a PR 




Highly reducing (HR) iPKS produce complex highly reduced compounds by carrying out a 
range of β-keto processing reactions.
5
 HR iPKS contain the KS, AT and the ACP required for 
chain elongation. In addition they contain a KR and DH. It has been found that many fungal HR 
iPKS contain a CMeT domain, some also contain an ER domain (Figure 8).
5
 Lovastatin 8, is a 
well-known product of a HR iPKS.
10
 It is formed of two polyketides; a nonaketide, produced by 
lovastatin nonaketide synthase (LNKS) and a diketide, produced by lovastatin diketide synthase 




A large number of bioactive polyketide derived compounds have been found which also contain 
amino acid moieties. Fusarin C, 38 consists of a heptaketide fused to a homoserine,
5, 45
 Tenellin, 






Figure 10 – Example compounds produced by HR PKS-NRPS, with the amino acid derived moieties 
highlighted in red.  
 All of these compounds are produced by hybrid PKS-NRPS systems. A non-ribosomal peptide 
synthase (NRPS) downstream of a HR PKS is responsible for adding the amino acid derivatives 
which are then incorporated into the PKS structure. The PKS and the NRPS can be combined in 
two ways. In modular PKS-NRPS, the PKS modules and the NRPS modules are organised in a 
processive production line. In iterative systems, an iPKS is followed by a single NRPS module; 
this domain organisation is found predominantly in fungi.
45
  
1.2.6  Type II PKS 
Type II PKS are composed of discrete proteins which associate together to form an active 
complex. Actinorhodin 40, is a blue pigmented antibiotic which is produced by a type II PKS 
(Scheme 9, A).
47
 The biosynthesis of 40 has been extensively studied and is thought of as a 
model compound for studying the type II PKS, both the key enzymes and the subsequent post-
PKS tailoring enzymes.  
 
Scheme 9 – A, Structure of actinorhodin; B, Representation of a type II PKS, the catalytic KSα, is shown 
in yellow and  the  structural KSβ is shown in grey. 
The complex works in an iterative manner, typically producing aromatic products.
9
 A minimal 
PKS, which contains two KS domains (one catalytic, KSα, the other structural, KSβ) carries out 
the repeated condensation reaction. The growing polyketide chain is attached to an ACP 
(Scheme 9, B). Typically an acetate starter unit is used to initiate the cycle, with malonate as the 
extender unit. A malonyl-CoA ACP (MCAT) recruits extender units. Other proteins can co-
operate with the minimal PKS to tailor the chain to the desired product, which can include KR, 
cyclases (CYC) and aromatase (ARO) domains.  
16 
 
1.2.7  Type III PKS 
Type III PKS are not organised into a multi-enzyme complex like type II PKS, instead a single 
KS-like active site repeatedly catalyses the condensation of acetate units (Scheme 10).
9
 Like 
type II, the type III PKS typically produce aromatic compounds which are mono or bicyclic in 
nature. Unlike type I and II PKS, type III PKS do not utilise an ACP to carry the growing 




Scheme 10 - Representation of a type III PKS. 
1.3  Structure and composition of FAS and iPKS proteins 
1.3.1  Structure of mFAS 
The crystal structure of a mammalian type 1 FAS (mFAS) has greatly increased our knowledge 
of the structure of mFAS (Figure 11).
33, 48
 mFAS consists of a 270 kDa polypeptide chain. In its 
active form mFAS assembles into an intertwined homodimer with an approximate “X” shape. 
The catalytic domains are organised into two units. The lower unit contains the condensation 
domains, ketosynthase (KS), and the malonyl-acetyl transferase (MAT). The upper unit contains 
the modification domains, the KR, DH and the ER. In addition to these three main 
β-modification domains, mFAS possesses two additional non-modification domains located on 




Figure 11 - Crystal structure of FAS (PDB: 2VZ8) and Cartoon structure of mFAS, the C-MeT domain 
(red) is present, but inactive. 
17 
 
The first of the non-modification domains is the pseudo-methyltransferase (ψCMeT), a domain 
homologous to the C-methyltransferase family in structure but having low sequence identity.
48
 
In order for the CMeT to be active it must be able to bind a SAM (31) co-factor. In mFAS the 
SAM (31) binding motif, ExGxGxG has mutated to ExLxGxG, resulting in the loss of co-factor 
binding site and subsequent loss of activity.
34, 48
  
The second non-modification domain is a structural part of the KR, referred to as the pseudo 
ketoreductase (ψKR). The dimerisation interface between the ψKR and the KR provides 
structural support to the active site of the catalytic KR.
48
  
1.3.2  Dimer interface 
The characteristics of a multi-enzyme complex are dictated by the nature of the interactions and 
linkers between the individual domains. Only 9% of the mFAS sequence is responsible for 
linkers between catalytic domains.
48
 The structural organisation of the complex is different to 
the organisation of the linear protein sequence. Very few of these linkers are present for 
structural integrity. There is only one structural linker responsible for connecting MAT to the 
KS in the condensation block. There is no direct contact between the MAT and KS domains.
48
  
The two polypeptides dimerise due to homophilic interactions of certain contact areas. The ER 
and KS form the main area of contact between the two polypeptide chains. The DH forms an 
additional area of contact between the two peptide chains. Within the β-modification unit, the 
KR is the central connector to all the other modification domains, interacting with the DH, ER 
and non-catalytic ψKR and ψCMet. Neither the DH nor the ER directly interact with the non-
catalytic domains.  
1.3.3  Relation of mFAS to PKS structure 
Although currently there are no intact crystal structures of full length iPKS or mPKS, isolated 
PKS domains have been crystallized.
6, 17, 49-52
 The structural insights gained from these 
crystallized domains has provided evidence of the evolutionary relationship between mFAS and 
HR-PKS.
35, 48
 On a sequence level, mFAS domains have a high sequence identity to HR-PKS 
domains.
32
 mFAS is more closely related to HR-PKS than to bacterial FAS. The similarities 
between mFAS and HR-PKS extend beyond the sequence level, to the linkers, the domain order 






Figure 12 - Cartoon structure of PKS, The C-Met domain (green) is present and active. 
The similarities in protein sequence between mFAS and PKS suggests that the domain 
organisation within the PKS is likely to be similar to that found in mFAS (Figure 12).
17
 Three 
crystal structures which were published almost simultaneously highlight the clear evolutionary 
connection between type 1 FAS and PKS.
53
 First, the crystal structure of porcine FAS was 
published by Ban et al.
34
 Although the resolution of the structure was not high enough to allow 
detailed amino acid mapping it was possible to fit previously reported domain structures with a 
high degree of confidence. The discovery of the structural KR domain by Keating Clay et al. 
resulted in the assignment of a large segment of linker sequence across the whole family of 
type I PKS modules.
54
 FAS contains an analogous region of linkers, which is highly likely to 
correspond to a structural KR domain. If the organisation of the type I FAS and PKS KR  
domains is similar it can be hypothesised that this commonality can be extended to the dimeric 
organisation of the DH and ER domains.
53
 Finally the crystal structure of the erythromycin KS-
AT region published by Khosla et al. showed striking similarities to lower half of type I FAS, 
further strengthening the connection between the FAS and PKS architecture.
55
 
mPKS function in a different way to mFAS, with each PKS module catalyzing only a single 
round of extension and β-modification. Each mPKS module contains the loading and 
condensation domains as well as a variety of β-carbon processing domains. mPKS modification 
units can have domains which are inactive and in some cases absent.
9
 For example DEBS 
module 1 only possesses one β-carbon modification domain, KR-ψKR.
48
 Comparisons of the 
KR-ψKR in DEBS and of the corresponding Section of mFAS found that the insertion of the ER 
domain in mFAS had no effect on the core folds of the KR-ψKR. The structural similarities 
found between mFAS and PKS imply that iterative and non-iterative chain elongation can be 




1.4  Programming of PKS 
Compared to fatty acids, Polyketides display a very wide diversity of chain-lengths and 
functionalisation. PKS must, therefore, have the ability to precisely control chain-length and the 
cycle of β-modifying reactions. They also have diverse alkyl substituents, added by methylation 




In mPKS, each chain extension is catalysed by a discreet module containing only the required 
catalytic domains (Scheme 11). The programming within the PKS is explicit in the number of 
modules (which controls chain length) and the composition of those module’s β-processing 
domains.  
 
Scheme 11 – The first four modules in the DEBS PKS. 
The programming within iPKS is far more subtle and less well understood. iPKS comprise a 
single module containing one copy of each catalytic domain, although not all the domains are 
active in every round of chain extension.
9
 Many questions surround the programming of iPKS, 
such as: how is the selection of starter and extender units controlled, what controls the length 
and release of the product; and also what controls the degree of β-processing.  
Work by Townsend and co-workers investigating PksA, an iPKS, which is responsible for the 
initial stages of the biosynthesis of aflatoxin B1, has given an insight into how these processes 
are controlled in NR PKS.
56-59
 Their work identified that the starter unit acyl transferase (SAT) 
controls the selection of starter unit,
56
 whereas the selection of the extension unit was controlled 
by the malonyl-acetyl transferase (MAT).
56, 57
 It was also found that while the product template 
(PT) domain controlled chain length and cyclisation and aromatisation,
58
 the SAT, MAT, KS 
and ACP domains also helped control the chain length. 
The programming of HR-PKS is more complex as they do not possess SAT or PT domains and 
the presence of CMeT, KR, ER and DH domains must contribute to the programming. It is 
20 
 
possible that individual catalytic domains possess selectivity for specific substrates. For 
example, the chain length could be controlled by the KS or AT recognising the length of the 
growing acyl-ACP. The AT domain could recognise the full length chain and not transfer it to 
the KS for further chain extension. Another possibility is that once the chain has reached the 
desired length the KS no longer recognises it and subsequently cannot catalyse the chain 
extension. The methylation pattern of a substrate may also play a part in whether or not a 
substrate is recognised.  
Work by Fisch et al. investigated the programming of the HR-PKS involved in the biosynthesis 
of tenellin 39 and desmethylbassianin.
45
 Catalytic domains from the tenellin PKS (TENS) and 
desmethylbassianin PKS (DMBS) were systematically swapped and the chain length and 
methylation patterns observed. The products formed gave an insight into the programming of 
these two PKS. It was found that neither the TENS nor DMBS KS, AT or ACP domains exerted 
any control over the substrate chain length and will indiscriminately extend the acyl ACP. 
The CMet domain on the other hand exhibited a high level of programming, the DMBS CMet 
was found to only recognise a diketide substrate, whereas the TENS CMet domain recognised 
both diketide and triketide substrates. The KR domain also exhibited programming which 
controls the chain length of the product. The TENS KR was able to act on di-, tri- and 
tetraketides but not pentaketides. In contrast, the DMBS KR was able to act on all substrates up 
to the pentaketide but not hexaketide. It was proposed that when the KR domain fails to act the 
chain is released.  
1.5  DH domains from FAS and PKS  
1.5.1  Function  
The dehydratase domain catalyses the dehydration of the β-hydroxy acyl ACP 41 to an α,β-
unsaturated thiolester (Scheme 12).
17, 21, 60
 The resulting α,β-alkene can potentially take either Z 
42 or E 43 geometry (Scheme 12). 
 
Scheme 12 - Function of the DH domain and the possible geometry of α,β-unsaturated thiolester. 
A great deal of our understanding of how the DH domain functions comes from the study of 
FAS and mPKS.
61
 There have been no reports of investigations of the workings of the iPKS DH 
domain. Sequence alignment of mFAS and mPKS shows limited sequence identity (Figure 13), 
mFAS is 18% to 23% identical to crystallised mPKS domains. Despite the low sequence 
21 
 
identity, analysis of the crystal structures has found mFAS and PKS DH domains have many 
structural features in common and  these will be discussed in more detail in Section 1.5.3. 
#  Percent Identity  Matrix - created by Clustal2.1 
 
     1: SQTKS_DH      100.00   12.69   17.96   16.91   17.27   18.06   19.42   18.18 
     2: 2vz8_mFASDH    12.69  100.00   22.79   21.48   18.18   15.81   21.67   20.08 
     3: 4LN9_Rif10DH   17.96   22.79  100.00   43.83   21.77   23.67   26.01   27.11 
     4: 3EL6_Ery4DH    16.91   21.48   43.83  100.00   18.56   21.22   21.80   21.66 
     5: 3KG7_CurH_DH   17.27   18.18   21.77   18.56  100.00   26.06   23.97   23.02 
     6: 3KG8_CurJ_DH   18.06   15.81   23.67   21.22   26.06  100.00   28.67   29.31 
     7: 3KG6_CurF_DH   19.42   21.67   26.01   21.80   23.97   28.67  100.00   68.42 
     8: 3KG9_CurK_DH   18.18   20.08   27.11   21.66   23.02   29.31   68.42  100.00 
Figure 13 – Percentage identity matrix of mFAS (2), crystallised mPKS DH domains (Rifamycin DH, 
Rif10DH (3), Erythromycin DH, Ery4DH (4), Curcin DH, CurH (5), CurJ (6), CurF (7), CurK (8))  and 
SQTKS (1), identified by PDB numbers, full alignment in Appendix 1.  
 The active site of PKS and FAS DH domains consists of a histidine (H) and an aspartic acid 
(D), which are highly conserved in both FAS and PKS.
6, 12, 13, 17, 48, 60-64
 Mutagenesis of these 
amino acids has demonstrated their catalytic importance.
60, 65
 The mutation of catalytic H in 
borrelidin BorDH2
60
 and pikromycin PikDH2 to a phenylalanine (F) and alanine (A), 
respectively, resulted in total loss of domain activity, showing that the H is vital to catalytic 
activity.
65
 The catalytic H abstracts the -proton and the D donates a proton to the leaving β-
hydroxyl group.
6
 The proton and water are lost from the α and β-carbon positions. The 
mechanism is most likely to be E1cb (Scheme 13). 
Scheme 13 – Mechanism of dehydration by DH domain. 
1.5.2  Substrate specificity  
There are two possible stereochemical outcomes of the dehydration of the β-hydroxy group. The 
double bond formed can potentially take either the Z or E geometry (Scheme 12). Currently the 
mechanism regarding the programming responsible for controlling the stereochemical outcome 
of the HR iPKS DH domain remains elusive. 
It has been found that FAS DH domains catalyse the dehydration of 3R-β-hydroxy-acyl ACP to 
form an α,β-unsaturated thiolester-ACP 43 with E geometry.
22-24
 All known DH dehydrations 
proceed via a syn mechanism where the C-2 proton and the C-3 hydroxyl group are lost from 
the same face of the molecule (Scheme 14A). In general, most polyketide compounds contain E 
double bonds,
12, 13, 17
 homologous to that found in FAS,
60
 although a small proportion have been 
22 
 





Scheme 14 - A, Stereochemical outcomes of syn elimination of 3R-OH and 3S-OH of a diketide substrate 
in FAS; B, Stereochemical outcomes of syn elimination of 3R-OH and 3S-OH of a methylated diketide 
substrate in PKS. Note: mechanism is likely to be E1cb, arrows indicate syn elimination.  
As enzymes have evolved over many millions of years, it is often thought that they always use 
the most favourable pathway when catalysing transformations.
68
 In non-enzymatic elimination 
reactions, syn pathways are not favoured due to the eclipsed geometry needed for the reaction. 
Anti elimination is more favourable due to stereoelectronic effects. It is therefore not surprising 
that a number of hydratase-dehydratase enzymatic reactions follow anti elimination pathways 
when the abstracted proton is in the α-position. There are seven known examples including 





However, it has been found that not all enzymatic dehydration reactions follow the favourable 
anti pathway.
68
 A group of dehydratases produce syn elimination of water, when the abstracted 
proton is α to a carbonyl. This group includes enoyl-coenzyme-A (CoA) hydratase, FAS and 
β-hydroxydecanoyl thiolester dehydratase. Work by Mohrig indicates that although syn 
elimination of water with thiolester substrates may not be the most chemically efficient 
pathway, it appears to be dependent on historically evolved pathways.
68
 As PKS have common 
evolutionary routes and a high homology to FAS, it is reasonable to assume that elimination of 
water in PKS proceeds via syn elimination. 
The elimination pathway taken by the PKS affects the stereochemical outcome of the product. It 
is generally assumed that PKS DH follows the syn elimination pathway. This assumption has 
allowed modelling of substrates in order to obtain insights into the relationship between 
substrate and product stereochemistry.
17
 It has been shown that in α-methylated substrates 
chirality of the α-methyl and β-OH plays a part in determining the geometry of the double bond 
(Scheme 14).
17, 60
 If the α-methyl and β-OH have anti stereochemistry, 2R,3R-44 or 2S,3S-45, a 
syn elimination will result in an E geometry alkene 46. Syn stereoisomers 2R,3S-47 or 2S,3R-48 
results in a Z alkene 49. The stereochemistry of the β-OH is dictated by KR ketoreduction.
69
  
In mFAS the C-Met domain is present but inactive, but this is not the case in some fungal PKS. 
The presence of a functional C-Met domain adds an additional level of programming. The 
presence of a methylated α-position may affect the stereochemical outcome of the dehydration 
reaction.  
Alkene geometry is not always dictated by the stereochemical outcome of the KR reduction.
60
 
While FAS DH domains FabA and FabZ both catalyse the dehydration of β-hydroxyacyl-ACP 
substrate,
70, 71
 FabA is also responsible for isomerising trans-2-enoyl fatty acid to cis-3-enoyl 
fatty acids.
70
 It has been shown that in some cases the geometry of E alkene arises from 
exogenous enzymes. One such example is the DH domain of borrelidin PKS.
60
 Borrelidin 50 is 
synthesised by a mPKS which contains five DH domains in total and the final structure contains 
both a Z and an E alkene (Figure 14). The second module gives rise to an E alkene 51 and the 
third gives rise to a Z alkene 52. Assays involving the isolated DH domains from the modules 
responsible for the formation of these double bonds (Scheme 15), module 2 and 3, found that 
only the 2R, 3R-53 diastereomer was accepted and turned over by the enzyme. 2S, 3S-54, 2R, 
3S-55, 2S, 3R-56 diastereomers were not converted at all (Scheme 15). It was found that only 
the E product 57 was formed. These results indicate that in this case, formation of the Z 





Figure 14- Borrelidin synthesis on a mPKS.
60
 
The Z alkene could arise from a number of different routes.
60
 All the double bonds could be first 
synthesised as E geometry followed by an E to Z isomerisation once the final product has been 
formed. The intervention of exogenous enzymes which bind to the module catalysing the 
formation of the E double bond, such as in avermectin PKS,
72, 73
 cannot be ruled out. Modest 
alterations in enzyme architecture or substrate can affect the stereochemical outcome. If a 
phosphopantetheine or full ACP based substrate were to be used as a substrate instead of the N-
acetylcysteamine (SNAC) based substrate, a different geometry double bond may be formed.   
 
Scheme 15 - Stereochemical outcome of Borrelidin DH assay. 
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There is still a great deal to discover and understand about the inner workings and programming 
in the DH domain. Literature searches have not identified any work published investigating the 
programming of the iterative dehydratase domains. 
1.5.3  Structures of DH Proteins 





 mammalian FAS DH
48
 and fungal FAS DH
33, 74
 domains. In 
addition a number of PKS DH domains have been crystallised and their structures solved. These 
include multiple curacin PKS DH domains, CurFDH, CurHDH, CurJDH and CurKDH.
17
  The 
DH domain from the fourth module of erythromycin, Ery4DH has also been crystallised,
6
 as has 
the terminal DH from rifamycin Rif10DH.
13
 Most recently, the PKS DH domain from 
mycocerosic acid (MASDH) has been crystallised.
75
 Investigation into the structure of FAS and 
PKS DH domains has increased the understanding of the DH active site,  how the dehydration 
occurs and how the stereochemical outcome of the reaction is controlled.   
1.5.4  Bacterial FAS DH 
FabA and FabZ are standalone dehydratases which are involved in the synthesis of fatty acids in 
the type II FAS pathway found in bacteria.
70
 They are homologous to each other and they are 
responsible for catalysing the dehydration of hydroxylacyl-ACP to the trans-2-enoyl-ACP. The 
protein sequences of FabA and FabZ were aligned using clustal omega (Figure 15),
76, 77
  
bA_4FQ9      GMTKQHAFTREDLLRCSRGELFGPGN---------AQLP-APNMLMIDRIVHISDVGGKY 50 
FabZ_1U1Z      ------MGSSHHHHHHS-SGLVPRGSHMMDINEIREYLPHRYPFLLVDRVVELDIEGKR- 52 
                       : ..  : * . *.  *.           **    :*::**:*.:.  * :  
 
FabA_4FQ9      GKGELVAELDINPDLWFFACHFEGDPVMPGCLGLDAMWQLVGFYLGWQ---GNPGRGR-- 105 
FabZ_1U1Z      ----IRAYKNVSINEPFFNGHFPEHPIMPGVLIIEAMAQAAGIL-GFKMLDVKPADGTLY 107 
                   : *  ::. :  **  **  .*:*** * ::** * .*:  *::    :*. *    
 
FabA_4FQ9      -ALGSGEVKFFGQVLPTAKKVTY--NIHIKRTINRSLVLAIADGTVSVDGREIYSAEGL- 161 
FabZ_1U1Z      YFVGSDKLRFRQPVLPGDQLQLHAKFISVKRSIWKF------DCHATVDDKPVCSAEIIC 161 
                 :** :::*   ***  :   :   * :**:* :       *  .:** : : *** :  
 
FabA_4FQ9      ---RVGLFTSTDSF 172 
FabZ_1U1Z      AERKLGS------- 168 
Figure 15 - Protein sequences alignment of FabA (PBD: 4FQ9) and FabZ (PDB: 1U1Z). An * (asterisk) 
indicates positions which have a single, fully conserved residue. A : (colon) indicates conservation 
between groups of strongly similar properties. A . (period) indicates conservation between groups of 
weakly similar properties as defined by clustal omega. The catalytic amino acids. H70 and D84 in FabA 
and H69 and E83  in FabZ are highlighted in yellow.
76-78
  
The monomeric structures of FabA and FabZ are similar, comprising an α, β hotdog fold. 
(Figure 16).
6
 Its name arises from six stranded anti-parallel β-sheets (the bun) which curves 
around the hydrophobic α-helix (hotdog). The α-helix (hotdog) is shown in blue and the anti-




Figure 16– Crystal structure of 3-hydroxydecanoyl-acyl carrier protein dehydratase monomer (FabA) 
from Pseudomonas aeruginosa, PDB: 4FQ9.
63
 
In FabA and FabZ the active site contains a histidine, (H70 in FabA and H69 in FabZ) which is 
responsible for abstraction of an α-position proton from substrate
70, 71
 and an acid (D84 in FabA 
and E84 in FabZ). In FabA, D84 is part of a large hydrogen bonding network which is thought 
to help facilitate the protonation of the β-hydroxyl group. 
 
Scheme 16 – Dehydration in FabA, 3R-hydroxyl group of the substrate mimic is able to form a hydrogen 
bond with the D84.  
Both FabA and FabZ dehydrate the 3R-hydroxylacyl-ACP to the trans-2-enoylacyl-ACP. The 
crystallisation of FabA with a 3R-hydroxylacyl substrate mimic reported by Moynie et al. 
rationalises the stereochemical outcome of this reaction.
70
 The 3R-hydroxyl group of the 
substrate mimic is positioned so hydrogen bonding with D84 can occur (Scheme 16). A 3S-
hydroxyl group would be positioned away from D84 and hydrogen bonding would be unable to 
take place, resulting in the dehydration not occurring.  
1.5.5  mFAS and PKS DH 
Like bacterial FAS DH, mFAS and PKS DH also contain the hotdog fold structure, although in 
mFAS and PKS the DH consist of dimers, with each monomer containing two repeats of the 
hotdog fold.
17















 were aligned using clustal omega (Figure 17, full alignment 
shown in Appendix 1),
76, 77
 amino acid numbering will be based on this sequence alignment.  
SQTKS_DH         RHFIRVQD-IPWIRDHVVQSALVYPGAGFICMAMEAMVQLHELRDSQSRKVAGYRLAEVD 88 
mFAS             KFDVSPESPDHYLVDHCIDGRVLFPGTGYLWLTWKTLARALSQNL----EETPVVFEDVT 102 
CurHDH_3KG7      HQDINLNN-HPWIGDHRVYDTPVIPGVSYIAMTLAAV-------------GVPAAVEDIN 72 
CurJDH_3KG8      ESYFSTEN-LPFLADHIVYEQVVVPGASHISLLLAAASLTF--------AATECQIEDIL 77 
CurFDH_3KG6      QSYIGAES-PGYLNHHQVFGKVLFPSTGYLEIAASAGKSLF---T----SQEQVVVSDVD 74 
CurKDH_3KG9      QSYLTAES-PAYLSQHQVFNKVLFPATGYLEIAAAVGKNLL---T----TGEQVVVSDVT 79 
MASDH_5BP2       QGDVGTEA-HPWLSDHRVHQVAVLPGAAYCEMALAAVTPVL---------GDTGEVHDLK 88 
EryDH_3EL6       TGRLSTDE-QPWLAEHVVGGRTLVPGSVLVDLALAAGEDVG---------LP--VLEELV 102 
RifDH_4LN9       TSRLSLRS-HPWLADHAVRDVVIVPGTGLVELAVRAGDEAG---------CP--VLDELV 103 
                    .       :: .* :    : *.     :   .                   . ::  
 
SQTKS_DH         ILRAMLIPDTSEGLEAHISLRPCSTKLLLTNEWYDFCVSSVGDD---------------D 133 
mFAS             LHQATILPKTGTV-SLEVRLLEA--------SH-AFEVSD-------------------S 133 
CurHDH_3KG7      FQQPLFLAESNTTRETQLMLHTA-----DNVGK-QF------------VEVFSRDGAKQE 114 
CurJDH_3KG8      FPQALAIPEQGVR-TVQVVLT-P-----QNNSF-SFQVISFDDSLESQINQVSNNGSHIS 129 
CurFDH_3KG6      ILQSLVIPETEIK-TVQTVVSFA-----ENNSY-KFEIFSPSEG----------ENQQTP 117 
CurKDH_3KG9      IVRGLVIPETDIK-TVQTVISTL-----ENNSY-KLEIFSTSEG----------DNQQAN 122 
MASDH_5BP2       FHDMLLLDDATPV-WVSAAVTAP-----GTAEF-GVETHQ------------------SG 123 
EryDH_3EL6       LQRPLVLAGAG-A-LLRMSVGAP-----DESGRRTIDVHAAEDV----------ADLADA 145 
RifDH_4LN9       IEAPLVVPRRGGV-RVQVALGGP-----ADDGSRTVDVFSLRED--------------AD 143 
                 :     :            :               .                         
 
SQTKS_DH         KFVDHCRGRITIEFDTSGSADTPRTSLRERSRSTGLMRSVDPSNLYSFLRAQGIYHGPIF 193 
mFAS             NGSLIASGKVYQWESPDPKLFDTRAAVD--PADSTAEFRLSQGDVYKDLRLRGYDYGPFF 191 
CurHDH_3KG7      EWQQHASMSVSENPPPPPTLSVD---I---PALCEQLRPLDTDTLTEIYASISLVYGPML 168 
CurJDH_3KG8      DWAVHATGKLSVAN--AEQSLIPLEEI---QARCSQ--KIDSAEIYQHLWDRQIHLGQSF 182 
CurFDH_3KG6      QWVLHAQGKIYTEPTRNSQAKIDLEKY---QAECSQ--AIEIEEHYREYRSKGIDYGSSF 172 
CurKDH_3KG9      QWTLHAEGKIFLDSTTNTKAKIDLEQY---QRECSQ--VIDIQQHYQQFKSRGIDYGNSF 177 
MASDH_5BP2       DRTQRATAVLRGDVDAERPAAHSIDAL---LAAHPN--RVDGDELRAGFGTVGIGHGAAF 178 
EryDH_3EL6       QWSQHATGTLAQGV---AAGPRDTEQW---PPEDAV--RIPLDDHYDGLAEQGYEYGPSF 197 
RifDH_4LN9       SWLRHATGVLVPENRPRGTAAFDFAAW---PPPEAK--PVDLTGAYDVLADVGYGYGPTF 198 
                 .    .   :                             :                *  : 
 
SQTKS_DH         QNLKTISSRKDHSES----SFVVANTASVMPNGFQSPHVIHPTTLDSIFQGAYTA-LPGA 248 
mFAS             QLVLESDLEGNRG------R--------------LQWNDSWVSFLDAMLHMSILAP---- 227 
CurHDH_3KG7      QAVRQAWIGEETS----LLEIEVPKALA----FQLAGEPIHPVLIDACTRLT-PDLFDFS 219 
CurJDH_3KG8      RWIEQVWLGEGEV----LCQMKVPKTIL----N-TTKYQLHPTLVDSCFQSIIALVLDQS 233 
CurFDH_3KG6      QGIKQLWKGQGKA----LGEMAFPEELT----AQLADYQLHPALLDAAFQIV-SYAIPHT 223 
CurKDH_3KG9      QGIKQLWKGQGKA----LGKIALPEEIA----GQATDYQLHPALLDAALQIL-GHAIGNT 228 
MASDH_5BP2       AGLSEAYVATAAE-PTVVAAVALPGPLR----SGQRGYTVHPALLDACFQSVIAHPEV-- 231 
EryDH_3EL6       QALRAAWRKDDSV----YAEVSIA--------ADEEGYAFHPVLLDAVAQTLSLGALG-- 243 
RifDH_4LN9       RAVRAVWRRGSGNTTETFAEIALPEDAR----AEAGRFGIHPALLDAALHSTMVSAAADT 254 
                   :                                         :*:  :           
Figure 17 - Protein sequences alignment of SQTKS DH, mFAS (PDB: 2VZ9), CurH (PDB: 3KG7), CurJ 
(PDB: 3KG8), CurF (PDB: 3KG6), CurK (PDB: 3KG9), MASDH (PDB: 5BP2), Ery4DH (PDB: 3EL6) 
and RifDH (PDB: 4LN9). An * (asterisk) indicates positions which have a single, fully conserved 
residue. A : (colon) indicates conservation between groups of strongly similar properties. A . (period) 
indicates conservation between groups of weakly similar properties as defined by clustal omega. The 
catalytic amino acids. H70 and D84 in FabA and H69 and E84  in FabZ are highlighted in yellow.
76-78
  
As discussed in Section 1.3.1, mFAS forms an “X” shaped dimer with the dimers interfacing 
down the middle of the X, resulting in the main interfacing interactions occurring at the KS, ER 
and DH. The DH domain dimerises through homophilic interactions between the hotdog folds. 
Each DH domain monomer in mFAS adopts a pseudo dimeric double hot dog fold,
48
 which 
contains a single composite active site ( Figure 18, A and B).
48
 The active site is formed by H62 
on the N-terminal hot dog fold and D217 on the C-terminal hot dog fold (mFAS numbering). 
H62 and D217 are the key catalytic amino acids which participate in the protonation and 
deprotonation of substrate.  
In chicken and pig FAS, a histidine, H220 is found close to D217. In all other sequenced FAS, 
glutamine is found in this position. The H220 is positioned within hydrogen bonding distance of 
D217 and is thought to provide a stabilising effect for D217. Mutagenesis experiments showed 
28 
 
that the histidine and glutamine are equivalent at this position. The hydrophobic substrate 
binding tunnel opening is situated at the pseudo-dimer interface. The tunnel stretches through 
the C-terminal hot dog fold (Figure 18, C and D). 
 
Figure 18: A, Overall crystal structure of mFAS DH domain monomer; B, catalytic amino acids H62 and 
D217 in active site; C, Side view of mFAS substrate tunnel with H62 and C217 shown; D, Cut through of 
overall crystal structure of mFAS DH domain monomer showing substrate binding tunnel and catalytic 
amino acids. (PDB: 2VZ8).
48
 
1.5.6  Erythromycin, Ery4DH 
Erythromycin 4 is a macrolide antibiotic, the biosynthesis of which can be divided into two 
parts. A mPKS produces 6-deoxyerythronilide B 59 by catalysing the sequential condensation 
and tailoring of one propionyl CoA starter unit and six methylmalonyl CoA extender units. 
Once 6-deoxyerythronoilide B has been produced and released from the PKS, a series of further 
tailoring reactions decorate the peripheral structure (Scheme 17).




Scheme 17 – Biosynthesis of erythromycin. 
The PKS consists of three large polypeptides, DEBS1, DEBS2 and DEBS3. Each polypeptide 
contains two PKS modules (Scheme 18).
21
 Of the 6 modules, only module 4 contains a DH 
domain, known as Ery4DH. This catalytic domain has been isolated as a stand-alone protein by 
Keating-Clay
6
 and its structure solved.  
Ery4DH is formed of a single polypeptide chain which folds to form a double hotdog fold and 
contains the HXXXGXXXXP signature sequence motif found in all PKS DH domains near the 
N-terminus. Within the active site there are a number of key amino acids, including the catalytic 
histidine (H69) required for activity. H69 is highly conserved and invariant. Nearby amino acids 
(Figure 19), which are also highly conserved, contribute to a hydrogen bonding network which 
ensures the correct orientation of the histidine. A turn in the protein structure allows P78 to 
make contact with H69 via Van der Waals bonding interactions. An additional amino acid, L76, 
hydrogen bonds to H69 helping to maintain the correct orientation for catalytic efficiency.   
 
Figure 19 – A. Overall crystal structure of Ery4DH B. Key catalytic amino acids H69, D231. Supporting 










The second catalytic amino acid, aspartic acid is highly conserved in type I PKS DH domains, 
whereas in type II dehydratases this role is taken by glutamic acid (Scheme 19). Within the 
active site of Ery4DH, D231 is anchored in position by hydrogen bonding to Q235. In the 
crystal structure,  water was found bound to S80. It was hypothesised that this water was the 
result of dehydration of the substrate’s acyl chain.  
 
Scheme 19 – Cartoon of substrate docked into the active site and the interaction of amino acids in 
Ery4DH active site. 
Ery4DH’s natural substrate, the pentaketide 60, is dehydrated by the DH domain to form 61 
(Scheme 20, A). Substrate 60 is difficult to isolate so assays carried out to assess the activity of 
Ery4DH utilised a simplified substrate, the 2R,3R-3-diketide SNAC 62.
6
 However, analysis by 
liquid chromatography-mass spectrometry (LC-MS) did not observe formation of product 63 
(Scheme 20, B).    
 
Scheme 20 – A. Natural substrate 60 for Ery4DH which is dehydrated by Ery4DH; B.
6
 Substrate mimic 
62, which did not undergo dehydration.  
A later paper by Cane et al.
12
 repeated the assays of Ery4DH using ACP bound substrate 
mimics 64-68 (Scheme 21). Incubation of the recombinant Ery4DH with 2R,3R-64  resulted in 
the formation of dehydrated product 69. A reverse catalytic reaction was observed when 
Ery4DH was incubated with 69, resulting in a ~3:1 equilibrium of 64 and 69. The results of 




Scheme 21 - Cane et al. assays to assess the selectivity of Ery4DH and the outcome.
12
 
Further assays were carried out by Cane et al. to assess the selectivity of Ery4DH.
12
 The enzyme 
was found to be highly selective. Only the 2R,3R-ACP 64 was dehydrated to give the E-69-ACP 
product. The 2S,3R-65-ACP, 2R,3S-66-ACP and 2S,3S-67-ACP substrates did not undergo 
dehydration to give the  E-69-ACP or Z-70-ACP products. 2R,3R,4S,5R-2,4-dimethyl-3,5-
dihydroxyheptanoyl-ACP 68, was also incubated with Ery4DH to further confirm the 
stereoselectivity of the DH domain, and this substrate underwent dehydration to form product 
71. 





is an ansamycin antibiotic and a number of semi synthetic derivatives of 
rifamycin have been clinically approved as an effective treatment for tuberculosis. These 
include rifapentine, rifampicin and rifabutin.
81
 Rifamycin is produced by the actinomycete 
Amycolatopsis mediterranei and contains a number of unique structural features, including an 
amino naphthoquinone, a macrolactam ring and a tri-substituted Z alkene.  
 
Figure 20 – Position numbering refers to the activity by Rif modules. 
Rifamycin 72 is produced by a type I mPKS. The 10 PKS modules extend the 3-amino-5-
hydroxybenzoic acid starter unit with two malonate and eight methyl malonate extender units to 
33 
 
form the rifamycin skeleton (Scheme 23). Eight of the ten modules contain putative DH 
domains with 41-49% identity to Ery4DH. Of these eight, six possess a region which shows 
good similarity to a DH active site (modules 4, 6, 7, 8, 9 and 10). The presence of DH domains, 
which could potentially be active in Rif modules 6, 7 and 8 was unexpected as the 
corresponding positions in rifamycin B 72 are hydroxylated (Figure 20). It is possible these DH 
domains are inactive or, if they are active the hydroxyl groups are added at a later time. 
Rifamycin PKS does not contain a thiolesterase (TE) domain which would be responsible for 
the release of the fully processed undecaketide. Instead the release is catalysed by RifF, a 
separately encoded amide synthase. Mutation or deletion of RifF results in the release of a 2-
methyl-2-enoyl undecaketide. Two research teams investigated the effect of mutating or 
deleting RifF on the geometry of the double bond in the fully processed undecaketide and 
reported conflicting results.
82-84
 It was unknown if the Z geometry of the undecaketide double 
bond is installed by Rif10DH or by RifF. 
Work carried out by Gay et al. focussed on Rif10DH in more detail.
13
 Structural and sequence 
alignment of the Rif10DH did not reveal any indication of whether the alkene it produced would 
be Z or E in the final product. Rif10DH, was then isolated as a standalone protein and 
crystallised.  
Gay et al. reported that they had undertaken incubation of Rif10DH with acyl-SNAC, acyl-
Pantetheine and acyl-ACP substrate mimics.
13
 The exhibited selectivity towards a certain 
substrate varied depending on the substrate mimic’s design. When Rif10DH was incubated in 
the presence of an acyl-SNAC or an acyl-pantetheine, the DH exhibited high selectivity towards 
the 2R,3R-2-methyl-3-hydroxypentanoyl isomers 73 and 74 (Scheme 22). The resulting 
dehydration gave the E-2-methylpentanoyl products 75 and 76. The other substrate 2S,3S-77 
and 78, 2S,3R-79 and 80 and 2R,3S-81 and 82 were not turned over to any measurable extent 
(Scheme 22).  
 















Interestingly, when the assays were carried out using RifACP10 based mimics, a different 
selectivity preference was observed. Rif10DH was incubated with ACP based mimics for 1 
hour. The products were then hydrolytically released using the thiolesterase, PicTE, and 
subsequently derivatized using TMS-diazomethane. Samples were analysed by chiral GC-MS  
and compared to synthetic standards as appropriate. Only the Rif10DH domain catalysed the 
dehydration of 2S,3S-2-methyl-3-hydroxypentanoyl-Rif10ACP 83 to form the E-2-
methylpentanoyl-Rif10ACP 84 (Scheme 24). All other stereoisomers, 2R,3R-85, 2S,3R-86, 
2R,3S-87 were not substrates. There have been very few cases where this selectivity has been 
observed. The reverse reaction, syn hydration, was also observed when E-2-methyl-2-pentenoyl-
Rif10ACP 84 was incubated with Rif10DH. All other characterised DH domains, such as mFAS 
(1.2.1) and Ery4DH (1.5.6) have catalysed only the syn dehydration of 2R,3R-2-methyl-3-
hydroxyacyl substrates to give E-2-methyl-2-enoylacyl products.  
On replacement of the native Rif10ACP with the ACP from erythromycin, Ery6ACP, rather 
than the selectivity being degraded so a number of substrates were turned over, the selectivity of 
Rif10DH was altered completely. 2R,3R-2-methyl-3-hydroxypentanoyl-Ery6ACP 88 became 
the preferred substrate and was dehydrated to form the E-2-methylpentanoyl-Ery6ACP 89. 
Substrates 90 to 92 were not turned over to form either the Z or the E product. When the 
sequences of the two ACP were compared, Ery6ACP was found to be only 46% identical to 
Rif10ACP.  
 
Scheme 24 - Assays carried out by Gay et al. investigating the selectivity of Rif10DH using acyl-
EryACP6 or acyl-RifACP10 substrate mimics.
13
 
The substrates used in this study were diketide-based, and therefore much shorter in length than 
the natural substrate of Rif10DH, a 2S,3S-2-methyl-3-hydroxyacyl-undecaketide. The authors 
carried out a study to assess the effect of chain length and substitution pattern on the 
stereoselectivity of Rif10DH. Neither chain length or substitution pattern was found to influence 
the exhibited stereoselectivity. It was proposed that when SNAC, pantetheine and EryACP6 
36 
 
based substrates dock into the active site of Rif10DH, the critical interaction between the DH 
and the ACP are not formed. The loss of these interactions results in the different placement of 
the substrate within the active site, leading to alternative substrate stereochemistry being 
recognised and dehydration being catalysed.  
Structurally Rif10DH is highly homologous to other crystallised DH domains, such as Ery4DH 
and the Curacin DH domains from CurF, CurK, CurJ and CurH. Rif10DH possesses the 
characteristic double hotdog fold and catalytic dyad consisting of H70 and D240. In addition to 
the catalytic dyad Rif10DH also possesses a hydrogen bonding network which helps increase 
the pKa of D240, so it can act as a general acid for the dehydration reaction. In Rif10DH H244 
hydrogen bonds to D240, bridging the gap between the catalytic aspartic acid and the rest of the 
hydrogen bonding network. Five of the six known DH structures possess a similar hydrogen 
bonding network, utilising either a histidine or a glutamic acid residue. CurH is the only 
exception where an arginine residue is used.  
1.5.8  Curacin 
The anticancer lead agent curacin A 93 is produced by a type I mPKS. Curacin A 93 contains a 
diverse range of structural motifs including a cyclopropyl ring, a cis alkene, a thiazolidine ring 
and a terminal alkene. In total the PKS responsible for the synthesis of curacin A utilises at least 
41 catalytic domains across 13 polypeptide chains. The cyclopropyl ring is installed by a 
hydroxymethyl glutamate (HMG)-ACP synthase. The cysteine derived thiazoline ring is 
installed by a NRPS-PKS in the CurF module, while the terminal alkene is installed by a 
sulfotransferase thiolester domain in the CurM module. The other PKS modules CurG-L are 
typical monomodule PKS, possessing a range of β-processing domains, with CurJ and CurL 
also containing C-methyltransferase domains.  
Akey et al. undertook an in-depth study of the curacin DH domains, with the aim of identifying 
how the substrate and products are loaded and unloaded.
17
 They also wished to identify the 
mechanism behind the formation of cis and trans alkene. Based on the mature structure of 
curacin A and the gene cluster, a biosynthetic pathway has been proposed by Chang et al.
85
 It is 
expected that  dehydration reactions occur, with DH domains present in CurG, CurH, CurI, Cur 
J and CurK (Figure 21). Sequence analysis carried out by Akey et al., using newly available 
information on DH domains gained from the study of mFAS and ER, resulted in the 






Figure 21 – A. curacin A, the single letter codes refer to the module likely to be responsible for extension 
and modification of the functional group. B-F. Proposed dehydration reactions catalysed occurring on 
intermediates of curacin A. The proposed reactions have been based on the mature structure of curacin A. 
DH domains were identified in CurH, CurJ and CurK. The expected DH in CurI and CurG were 
not present, instead a DH was identified in CurF. The four identified DH domains were 
expressed as isolated soluble proteins and crystallised. The four CurDH domains had  moderate 
levels of sequence identity to each other (21-28%), although CurF and CurK were 68% 
identical. Despite the low sequence identity, the four domains possess strong structural 
similarities. All four DH domains are dimeric, with the monomer possessing a double hotdog 
fold, as observed in mFAS and other crystallised PKS DH domains.
6, 17, 48
 
As with Rif10DH, ERDH4 and mFAS, the active site comprises two catalytic amino acids, a 
histidine and aspartic acid residue (CurF: H37, D210; CurH: H41, D206; CurJ: H41, D219; 
CurK: H42, D215). The active site arrangement, substrate tunnel and tunnel entrance are all 
comparable to those found in mFAS, Ery4DH, FabA and FabZ.  
The modelling of substrate docking undertaken by Akey et al. found that, as with other DH 
substrates, the histidine abstracts a proton from the α-position, while the aspartic acid residue is 
involved in the protonation of the β-hydroxyl group and subsequent loss of water.
17
 They also 
identified that two water molecules present in the active site play a part in positioning of the 
38 
 
substrate. Comparison of all four CurDH sequences with the sequences of Ery4DH indicates the 
presence of the hydrogen bonding network as seen in Ery4DH (Figure 22). The proline (P78) 
and leucine (L76) residues observed in Ery4DH are also observed in all four CurDH domains. 
While the proline (CurF: P46, CurH, P50, CurJ: P50, CurK: P51) is highly conserved, the 
leucine is less well conserved and in CurH and CurJ a valine is found in this position (CurF: 
L44, CurH: V48, CurJ: V48, CurK L49, Figure 22). The proline and leucine/valine residues 
help ensure the correct positioning of the catalytic histidine. As found in Ery4DH the glutamine 
residue, which is involved in ensuring the correct orientation of the catalytic aspartic acid, is 
also conserved in the CurD domains with the exception of CurHDH, which possess an arginine 
residue at this position. (CurF: Q214, CurH: R210, CurJ: Q223, CurK: Q219, Figure 22). 
The modelling also indicated that while the positioning of the substrate α-protons and the β-
hydroxyl group is key for the dehydration reaction, exquisite substrate recognition is 
unnecessary due to the substrate being delivered to the active site by the ACP. As a 
consequence, the substrate tunnel lacks hydrogen bonding groups and is largely hydrophobic 
and lacking shapes tailored to the structure of the substrate.  
SQTKS_DH         RHFIRVQD-IPWIRDHVVQSALVYPGAGFICMAMEAMVQLHELRDSQSRKVAGYRLAEVD 88 
mFAS             KFDVSPESPDHYLVDHCIDGRVLFPGTGYLWLTWKTLARALSQNL----EETPVVFEDVT 102 
CurHDH_3KG7      HQDINLNN-HPWIGDHRVYDTPVIPGVSYIAMTLAAV-------------GVPAAVEDIN 72 
CurJDH_3KG8      ESYFSTEN-LPFLADHIVYEQVVVPGASHISLLLAAASLTF--------AATECQIEDIL 77 
CurFDH_3KG6      QSYIGAES-PGYLNHHQVFGKVLFPSTGYLEIAASAGKSLF---T----SQEQVVVSDVD 74 
CurKDH_3KG9      QSYLTAES-PAYLSQHQVFNKVLFPATGYLEIAAAVGKNLL---T----TGEQVVVSDVT 79 
MASDH_5BP2       QGDVGTEA-HPWLSDHRVHQVAVLPGAAYCEMALAAVTPVL---------GDTGEVHDLK 88 
EryDH_3EL6       TGRLSTDE-QPWLAEHVVGGRTLVPGSVLVDLALAAGEDVG---------LP--VLEELV 102 
RifDH_4LN9       TSRLSLRS-HPWLADHAVRDVVIVPGTGLVELAVRAGDEAG---------CP--VLDELV 103 
                    .       :: .* :    : *.     :   .                   . ::  
 
 
SQTKS_DH         QNLKTISSRKDHSES----SFVVANTASVMPNGFQSPHVIHPTTLDSIFQGAYTA-LPGA 248 
mFAS             QLVLESDLEGNRG------R--------------LQWNDSWVSFLDAMLHMSILAP---- 227 
CurHDH_3KG7      QAVRQAWIGEETS----LLEIEVPKALA----FQLAGEPIHPVLIDACTRLT-PDLFDFS 219 
CurJDH_3KG8      RWIEQVWLGEGEV----LCQMKVPKTIL----N-TTKYQLHPTLVDSCFQSIIALVLDQS 233 
CurFDH_3KG6      QGIKQLWKGQGKA----LGEMAFPEELT----AQLADYQLHPALLDAAFQIV-SYAIPHT 223 
CurKDH_3KG9      QGIKQLWKGQGKA----LGKIALPEEIA----GQATDYQLHPALLDAALQIL-GHAIGNT 228 
MASDH_5BP2       AGLSEAYVATAAE-PTVVAAVALPGPLR----SGQRGYTVHPALLDACFQSVIAHPEV-- 231 
EryDH_3EL6       QALRAAWRKDDSV----YAEVSIA--------ADEEGYAFHPVLLDAVAQTLSLGALG-- 243 
RifDH_4LN9       RAVRAVWRRGSGNTTETFAEIALPEDAR----AEAGRFGIHPALLDAALHSTMVSAAADT 254 
                   :                                         :*:  :           
 
Figure 22 – Sequence comparison of crystallised DH domains, conserved catalytic amino acids histidine 
and aspartic acid highlighted in yellow. Conserved amino acids involved in the hydrogen bonding 
network are highlighted in blue. 
1.5.9  Mycocerosic acid synthase75 
Mycocerosic acid (MAS) is a fully reducing iPKS found in mycobacterium smegmatis. MAS 
utilises C12 to C20 fatty acids as starter units.
75
 The start unit is iteratively elongated one to four 
times using methyl-malonyl-CoA extender units to form C20 to C28 branched fatty acids. These 
lipids are vital for the formation of the mycobacterial cell envelope. As with other PKS, MAS is 
comprised of two regions, a condensing region (ACP, KS, AT), and an extension region (DH, 
ψKR, ER and ER). MAS iteratively does not contain a CMeT domain, the branched methyl 
groups arise from the incorporation of methylated extender units. Work by Maier et al. 
crystallised MAS modifying and condensing region separately. 
75
 The MAS DH is the most 
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recently crystallised DH domain available, it is also the only iterative PKS DH domain to be 
crystallised at this time (Figure 23). MAS DH possess many features which have been observed 
in the other crystallised DH domains. The MAS DH connects the modifying and condensing 
regions together with flexible linkers. As seen in FAS, the modifying region dimerizes along an 
interphase formed by the DH and ER domains.  The DH dimer in MAS lacks the V-shape 
exhibited in FAS DH, instead it possesses the liner shape found in PKS DH dimers. The MAS 
DH is composed as to be expected with a double hotdog fold with each hotdog fold contributing 
one of the amino acids needed to from the catalytic active site. The hydrophobic substrate tunnel 









1.6  Project aims 
Work carried out on mPKS DH domains has shown it is possible for DH domains to be excised 
from the whole PKS enzyme and that they can function independently from the rest of the 
enzyme.
6, 12, 13, 60, 62, 63, 65, 67, 86
 The aim of the work described in this thesis is to investigate the 
programming of isolated SQTKS DH. The programming of the isolated SQTKS DH domain is 
to be probed using synthetic substrate mimics. No previous studies of iterative PKS DH 
domains have been reported and a key aim is to discover the chemo and stereo-selectivity of 
such domains.  
The aims of the project are as follows: 
 To synthesise a range of substrates which are distereomerically and enantiomerally 
pure. The synthesised substrates will be designed to probe the programming of the 
SQTKS DH domain.  
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 Optimise the production of the SQTKS DH domain protein to produced sufficient 
quantities of protein to carry out assays.  
 Characterise the selectivity of the SQTKS DH domain and carry out steady state kinetic 
analysis of the substrate processed by the domain.  
 Attempt to crystallise the DH domain to obtain a crystal structure. The active substrates 
will be docked into the active site to gain understanding of how the active site dictates 
the selectivity of the DH domain. In the absence of a crystal structures commercially 
available modelling programs will be used to create a model of the DH domain.  
1.6.1  Squalestatin S1 (SQS1) 
Squalestatins are secondary fungal metabolites produced by filamentous fungi and over the 
years many different squalestatins have been isolated and characterised.
87
 All squalestatins 
comprise a highly functionalised 4,8-dioxabicyclo[3.2.1.]octane core with varying 1-acyl and 6-
O-acyl side chains.  
Squalestatin S1 (SQS1, also known as zaragozic acid), 37, was first isolated in the early 1990’s 
from Phoma sp. C2932 (Glaxo) and an unidentified strain MF5453 (Merck), as a cholesterol 
lowering drug due to its potent inhibition of squalene synthase.
88, 89
 When first discovered, the 
unusual structure of 37 raised questions about the biosynthesis of the carbon backbone and the 
origin of the high number of oxygen atoms.
90
 Stable isotopic labelling studies showed 37 was 
composed of two polyketide chains. 
 
Figure 24 – Structure and origin of atoms in SQS1 37. 
The main chain (shown in black) is a hexaketide, comprising a benzoate starter unit, thought to 
derive from phenylalanine, and 5 acetate-derived extender units.
90
 The second chain (shown in 
red) is a tetraketide derived from an acetate starter and extender units. The distinctive bicyclic 
core structure is completed by the addition of 4 carbons deriving from oxaloacetate. Fungal PKS 
are known to possess a functional CMet domain which is able to transfer methyl groups from 






1.6.2  Previous work 
Previous work by the Cox group into the biosynthesis of SQS1 37 resulted in the identification 
and  isolation of the gene responsible for the production of the tetraketide side chain, phpks1 
which encodes squalestatin tetraketide synthase (SQTKS).
91
  
Further work by Cox et al. identified the full biosynthetic gene cluster responsible for the 
production of SQS1 for the first time.
92
 Full genome sequencing of the Phoma sp. C2932 
(Glaxo) and an unidentified MF5453 (Merck) strain was carried out. Using the previously 
characterised phpks1 gene it was possible to identify a putative SQS1 gene within the assembled 
genomes.  
The link between the gene cluster and the biosynthesis of SQS1 was strengthened by growing 
MF5453 under producing and non-producing conditions and looking at the gene expression 




fold increase in the 
expression levels of the genes in the putative SQS1 cluster.  
 
Scheme 25 – SQS1 and related analogues. 
The cluster was found to contain 2 PKS encoding genes. One is known to be responsible for the 
tetraketide side chain, therefore the other must encode the hexaketide chain. The hexaketide 
synthase contains an AT domain with suitable residues next to the active site to allow the 
selection of a benzoate starter unit. The cluster also contains a citrate synthase-like protein 
which is thought to be involved in  the linking of the hexaketide to the oxaloacetate moiety. 
 
Scheme 26 – In vitro substrates and  SQS1 product and analogues. 
In order to gain an insight into the order in which acyl groups are added into the final 
compound, phpks1 was knocked out. In the wild type, when grown under producing conditions 
SQS1, 37 is the main product, with trace amounts of 94, 95 and 96. In the phpks1 knockout, 
there was no production of SQS1 37, but there is very high production of 95. The results gained 
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from this experiment indicate that the transfer of the tetraketide is probably the final step of 
biosynthesis (Scheme 27).  
The SQS1 gene cluster contains two putative ATs, and it was possible to isolate and express one 
of these AT domains. To investigate the selectivity of the AT domain, various possible 
substrates were used: 94, 95 and 96, were incubated in the presence of the AT domain and 
various acyl groups (97 and 98) and acetyl, hexanoyl and octanoyl CoAs. The assays showed 
that the AT domain was unable to transfer the tetraketide pantetheine substrates. When the AT 
was incubated with the tetraketide CoA substrate, SQS1 37 was formed. In addition to 
transferring the tetraketide from its CoA substrate, the AT domain was also able to transfer 
acetate, hexanoate and octanoate from their corresponding CoAs to form 99, 100 and 101. The 
AT domain was unable to transfer acyl groups to the 12-alcohol in 94 or 96. The results 
confirmed that this AT domain is responsible for transferring the tetraketide to form SQS1 37. 
The acetate must be transferred to O-12 at an earlier stage in the biosynthesis. From examining 
the gene cluster, undertaking gene knock-outs and isolating the one of the AT domains, the Cox 
group could propose the biosynthesis of SQS1 (Scheme 27) 
 





1.6.3  Squalestatin Tetraketide Synthases (SQTKS) 
SQTKS is a type I, iterative, highly reducing fungal PKS, consisting of a single polypeptide of 
2603 amino acids.
93
 There are seven identifiable catalytic domains; KS, AT, DH, C-MeT, ER, 
KR and ACP. The KR domain is split into two parts; the catalytic KR and the structural ψKR. 
Currently, it has not been possible to obtain a crystal structure of the entire synthase or the 
isolated domains. Protein sequence alignment suggests that SQTKS has a similar structure to 
that found in FAS (Figure 3). 
SQTKS is interesting for a number of reasons; it is currently the simplest known HR-iPKS with 
all modifying domains present and active. SQTKS also exhibits complex programming. 





Figure 25 - Structure of squalestatin tetraketide 102. 
There are three rounds of chain extension and modification (Scheme 28). All domains are active 
in the first and second round of chain extension, resulting in a fully saturated diketide. In the 
third and final round of chain extension the C-MeT and ER domains are inactive. This results in 
the final product 102 lacking an -methyl substituent and retaining the ,-unsaturation. 
SQTKS must also contain some programming enabling control over the stereochemical 
outcome of certain steps in the biosynthetic cycle. As SQTKS lacks an obvious TE it is not clear 




Scheme 28 - Biosynthesis of squalestatin tetraketide. 
 
In the first biosynthetic cycle, the acetate starter unit is loaded onto the AT domain before being 
transferred onto the ACP and subsequently onto the KS domain (Scheme 29). The malonyl 
extender unit is then loaded on the ACP via the AT domain. Once both the starter and extender 
unit have been loaded, the KS catalyses the condensation of the two units via a Claisen 
condensation reaction to form an ACP bound β-keto thiolester.  
The ACP bound thiolester is then presented to the C-MeT domain, where it undergoes α-
methylation. The KR domain reduces the β-ketone group to a β-OH. The DH domain then 
eliminates water forming an α,β-unsaturated thiolester, which is then subsequently reduced by 




Scheme 29- Cycle one of SQTKS biosynthesis. 
The diketide, 103, is then fed back into the catalytic cycle for round two of the chain extension 
(Scheme 30). A second malonyl extender unit is loaded and coupled to form a triketide. The 
triketide thiolester is then methylated by the C-Met, reduced by the KR, dehydrated by the DH 




Scheme 30- Cycle two of SQTKS biosynthesis. 
In the final round of chain extension 104 is fed back into the catalytic cycle and again 
condensed with a third malonyl extender unit to form a tetraketide (Scheme 31). In this cycle 
the C-MeT domain has been “switched off” and does not methylate in the β-position. The KR 
and DH domain are active resulting in an α, β-unsaturated thiolester. As with the C-Met domain, 
the ER domain is inactive and does not react. This results in the final product 105, retaining the 
α,β-unsaturation. There is more than one stereochemical outcome possible for each stage of the 
biosynthesis, although only one final product is formed. All the possible outcomes for the 
diketide and triketide products are shown in Scheme 32. In the third cycle (Scheme 31) of chain 
extension the C-Met and the ER domain are inactive and the stereochemical possibilities have 
not been illustrated in this report. 
 The C-MeT, KR, DH and ER domain of SQTKS must contain a degree of programming in 
order to control the stereochemical outcome and ensure the correct product is produced. The ER 
domain dictates the stereochemistry of the final product in the first and second round of chain 




A number of questions arise regarding the programming of the SQTKS. Although the ER 
domain affects the final stereochemistry of the product, the stereochemical outcomes from each 
stage in the biosynthesis are important. The outcome from one domain is likely to affect the 
action of the subsequent domain. By discovering the selectivity of SQTKS DH, it will be 
possible to predict the product formed by the KR and the CMeT domain.  
Currently it is known that the ER domain catalyses the reduction of the α,β-unsaturated 
thiolester resulting in methyl groups having S stereochemistry. It is not known what causes the 
ER domain to become inactive in the final round of chain extension. Currently work is under 
way in the Cox group to investigate the programming of the ER domain. The programming of 
the domain could be affected by a number of factors including chain length or methylation 
pattern (e.g. the lack of α-methylation). Current findings from ER studies show Z alkenes can 
also be a substrate for the ER domain,
94
 this makes the understanding of the DH domain 
programming even more important.  
 




1.6.3.1 Dehydratase domain of SQTKS 
Previous work done within the Cox group
95
 by David Ivison resulted in the purification of the 
SQTKS DH as a standalone protein and initial testing to characterise it structurally and 
chemically was carried out.  
 
Figure 26 - DH Natural substrates. 
There are three natural substrates for the DH domain. The diketide 106, triketide 107 and the 
tetraketide 108. The diketide 106 has four possible stereoisomers 109a - d (Scheme 32). The 
triketide 107 has eight possible stereoisomers (4 are shown in Scheme 32 110a - d), although 
the 4-methyl must be as shown in 107. 
Due to the number of possible substrates for the triketide 107, previous work was carried out 
using the diketide substrate. A diketide DH substrate mimic, 3-hydroxy-2-methylbutanoyl-
SNAC 111, was synthesised as a mixture of diastereomers and assayed. There are two possible 
products from the reduction of 111, tigloyl-SNAC 112, (E-enone) and angelic-SNAC 113, (Z-
 enone).  
 
Figure 27 - 3-Hydroxy-2-methylbutanoyl-SNAC 111,  tigloyl-SNAC 112, and angelic-SNAC 113. 
An assay was carried out by incubating the DH protein at 37 °C in the presence of racemic 3-
hydroxy-2-methylbutanoyl-SNAC 111 overnight, alongside a control assay.  When analysed by 
LC-MS, a new peak was observed in the enzyme assay but not in the control assay. The peak 
was found to have a m/z 224, which corresponds to the formation of α,β-unsaturated thiolester-
SNAC [M] Na
+
. In order to fully identify the new peak at 5.1 mins, the assay was repeated and 
the assay mixture extracted with deuterated chloroform and analysed by NMR which confirmed 
the formation of  tigloyl-SNAC 112. 
The SQTKS DH catalysed reaction is predicted to proceed via a syn-elimination mechanism. 
Syn-elimination reactions occur via an E1cB mechanism with the formation and collapse of an 





Scheme 32 - A. Flow diagram showing all stereochemical possibilities of diketide β-processing. The product produced by SQTKS after the first cycle is highlighted in green. B. 
Flow diagram of SQTKS domain reaction and all possible stereochemical outcomes for triketide product. The product with the correct stereochemistry at the end of the second cycle 




Currently the stereochemistry of the actual DH substrate is unknown. There are four possible 
stereochemical isomers for the diketide substrate; (2R, 3R)-3-hydroxy-2-methylbutanoyl-SNAC 
114, (2S, 3S)-3-hydroxy-2-methylbutanoyl-SNAC 115, (2R, 3S) - 3-hydroxy-2-methylbutanoyl-
SNAC 116 and (2S, 3R) - 3-hydroxy-2-methylbutanoyl-SNAC 117.  
 
Figure 28 - Natural substrate mimics. 
Assuming that the , unsaturated thiolester forms via syn elimination and that tigloyl-SNAC 
112 is the only product, it can be predicted that (2R,3R)-114, or (2S,3S)-115, can be used as a 
substrate for the SQTKS DH. Syn-elimination of the (2R,3S)-116 and (2S,3R)-117 substrates 
would produce the angelic-SNAC 113 (Scheme 33). In order to test this hypothesis a small 
library of substrate mimics will be synthesised which are diastereomeric and enantiomerically 
enriched in order to probe the selectivity of the SQTKS DH domain.  
 





Chapter 2 - Synthesis of DH substrate mimics  
2.1  Introduction  
The stereochemistry of the final product of SQTKS, squalestatin tetraketide 108, is a result of 
the programming present in the iPKS. Each domain present in the iPKS will possess a degree of 
programming. Work by Douglas Roberts and Christoph Bartel within the Cox group has  probed 
the programming of the SQTKS ER domain.
94, 96
 Their work has shown that the isolated ER 
domain is able to tolerate and turn over a wide range of substrates regardless of the methylation 
pattern, chain length or double bond geometry (Figure 29). In order to probe the programming 
of the SQTKS ER domain, a library of ER substrates was synthesised. The different 
stereochemistry of the substrates was designed to interrogate the programming of the active site 
and shed light on the selectivity of the SQTKS ER domain.  
 




Several PKS domains have been interrogated with substrate mimics in order to gain an 
understanding of their programming.12, 13, 17, 60, 64 During PKS biosynthesis, the substrate is 
bound to an ACP and ideally, assays to investigate the programming within SQTKS DH would 
be carried out using synthetic analogues of natural substrates attached to the ACP. Within the 
Cox group, work was carried out by David Ivison to produce SQTKS-ACP as a soluble 
protein.95 SQTKS-ACP was cloned into a pOPINF vector, which was subsequently 
transformed into E. coli for expression. There was no expression of ACP observed under any of 
the experimental conditions trialled. Also although it is possible to produce acyl-ACPs,13, 71, 
97, 98 they are not ideally suited to kinetic based assays, due to their large mass, resulting in 
large quantities being required. Also the ACP must be cleaved from the acyl product before 
analysis can be done.    
 
Figure 30 - Polyketide chain, shown in red, attached to a phosphopantetheine ACP. 
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Acyl substrates are attached to the ACP via a phosphopantetheinyl group (Figure 30) which acts 
as a long flexible arm, allowing the movement of the polyketide chain from domain to domain 
within the PKS module.
21
 Substrate mimics have been synthesised which, rather than utilising 
the native ACP, are attached to only the phosphopantetheinyl group or shortened even further to 
an N-acetylcysteamine (SNAC) thiolester.  
A number of PKS DH domains have had their substrate specificity investigated.
6, 13, 60, 62, 65-67
 
The majority of DH domains investigated are from type I mPKS, with the exception of curacin 
93 which is produced by a PKS-NRPS.
17
 The substrate specificity of the DH domains was 
probed using SNAC, phosphopantetheinyl and ACP based substrates. Typically substrate 
mimics have been produced using synthetic organic chemistry, utilising chiral auxiliaries to 




Work by Vergnolle et al. utilised SNAC substrates when investigating the formation of cis 
double bond formation in borrelidin 50.
60
 In order to probe the selectivity of these domains, a 
range of diketides substrate mimics 118 and 119  were synthesised. The non-methylated 
diketide mimics for BorDH2 were simply synthesised by coupling the SNAC to the required 3-
(S) or (3R)-hydroxybutanoic acid 120 in the presence of DCC and DMAP (Scheme 34, A). For 
the methylated diketide substrate mimics Vergnolle et al. utilised oxazolidinone auxiliary 





Scheme 34 – Synthesis routes used by Vergnolle et al.
60
 to produce borrelidin substrate mimics; A, 
diketide mimic synthesis; B, methylated diketide mimic synthesis. 
The DH domain from pikromycin, PikDH2, is another type I mPKS DH which has had its 
selectivity probed.
65, 67
 The substrate mimics synthesised by Li et al. were also based on simple 
diffusible SNAC thiolesters.
65, 67 
Although there was one difference in the design of the 
triketides; one or two methylene spacers had been inserted in between the carbonyl and the 
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SNAC moiety to remove the risk of internal lactonisation occurring in the substrate mimics. As 
was the case with the work by Vergnolle et al., Li et al. which utilised chiral auxiliaries 121 to 
control the stereochemical outcome aldol reactions when synthesising substrate mimics 
(Scheme 35). Although rather than using oxazolidinone auxiliaries, Li et al. used a 
thiazolidinedione auxiliary 122, also known as Masamune auxiliary. 
 
Scheme 35 – Aldol reaction carried out by Li et al. using thiazolidinedione auxiliary.
67
 
Wu et al. also investigated the formation of olefin in pikromycin, but rather than investigating 
the DH domain PikDH2 in isolation, the entire Pik2 module was used.
65
 Wu et al. synthesised 
DH diketide substrates based on simple diffusible SNAC thiolesters. The substrate was 
synthesised using Evans oxazolidinones to control the stereochemistry of the acyl substrates 
synthesised.
65
 In order to study the terminal rifamycin DH, Rif10DH, Gay et al. produced all 
four stereoisomers of 2-methyl-3-hydroxypentanoyl-RifACP10.
13
 Previous work by the 
Keating-Clay group had shown it was possible to employ mPKS KR domains as biocatalyst to 
make chiral diketide mimics 83 and 85-86.
99
 The stereoisomers were formed by incubating 
(2RS)-2-methyl-3-oxopentanoyl-RifACP10 123 with KR domains from rifamycin, (RifKR7), 
tylosin (TylKR1), erythromycin , (EryKR1 and EryKR6), (Scheme 36). 
 
Scheme 36 – Chemoenzymatic synthesis of diketide substrate mimics using various PKS KR domains.
13
 
Although work by Piaskecki et al. showed that it was possible to scale up the chemoenzymatic 
reactions allowing over 100 mg of product to be isolated,
99
 this approach for substrate mimic 
54 
 
synthesis was not suitable for our studies. In order to use this approach, it would require 
expression of SQTKS ACP as a soluble isolated protein and currently this is not possible,
95
 It 
would also require access to the KR domains used in the study which are also not easily 
available.
99
 The cost of obtaining methylmalonyl-CoA and NADPH is another deterrent to using 
chemo enzymatic reactions to synthesis substrates on a useable scale.  
Another factor to take into account with the chemoenzymatic route, is substrate fidelity. 
Changes in a domain’s selectivity can occur when the ACP is changed from a native to a non-
native ACP.
13
 This was observed during the investigation into the selectivity of rifamycin DH 
(Rif10DH) and is discussed in Chapter 1, Section 1.5.7. It is unknown if the stereochemical 
outcome of the enzymatic reactions will be retained if  the ACP from SQTKS is used.   
When designing substrate mimics for this study, it was important to consider how the assays 
were to be carried out. A range of assay conditions and sample work-ups have been reported by 
others. The simplest assay conditions were used by Vergnolle et al.
60
 and Li et al.
67
 Vergnolle 
incubated the borrelidin substrate mimics (12 mM) with 25 mM HEPES, 100 mM NaCl and up 
to  8 mg mL
-1
 of either the BorDH2 or BorDH3 protein.
60
 The reactions were incubated at 37 °C 
for 16 hours. The work-up of the assay involved carrying out an extraction (2 × 1 mL) using 
EtOAc. The samples were then evaporated to dryness and resuspended in 50 µL of isopropanol 
and subsequently analysed by LC-MS.  
Li et al. also used a simple assay.
67
 The substrate was incubated with the buffer and  PikDH2 
protein for 40 minutes at 25 °C. At certain time points, 5 µL samples were taken and quenched 
in 495 µL of 1:1 MeCN and buffer. This resulted in rapid protein precipitation. The samples 
were then centrifuged to precipitate the protein and 60 µL was added to a HPLC vial for 
analysis by LC-MS/MS. Not only were Li et al. able to carry out assay of PikDH2 using SNAC 
based substrates, they were also able to carry out kinetic assays, allowing the kinetic 
characteristics of the PikDH2 domain to be probed. The reaction conditions were the same for 
the kinetic assays, although the assays were quenched after only 15 minutes.  
The aim of the assay carried out by Wu et al. was to incubate the diketide substrate, with Pik 
module 2 in the presence of malonyl-CoA and NADPH and observe the formation of the 
unsaturated triketide product.
67
 This resulted in a more complicated assay and sample 
processing. The Pik module 2 had been modified so a functional TE domain was appended 
downstream of the ACP, in order to release the product as a carboxylic acid rather than as a 
SNAC derivative. The formation of product was initially detected using TLC phosphor imaging. 




NMR and GC-MS. In 
order to achieve this a preparative scale assay was required, followed by extraction and 
purification of the product. In order for the products to be analysed by GC-MS, derivatisation 
had to be carried out using bis(trimethylsilyl)trifluoroacetamide (BSFTA). 
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These findings suggest that using synthetic organic chemistry to prepare the required substrate 
is the most reliable route. There is a strong literature precedent for the use of oxazolidinone 
auxiliaries to control the outcome of aldol reactions, Evans chemistry can be used for accessing 




The method by which the samples are to be analysed dictated how the samples will need to be 
prepared. In order for SNAC mimics to be analysed by GC-MS, they require extraction from the 
assay mixture, purification and derivatisation, which can be time consuming and possibly lead 
to the introduction of errors, if kinetic data was to be collected in this fashion.
13, 65
 
The work carried out by Li et al. gave the best grounding when designing the substrate mimics 
and assay protocol for the investigation into SQTKS.
67
 The study utilizes simple substrate 
mimics, which are easy to synthesise with a high level of  purity. In order to test the selectivity 
of SQTKS it is vital to be able to synthesise each stereoisomer in a pure form. The assays used 
are simple and quick to set up, with minimal work needed to quench and work up the assay 
samples. The design of the substrate and assay conditions allows the samples to be analysed by 
LC-MS, which obviates the need for derivatisation, which is required for analysis via GC-MS. 
Also Li et al. were able to carry out kinetic analysis of the PikDH2 domain. Currently it is not 
known how selective the SQTKS DH domain is towards certain substrate mimics. Kinetic 
analysis of the substrates would allow further insight into the efficiency of the DH enzyme.   
2.2  Natural substrates  
As discussed in Chapter 1, Section 1.6.3.1 there are three natural substrates for the SQTKS DH 
domain; the diketide 106, the triketide 107, and the tetraketide 108 (Figure 31). The diketide 
106 has four possible stereo-isomers 114, 115, 116 and 117 and the triketide 107 has eight 
possible stereoisomers. 
 
Figure 31 -  A, Natural SQTKS DH substrates 106,  107 and 108; B, natural (114, 115, 116 and 117) and 
non-natural (124 and 125) SQTKS DH diketide substrate mimics. 
Due to the number of possible triketide substrates, it was decided to initially investigate the 
selectivity of the SQTKS DH domain towards diketide substrates 114-117. There are four 
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possible stereochemical isomers for the diketide substrate and to make the synthesis as simple 
as possible it was decided that the acyl substrate mimics would be made as N-acetylcysteamine 
(SNAC) thiolesters. Non-natural substrates 124 and 125 were also synthesised to assess the 
importance of the methyl group in substrate recognition.  
2.3  Synthesis plan for diketide substrate mimics 
2.3.1  Synthesis of syn diastereomers  
The synthesis of enantioenriched compounds using oxazolidinone methodology is well 
documented.
101-103
 This methodology has been employed to make enantioenriched DH diketide 
substrate mimics in a number of DH studies.
60, 65, 67, 99, 102, 104
  Oxazolidinone chemistry, also 
known as Evans auxiliary chemistry, offers a short route (four steps) to reach the desired 
compounds. A range of Evans auxiliaries 121, 126-128 are commercially available and various 
reaction conditions which allow the synthesis of all four stereoisomers have been described in 
the literature.  
 
Figure 32 – Examples of commercially available oxazolidinone auxiliaries. 
The Evans auxiliary, (S)-4-benzyl-2-oxazolidinone, 127,  has been used to synthesise SNAC 
related substrates.
102, 105
 Staunton et al. used the acylated auxiliary 129, as well as its 
enantiomer, 130, during the synthesis of a range of diketide analogues of DEBS intermediates 
(Scheme 37).
102
 (S)-4-benzyl-2-oxazolidinone 129 was used to prepare the (2S,3R)-substrate 
131, whereas (R)-4-benzyl-2-oxazolidinone 130 was used to access the (2R,3S)-substrate 132. 
Keating-Clay employed an identical route when synthesising a range of diketide standards for 








It is possible to use Evans auxiliary chemistry to access the anti diastereomers as well as syn 
diastereomers by altering the base used during the aldol reaction.  The auxiliary (4R)-3-
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propionyl-4-isopropyl-2-oxazolidinone 133 was used by Harris et al.
102
 It was also used by Wu 








Chiral auxiliaries, such as oxazolidinones, control the stereochemical outcome of reactions in a 
number of ways depending on the type of reaction.
106
 In aldol reactions, (Scheme 39), where 
129 is transformed to 135, oxazolidinones achieve stereochemical control by influencing the 
transition state of the reaction (136 and 137).  
 
Scheme 39- Formation of chiral enolate.  
The use of oxazolidinones enables a chiral enolate to be formed by complexing  to the butyl 
boron triflate (Scheme 39) and inducing the formation of the Z-enolate 136. The Z-enolate is 
favoured, because the E-enolate 137 would result in greater alkylic strain between the methyl 
group (shown in red) and the benzylic group of the Evans auxiliary. 
  
Scheme 40 -  Stereochemical outcome of Evans aldol reaction under boron triflate conditions.
105
 
Once the enolate has been formed and an aldehyde (red in Scheme 40) added, the boron 
complex forms a closed transition state in a pseudo chair conformation (Scheme 40).
107
 In order 
for the chair conformation to form, the Evans auxiliary must orientate with the 5 membered ring 
and the methyl groups in pseudo axial positions. The orientation of the aldehyde can allow the 
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hydrogen to take either an axial or equatorial position, but  the 1,3-diaxial interaction between 
the aldehyde and the oxazolidine forces the hydrogen onto the axial position and the R group to 
take the equatorial position.   
The synthetic route (Scheme 41) utilizes oxazolidinone chemistry to install the syn stereocenters 
in substrate 116 and 117. It was decided to use (4S) and (4R)-4-benzoyl-2-oxazolidinones as 
there was a literature precedent for use of this Evans auxiliary.
99, 102
 Evans auxiliaries have been 
reported to result in high stereoselectivity. Danda et al. reported diastereomeric ratio (d.r.) of 
98:2 in favour of syn adducts.
108
 Hayashi et al. also reported high selectivity for syn adducts, d.r. 
100:0, when the aldol reaction was carried out using NEt3 and Bu2BOTf conditions to give 
138.
107
 Once the aldol reaction had taken place, the Evans auxiliary can be cleaved by LiOH and 
H2O2 to give the acid 139. The formation of 117 is achieved by coupling the acid 130 to SNAC 
in the presence of EDCI and DMAP.  
 
Scheme 41 - Plan of (2S, 3R)-3-hydroxy-2-methylbutanoyl-SNAC 117 synthesis. 
2.3.2  Synthesis of anti diastereomers  
It is possible to produce the anti diastereomers via alternative methodology. Fráter-Seebach 
alkylation allows the diastereoselective alkylation of β-hydroxyl esters.
100
 A strong base such as 
LDA is added to the β-hydroxyl ester, this deprotonates the hydroxy group and an α-proton 
allowing enolate formation (Scheme 42). The lithium ion co-ordinates to both of the oxygens, 
this causes one face of the enolate to be shielded, therefore the alkylation occurs on the least 
hindered face. In Fráter-Seebach alkylation, the least hindered face is the opposite face to the 
chiral β-hydroxyl group.
100
 Fráter et al. reported the diastereoselectivity of the reaction to be 
95:5 (19:1).  
 





The synthesis route shown in Scheme 43 was proposed using Fráter-Seebach alkylation to 
introduce the desired anti stereochemistry in substrates 114 and 115. Polyhydroxybutyrate 140 





Scheme 43 - Plan of (2R, 3R)-3-hydroxy-2-methylbutanoyl-SNAC 114 synthesis. 
After the installation of the α-methyl group, the synthesis can proceed in a similar fashion to the 
planned route to the (2S,3R)-diastereomer.
102, 110, 111
 It is also possible to synthesise the 
enantiomer (2S, 3S)-3-hydroxy-2-methylbutanoyl-SNAC 115 substrate using the same 
chemistry as described in Scheme 43. Instead of using R-hydroxybutanoate 141 the opposite 
enantiomer, S- hydroxybutanoate, can be used. 
2.4  Synthesis plan for triketides substrate mimics 
In order to further probe the stereoselectivity of the SQTKS DH domains, triketide substrate 
mimics could also be synthesised. The SQTKS DH triketide substrate has 8 possible 
stereoisomers, (Chapter 1, Section 1.6.3.1.). However as the stereochemsitry of the 4-position is 
known to be S from the structure of the tetraketide 108, this allows the number of possible 
triketide substrates to be reduced to 4, 110a-d.(Scheme 32). 
 
Scheme 44 – Structure of the final product, squalestatin tetraketide 108 and the triketide substrate 107.  
The carbon atoms in the final product which arising from the triketide highlighted in red. 
A literature search showed no evidence of Evans auxiliaries being used to synthesise similar 
compounds to 107 but camphorsultam directed aldol reaction had been used.
112, 113
 For example 
Sang et al. utilised this reaction in their total synthesis of rakicidin A (Scheme 45, A).
112
 
McKillican et al.  also carried out an asymmetric aldol reaction during their synthesis of 






Scheme 45 - Synthetic routes utilizing camphorsultam directed aldol reactions to synthesise A, rakicidin 
A; B, avermectins. 
The camphorsultam directed aldol reaction was developed by Oppolzer et al. in the early 
1990s.
114, 115
 It is possible to synthesis syn and anti aldols using boranesultam directed 
conversions by varying the conditions of the reaction. In order to achieve the 2,3-anti 
stereochemistry in 146 the propionylsultam 147 is first treated with TBDMSOTf and NEt3, this 
results in the formation of a Z-silyl enol ether 148, (Scheme 46). The camphorsultam group 
directs the silyl enol ether to form the Z geometry 149 preferentially (Scheme 47).  
Scheme 46 – Oppolzer boranesultam directed aldolization reaction. 
Once the silyl enol ether has formed, the aldehyde is added, followed by a Lewis acid, for 
example TiCl4. The Lewis acid co-ordinates to the aldehyde 146, increasing its reactivity, which 
subsequently undergoes electrophilic attack via the Cα-Re face of 150, resulting in the 2,3-anti-
stereochemistry of the final product 146.  
 




2.5  Results and Discussion 
2.5.1  Synthesis of diketides  
2.5.1.1 Synthesis of anti 3-hydroxy-2-methylbutanoyl-N-acetylcysteamine  
The synthesis of (3R, 2R)-114 was achieved in 6 steps with an overall yield of 9% (Scheme 48).  
 
Scheme 48 - Synthesis of (3R, 2R)-3-hydroxy-2-methylbutanoyl-N-acetylcysteamine. 
Poly-(3R)-hydroxybutyrate 140 was heated in the presence of ethanol, 1,2-dichloroethane and 
concentrated sulfuric acid for 96 hours to give ethyl-(3R)-3-hydroxybutanoate 141 in a 55% 
yield. It was possible to carry out the synthesis of 141 on a 20 g scale.  
Ester 141 was then methylated using LDA and methyl iodide at -78 °C and the hydroxyl group 
protected using tert-butyldimethylsilyl triflate (TBDMS triflate), to give (3R,2R)-143, in a 86% 
yield over the two steps. From the 
1
H NMR spectrum the d.r. was calculated by the integration 
of the 3-CH3 signals (Figure 33). A d.r. of 80:20 (4:1) was achieved in the alkylation step, the 
selectivity achieved in this step was lower than reported in the literature (95:5).
100
 Comparison 
of the literature 
1
H NMR chemical shifts for 2R,3R-143 (2-CH3: 1.11, d, J = 7.0 Hz; 3-CH3: 
1.16, d, J = 6.0 Hz)
111
 identified the major product as 2R,3R-143 (2-CH3: 1.07, 3H, d, J = 7.1 
Hz; 3-CH3: 1.10, 3H, d, J = 6.2 Hz). In addition to the NMR the     was measured (    
     - 
36.0) and found to correlate with the value reported in the literature ([lit      -31.5).
116
  
The acid 144 was formed by dissolving 143 in THF, water, methanol with lithium hydroxide 
and heating to 60 °C overnight, (2R,3R)-144 was formed with a 41% yield. The acid 144 was 
reacted with N-acetylcysteamine 151 in the presence of DMAP and EDCI to give (3R,2R)-145 
with a 59% yield. The TBDMS protecting group was removed from 145 by stirring in the 
presence of acetic acid and CH2Cl2 for 5 days to give the product (3R,2R)-114 with a 79% yield, 
in a d.r. of 80.5:19.5. It may be possible to achieve deprotection on a shorter time scale by using 
a stronger acid, but the conversion of starting material to product produced no side products. 
This allows the product 114 to be extracted with no need for further purification. After the 
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coupling of the acid to SNAC it was possible to purify the desired diastereomers 114, the 
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Thiolester (3S, 2S)-115 was prepared using the same conditions used to synthesise 114 with an 
overall yield of 8 % from the commercially available (3S)-3-hydroxybutyrate 152 (Scheme 49). 
 
Scheme 49 - Synthesis of (3S, 2S)-3-hydroxy-2-methylbutanoyl-N-acetylcysteamine 115. 
The methylation and protection was carried out using 152 and to give 153 resulted in an overall 
yield of 63%. The d.r. was measured by NMR and found to be 91:9 (10:1) in favour of the 
desired product (Figure 35). Two diastereomers were visible in the NMR spectrum. Comparison 
of the literature NMR shifts for 2S,3S-153 (2-CH3: 1.05, d, J = 7.1 Hz; 3-CH3: 1.10, d, J = 6.1 
Hz)
117
 and the 2R,3S-diastereomer  (2-CH3: 1.13, 3H, d, J = 6.1 Hz; 3-CH3: 1.14, 3H, d, J = 7.0 
Hz)
117
 identified the major product as 2S,3S-153  (2-CH3: 1.06, 3H, d, J = 7.1 Hz; 3-CH3: 1.10, 
3H, d, J = 6.3 Hz). The measured [α]D (    
     +37.3) also correleated the [α]D for the 2S,3S-
153 isomer ([lit      +37.1).
118
 
Cleavage of the ester 154 afforded the acid 155 in a yield of 44%. The acid 155 was reacted 
with N-acetylcysteamine 151 in the presence of EDCI and DMAP to give 156 with a 55% yield. 
Deprotection of the hydroxyl group on 156 gave the final product 115  in a 56% yield. As was 
the case with 115, over the course of the reactions the initially formed minor diastereomer was 
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2.5.1.2 Synthesis of (3R) and (3S)-hydroxybutanoyl-N-acetylcysteamine  
The synthesis of substrate mimics (3R)-124 and (3S)-125 was achieved using the experimental 
conditions used previously in the synthesis of 114 and 115. The synthesis of (3R)-124 was 
achieved in five steps with an overall yield of 4% The yields of each reaction are summarised in 
Scheme 50 and the
 1
H NMR of 124 in Figure 37. The enantiomer (3S)-125 was prepared using 
identical conditions to 124 from the commercially available (3S)-3-hydroxybutyrate 152 and the 
synthesis was achieved in four steps with an overall yield of 8%. 
 
Scheme 50 - Synthesis of (3R)-124. 
 
 
Figure 37 - 
1
H NMR, 400 MHz, of (3R)-124 in CDCl3 
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2.5.1.3 Synthesis of syn 3-hydroxy-2-methylbutanoyl-N-acetylcysteamine 117 
The synthesis of (2S,3R)-117 and (2R,3S)-116 was carried out using oxazolidinones auxiliaries 
129 and 130 in 6 steps, with overall yields of 2% and 9% respectively. The summary of 
(2S,3R)-117  reaction yields is summarised in (Scheme 51). (S)-4-Benzyl-2-oxazolidinone 127 
was reacted with propionyl chloride to give the acylated Evans auxiliary 129 as a white solid in 
a 72% yield. The acylation of  (R)-4-benzoyl-2-oxazolidinone gave 130 in a 99% yield. 
 
Scheme 51 - Synthesis (2S,3R)-117. 
The second stage of the synthesis, the formation of the aldol 138 was problematic. The acylated 
Evans auxiliary 129 was reacted with acetaldehyde in the presence of dibutyl boron triflate and 
triethylamine (Scheme 51). Initial reactions carried out using the procedure described by Harris 
et al.
102
 were unsuccessful, with either very low or no formation of the desired product.  
Literature research identified that the purity and dryness of reagents was vital for a successful, 
high yielding reaction.
105, 119
 Triethylamine (NEt3) was dried over potassium hydroxide prior to 
use and stored under nitrogen in the presence of molecular sieves to ensure adequate dryness on 
use. Acetaldehyde was distilled from calcium hydride before every reaction. The purification of 
the commercially purchased boron triflate was deemed too hazardous due to the reagent’s 
exothermic nature.  
NMR analysis of the dibutyl boron triflate reagent was undertaken with the 
1
H NMR (Figure 38, 
A.) showing the one triple peak, indicative of a CH3 group at the end of the butyl chains. Two 
other proton environments were present, accounting for the three CH2 groups of the butyl 
chains. 
19
F NMR (Figure 38, B.) showed only one fluorine environment was present, and one 
environment was also detected in the 
11
B NMR (Figure 38, C.). If the product had degraded, a 
more complicated NMR spectra would have been expected. The reagent was deemed fit for 




Figure 38 – A, 
1
H NMR, 400 MHz, of dibutyl boron triflate reagent; B, 
19
F NMR, 300 MHz of dibutyl 
boron reagent; C, 
11




A reaction was carried out using a different aldehyde (Scheme 52). Benzaldehyde was chosen, 
as it possessed an aromatic ring, making it less volatile to handle and monitor the progress of 
the reaction via TLC. Benzaldehyde and NEt3 were distilled over calcium hydride and stored 
under an inert nitrogen atmosphere prior to use. The test reaction with benzaldehyde was 
successful and formed 163 but a subsequent reaction with acetaldehyde was poor yielding and 
with low stereo selectivity.  
 
Scheme 52 - Reaction scheme of Evans auxiliary and benzaldehyde. 
The Evans aldol reaction proceeds via a pseudo chair closed transition state (Scheme 40) and 
many variables need to be correct for the desired product to be formed. There are three variables 
that could result in the incorrect stereochemical outcome. The first is the formation of the 
enolate; it is possible that the temporary chiral enolate could take the E rather than the Z 
geometry, this would affect the α position.  
Secondly the aldehyde could approach the wrong face of the enolate, affecting the 
stereochemistry of the α and β positions. Finally, the aldehyde could orientate with the hydrogen 
in the equatorial rather than in the axial orientation. This would result in the wrong 
stereochemistry at the β position. It is most likely that the aldehyde would take the wrong 
orientation. 
When the aldol reaction was carried out using benzaldehyde only one stereoisomer was formed. 
Comparison of the literature NMR and the [α]D for syn and anti products confirmed the 
formation of the syn product (experimental:     
   +47.5 (c 1.0, CHCl3), syn lit: [α]D 70.4 (c 
1.04, CHCl3)
102
, anti lit: [α]D -8.6 (c 1.51, CHCl3)
120
). The benzaldehyde is a bulky reagent, so 
the steric clash from the desired orientation between the aldehyde and the Evans benzyl group 
would be highly unfavourable.  The acetaldehyde on the other hand, is a small methyl group. 
The steric repulsion between the aldehyde and the Evans benzyl group would be reduced, 
resulting in a greater likelihood of the wrong orientation occurring and a reaction taking place. It 
was found that the length of time the reaction was stirred before the addition of acetaldehyde 
was vital for high selectivity. Stirring the reaction mixture at -78 °C for 1 hour and then 100 
minutes at 0 °C before the addition of acetaldehyde, allowed the desired Z-enolate to form, 
resulting in an increased selectivity. 
71 
 
The Evans derivatives 129 and 130 were reacted with acetaldehyde in the presence of dibutyl 
boron triflate and trimethylamine to form the aldol (2S, 3R)-138 and (2R, 3S)-164 respectively. 
The oxazolidinone-directed aldol reactions resulted in high stereoselectivity. NMR was used to 
measure the d.r. of each compound, (2S, 3R)-138 was synthesised with a d.r. of 100:1 and 
(2R, 3S)-164 was synthesised with a d.r. of 100:3. The selectivity of these synthesise are 
comparable to those quoted in the literature by Evans et al. and Hayashi et al.
105, 107
 The      of 
the two aldol products were measured (2S, 3R)-138:     
   +48.8 (c 1.0, CHCl3) and (2R,3S)-164 
    
   -47.2 (c 1.0, CHCl3). Comparison of the measured      to the literature       values of 
the syn and anti products confirmed the formation of the syn aldol product (syn Lit. (2S,3R)-
129:     +51.1 (c 1.0, CHCl3),
102, 121
 (2R,3S)-164:      -58.8 (c 1.0, CHCl3)
122
 and anti 





Figure 39 - 
1
H NMR, 400 MHz, of (2S, 3R)-138 in CDCl3, 2-CH3 peak used to calculate d.r. 
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After the formation of the aldols (2S,3R)-138 and (2R,3S)-164, they were subsequently treated 
with tert-butyldimethylsilyl chloride to give the silyl ethers (2S,3R)-160 and (2R,3S)-165. The 
Evans auxiliary was cleaved in the presence of hydrogen peroxide and lithium hydroxide to give 
the acids (2S,3R)-161 and (2R,3S)-166. Acids (2S,3R)-161 and (2R,3S)-166 were treated with N-
acetylcysteamine in the presence of EDCI and DMAP to form (2S,3R)-162 and (2R,3S)-167. 
Removal of the protecting group was achieved by stirring (SR,3R)-162 and (2R,3S)-167 in the 
presence of acetic acid for 5 days giving the final compounds (2S,3R)-117 (Figure 40) and 
(2R,3S)-116.  No diastereomer was observable in the NMR of either compound. 
 
Figure 40 - 
1
H NMR, 400 MHz, of (2S,3R)-117 in CDCl3. 
2.5.2  Synthesis of triketide substrate mimic  
The results from the selectivity assays (discussed in chapter 4) show the SQTKS DH domain to 
be highly selective. It is probable that the DH would show the same selectivity towards 
triketides as was observed towards diketide substrate mimics, therefore only the triketide 168 
would be synthesised in order to test this theory. 
 
Figure 41 – triketide substrate mimic. 
Utilizing the camphorsultam 169 directed aldol reaction, synthesis of 168 was proposed, 




Scheme 53 – Proposed synthesis for 168. 
2.5.2.1 (4RS,3R,2R)-2,4-dimethyl-3-hydroxyhexanoyl-N-acetylcysteamine 178 
Initially the aldol reaction to form 170 was to be carried out using (2S)-methylbutyraldehyde 
171, unfortunately the compound was not available commercially, but it could be prepared by 
oxidising (S)-(-)-2-methylbutan-1-ol with TEMPO in the presence of KBr in water.
123
 However, 
isolation of the product in a dry enough state to allow the aldol reaction to occur proved difficult 
due to the volatile nature of the product. The aldol reaction was attempted using crude (2S)-
methylbutyraldehyde 171 in DCM, rather than isolating the product fully.  Attempts were made 
to dry the (2S)-methylbutyraldehyde 171/DCM solution prior to aldol reaction with MgSO4, but 
none of the required product 170 formed. 3 and 4 Å molecular sieves were also added prior to 
the aldol reaction, but again this led to none of the required product. In the interest of time, it 
was decided to carry out the aldol reaction step using racemic ±2-methylbutanal 173 (Scheme 
54).  
 
Scheme 54 – Synthesis of (3R,2R)-2,4-dimethyl-3-hydroxyhexanoyl-N-acetylcysteamine (2R, 3S)-178. 
 (1R)-(+)-Camphorsultam 172 was reacted with propionyl chloride to give acylated sultam 169 
in a 90% yield. Acylated sultam 169 underwent an aldol reaction with ±2-methylbutanal 173 in 
the presence of triethylamine and  titanium (IV) chloride to form 174 in 72% yield. The aldol 
product 174 was subsequently reacted with tert-butyldimethylsilyl triflate to protect the 
hydroxyl group and gave 175 in a 58% yield. The camphorsultam group was cleaved by stirring 
175 with hydrogen peroxide and lithium hydroxide in solvent to give the acid 176 in 56% yield. 
Acid 176 was reacted with N-acetylcysteamine in the presence to EDCI and DMAP to form 177 
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in 46% yield.  The removal of the TBDMS protecting group on 177 to give 178 was attempted 
using the gentle method used on diketide SNAC substrate previously, by stirring at room 
temperature in acetic acid. After 4 days, only a small amount of deprotected product was 
observed. Deprotection using p-toluenesulfonic acid (pTsOH) was also attempted, but was 
unsuccessful. Further methods of deprotection could not be attempted due to time constraints.  
2.6  Conclusion  
Six of the natural and non-natural diketide N-acetylcysteamine substrates were synthesised. The 
natural methylated SQTKS DH anti-substrate mimics, 114 and 115, were accessed using Fráter-
Seebach alkylation. The selectivity of the initial alkylation step to form (3R,2R)-142 and 
(3S,2S)-153 was found to be lower than reported in the literature (95:5) 
100
 with a selectivity of 
77:23 and 91:9 respectively. Although the selectivity of the alkylation step was lower than 
desired, over the course of the subsequent reactions, it was possible to separate the two 
diastereomers. The NMR of the final compounds showed only one diastereomer was present 
(2R,3R)-114 (Figure 34) and (2S,3S)-115 (Figure 36) and used in the assays discussed in 
chapter 4.  
The synthesis of the syn products, (2R,3S)-116 and (2S,3R)-117 using Evans auxiliary directed 
aldol reactions gave a greater selectivity towards the desired diastereomers of 99:1 and 97:3 for 
(2S,3R)-138 and (2R,3S)-164 respectively comparable to the literature d.r. of 98:2.
107
 Subsequent 
hydroxyl group protection and purification of compounds (2S,3R)-160 and (2R,3S)-165 allowed 
the unwanted minor diastereomer to be removed. There was no observable diastereomer visible 
in the NMR of the final compounds (2S,3R)-117 (Figure 40) and (2R,3S)-116 . Overall the 
yields for each stage of synthesis were acceptable, between 60 and 80%. The formation of the 
acids (2R,3R)-144, (2S,3S)-155, (3S)-179 and (3R)-158 were all lower than desired, with yields 
ranging from 36-44%.  
 




Synthesis of the triketide substrate mimic 168 proved more difficult. Initially the 
camphorsultam aldol reaction was attempted using (2S)-methylbutanal 171 but was 
unsuccessful. When the camphorsultam directed aldol reaction was carried out using racemic 
±2-methylbutanal 173, the reaction was successful. Cleavage of the auxiliary and coupling to 
the SNAC was achieved with no issues. The deprotection of 177 to afford the final compound 
178 proved problematic and none of the target compound 178 was isolated.  
2.7  Future work  
The diketide substrates were synthesised as N-acetylcysteamines. While this was suitable for 
assessing the selectivity and kinetics of the DH domain, discussed in detail in Chapter 4. 
Synthesis (2R,3R)-114 as a pantetheine derivative may allow a more accurate assessment of the 
KM of the DH domain. Further investigation into the correct conditions for the deprotection of 






Chapter 3 - Optimisation of DH protein expression  
3.1  Introduction  
Although there are many systems available by which it is possible to heterologously express 
protein, the bacterial system Escherichia coli. (E. coli) remains one of the most popular.
124
 E. 
coli is attractive as it is easy to genetically manipulate, inexpensive to culture and has the ability 
to undergo rapid growth.
125
  While there are many advantages to using E. coli to produce 
protein, there are also a number of disadvantages. The rapid growth allows proteins to be 
produced in one day, but the rapid production can result in unfolded, misfolded or partially 
folded insoluble protein due to the speed at which E. coli is able to transcribe and translate the 
target genes. A wide number of mutant host strains, cloning vectors and strategies have been 
developed to help overcome these difficulties. There are many parameters which can be varied 
in order to optimise an expression protocol, these include cell strain, media composition and 
growth conditions.  
In the initial stage of protein production, the genes of interest are cloned into a plasmid 
containing an antibiotic resistance gene and T7 RNA promoter.
126
 The T7 promoter contains a 
lac operon which allows expression of the desired protein to be controlled by the addition of 
lactose or Isopropyl β-D-1-thiogalactopyranoside (IPTG). The second stage involves the 
transformation of the plasmid into the desired E. coli strain. The presence of an antibiotic 
resistance gene allows selection of correctly transformed E. coli.. Routinely E. coli BL21 and 
K12 or their derivatives are used for protein expression.
124
  In the final stage, the transformed E. 
coli is grown and the protein expression induced, before harvesting the cells and extracting the 
protein.  
There are many examples in literature, of isolated DH domains which have been produced as 
soluble active proteins using a range of cell strains and growth conditions. Borrelidin DH2 was 
produced using E. coli BL21 (DE3)-CodonPlus RP cells, grown in 2TY media, with the 
expression of the protein being controlled by IPTG.
60
 The DH domains from  Pikromycin DH, 
(PikDH2),
67
 Curacin DH domains (CurF, CurJ, CurK, CurH)
17





 have all been expressed using the E. coli BL21 (DE3) cell strain. 
PikDH10 and the curacin DH domains used TB media,
17, 67
  while RifDH10 and ErDH4 were 
cultured in LB media.
6, 13
 Protein expression in all of these examples was induced by various 
concentrations of IPTG.  
3.2  Previous work 
Previous work, undertaken by David Ivison, investigated the possibility of isolating the 
individual catalytic domains from SQTKS and producing them as isolated proteins.
95
 SQTKS 
was systematically dissected to give constructs of isolated catalytic domains such KR and DH 
or groups of domains such as KR-ACP or KS-AT-DH. In total 22 plasmids containing these 
78 
 
constructs were produced and subjected to high throughput screening to identify which domains 
expressed as soluble protein. One of the isolated domains to be expressed as soluble protein in 
reasonable amounts, was construct #7615, SQTKS DH.
95
  
Expression of the Construct #7615 was scaled up in order to isolate enough protein to carry out 
assays to assess the isolated domain’s activity. The construct was transformed into E. coli 
BL21(DE3) and grown on 2TY media. Following IPTG induction at 16 C overnight, cells were 
harvested and lysed by sonication. The SQTKS DH was isolated and purified. Once pure, the 
protein was incubated with racemic 2-methyl-3-hydroxy-SNAC 111, and the domain was found 
to be biochemically active. Full details of this assay and subsequent assay work is detailed in 
chapter 4. To explore the programming of the SQTKS DH domain it was vital that sufficient 
quantities of soluble active protein could be produced. Although the SQTKS DH had previously 
been produced, there was much scope in the protocol for optimisation. 
3.3  Results 
3.3.1  Optimisation of expression strain and media 
When over expressing protein in E. coli there are two commonly encountered problems: poor 
expression and insoluble protein.
124, 127
  The work investigating the DH domain encountered 
many of these problems, this set of experiments investigates both strain and medium. 
A number of bacterial host strains have been developed to help overcome many of the issues 
encountered when heterologously expressing protein.
125
  The E. coli BL21 strain and its many 
derivatives are routinely used to express protein on an industrial scale.
125, 127
 This strain and its 
derivatives are lon and ompT protease deficient, this genetic mutation gives increased protein 
stability.
127
 Lon protease, also known as protease La, is a homo-oligomeric ATP-dependent 
protease.
128
 Its main function is to act as a quality control protease, degrading misfolded or 
recombinant proteins.
129
 OmpT is also a housekeeping protease, which degrades endogenous or 
fusion proteins which come into contact with the outer membrane.
130
 Work by Gottesman et al. 




A common reason heterologous expression fails is the presence of codons in the target’s mRNA 
which are used infrequently by E. coli. The presence of rare codons such as arginine (AGA, 
AGG) and isoleucine (AUA) can cause translational stalling which can result in low expression 
of proteins or expression of truncated protein. Two approaches can be taken to overcome this 
problem. Firstly, it is possible to quantify the number and the locations of rare codons using 
websites such as RaCC (the rare codon calculator; http://nihserver.mbi.ucla.edu/RACC). This 
allows genes to be “codon optimized” where rare codons are replaced with codons more 
commonly found in the host, either by site directed mutagenesis or gene synthesis. The second 
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approach is to modify the expression host. Alternative E. coli. strains are available which can 
co-express genes encoding for rare tRNAs, for example Rosetta cells from Novagen.  
An initial cell screen was carried out by Dr Alan Scott to identify a suitable strain. The cell 
screen showed that both the BL21 (DE3) and Rosetta (DE3) strains produced the DH protein. 
The level of expression in each strain was comparable. The expression construct contained the 
native fungal sequence and had not been codon optimised. It was decided to proceed using the 
E. coli. Rosetta (DE3), as this strain encodes a number of rare codon tRNAs.
125
 Further work 
with the Rosetta (DE3) strain encountered a number of issues; the two main problems were 
inconsistent growth of cultures and low or inconsistent expression of soluble protein. 
It was thought that the inconsistent growth of cultures could be due to several reasons. Loss of 
the plasmid from the transformed E. coli cell would result in loss of antibiotic resistance and 
subsequent cell death. The protein produced could be toxic to the E. coli causing cell death. 
Although the plasmid has been designed to only express the protein under certain induced 
conditions, some background expression may occur. Background expression of the protein 
would result in less than optimal growth of the E. coli if the protein were toxic, as cell death 
would occur during the growth phase of the culturing.  
In order to try and overcome these problems a number of expression trials were undertaken. The 
effect of cell strain, media, growth conditions and antibiotic loading on protein production were 
investigated (Figure 43).  
The following cell strains were trialled: Rosetta, JM109, BL21 (DE4), C43(DE3) and BL21 
(DE3) CodonPlus – RP. C43(DE3), a mutant strain of E. coli BL21(DE3), was chosen as it has 
frequently been used to overcome toxicity associated with over expression of proteins using a 
T7 RNA polymerase expression system.
131
 BL21 (DE3) CodonPlus - RP strain was chosen as it 
is optimised for expression of proteins which contain rare codons, not normally found in E. coli. 
Unlike the Rosetta strain, which is codon optimised for arginine (AGG/AGA, CGS), isoleucine 
(AUA), leucine (CUA), proline (CCC) and glycine (GGA), BL21(DE3) CodonPlus – RP is 
optimised for arginine (AGG, AGA) and proline (CCC). 
The standard expression protocol, detailed in Section 7.37.3, was followed using IPTG (final 
concentration, 0.4 mM) to induce expression. Non-induced conditions were also trialled, the 
standard expression protocol was followed and incubated at 37 °C with shaking until the OD600 
reached 0.6. Once the appropriate OD600 had been reached, the temperature of the culture was 
then adjusted to the expression temperature of 19 °C and no induction agent added.  
The investigation trialled Rosetta in rich medium (enriched with metal salts and other 
additives), as it was thought it would help improve the growth of the E. coli, allowing a higher 
cell density to be reached, leading to an increased yield of protein. All other cell strains were 
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grown in 2TY media under the following conditions: standard conditions, low antibiotic 
loading, additional antibiotic loading and media exchange.  
As toxicity of over expressed protein is a common problem it was decided to trial media 
exchange as a way of overcoming this problem. Media exchange conditions consisted of the 
production culture being grown at 37 °C to an O.D600 of 0.6. The cells were then harvested 
gently and suspended in fresh production media. Expression of the culture was then induced 
with IPTG and the incubation temperature reduced to 19 °C. The exchange of media before 
induction allows the removal of any toxins which may have built up in the media during the 
initial growth of the cells. Glucose was added to the media to reduce the level of background 
protein expression as it prevents the activation of the T7 promotor. 
In order to overcome the potential loss of the plasmid from the transformed cells and therefore 
subsequent loss of antibiotic resistance, growth conditions involving high loading of 
carbenicillin (0.5 mM) and low loadings of carbenicillin (0.2 mM) were trialled.
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 In addition, some flasks were topped up with additional antibiotic. Additional antibiotic 
conditions consist of the production culture being grown at 37 °C to an O.D600 of 0.6. 
Expression of the culture is then induced with IPTG and the incubation temperature reduced to 
19 °C. Upon induction an additional 200 µl of 0.2 M carbenicillin stock was added to 200 mL 
flasks of low antibiotic loading, final carbenicillin concentration was 0.4 mM. 500 µl of 0.2 
carbenicillin stock was added to 200 mL flasks of high antibiotic loading final carbenicillin 
concentration was 1.0 mM.  
The range of cell strains selected were transformed with the plasmid #7615. All strains were 
transformed successfully and grew well on LB Glu/Carbenicillin plates apart from BL21 (DE3), 
where no colonies were observed. Single colonies from each successful transformation were 
used to inoculate 50 mL LB Starter cultures with a high (0.5 mM) or low (0.2 mM) loading of 
carbenicillin. All the starter cultures grew well apart from E. coli C43 strain, which had no 
growth. 
Starter cultures were used to inoculate flasks of 2TY media and subjected to different growth 
conditions. A sample of each culture was taken and the cells lysed allowing analysis of the 
soluble and insoluble fractions to take place (Figure 43). The over expressed DH protein was 
expected to have a size of approximately 38 kDa. Analysis of the soluble and insoluble fractions 
by SDS PAGE gel show a band at approximately 38 KDa in both the soluble and insoluble 
fractions.  
Of all the cells screened, the BL21(DE3) codon plus were the most suitable to take forward for 
further optimisation. The cells grew well, gave good production of the protein in all conditons 
and tolerated high loadings of antibiotic. As the variations of growth conditions showed no 
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major difference in the levels of production, the standard growth conditions were taken forward. 
These conditions were also the easiest to reproduce accurately in future trials. As the cells were 
able to tolerate the higher antibiotic loading subsequent trials were carried out using an 
antibiotic loading of 200 µl of 100 mg/ml carbenicillin stock per 200 mL flasks. 
 
Figure 43 – A. SDS PAGE gel showing the levels of soluble and insoluble protein expressed by Rosetta 
and JM109 E. coli strains; B-D SDS page gel showing the levels of soluble and insoluble protein 




3.3.2  Optimisation of expression growth conditions  
In addition to poor expression, insoluble protein is a commonly encountered problem during 
protein over expression in E. coli, with more than 30 % of the proteins expressed appearing 
insoluble.
127
 The main purpose of protein expression is to accumulate a significant amount of 
soluble protein within the cell. Unfortunately, it is common for protein to be misfolded during 
over expression, leading to insoluble aggregates known as inclusion bodies. Non-optimal 
conditions during expression can also lead to difficulties when purifying, storing and handling 
the protein, such as precipitation.
133, 134
  
Once the BL21(DE3) codon plus strain had been identified as a suitable expression host, it was 
possible to optimise conditions to increase the amount of soluble protein expressed by the E. 
coli. The solubility of proteins can be improved by changing expression conditions.  
Lowering the expression temperature causes the cell processes to slow down, resulting in a 
reduction in aggregation of protein.
135, 136
 The rates of transcription, translation and cell division 
are also slowed down resulting in a reduction in the rate of protein synthesis, necessitating the 
need for longer induction times.
137
  
A cheap and easy way of improving the solubility of an expressed protein is to optimise the 
culture media. In some cases the concentrations of certain salts, peptone and yeast can increase 
the concentration of soluble protein.
127
 Although it has been reported that the increase in protein 
concentration is due to higher biomass of the culture;
138
 rather than the media composition 
having any major effect on the proteins inherent solubility. Luria broth (LB) is the most 
commonly used media, composed of bactotryptone, yeast extract and sodium chloride.
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Terrific broth (TB) has been formulated to increase the yield and solubility of the expressed 
protein. 
Culture conditions also play a large role in achieving high protein expression;
127
 the formation 
of inclusion bodies can be limited or avoided by reducing the rate at which a protein is 
synthesised. There are a number factors which are tuneable; the cell density before induction 
can play a major role in achieving good protein solubility. Protein expression is generally 
induced during the mid-log phase of the cell growth although it can be done at a later stage.   
Another way of slowing the synthesis of protein is to tune the level of induction by altering the 
concentration of inducer used.
125
 Although if the concentration of inducer is too low, ineffective 
induction of expression will result in low yields of protein. There are no hard or fast rules to 
finding the optimum post induction temperature or duration, so trial and error must be used. 
To investigate the effect of media composition on expression levels, BL21 (DE3) codon plus 
was transformed and grown in a range of different media under induced and non-induced 
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conditions (Figure 44). Five different media were chosen as potentially suitable candidates; 
2TY, 2TY enhanced (2TYE), terrific broth and terrific broth enhanced and Auto induction 
LB5052. Enhanced media contained additional metals and salts.  Induction when needed was 
induced with 0.4 mM IPTG. Auto induction was not trialled under induced and non-induced 
conditions as the media contains glucose and lactose. The presence of glucose inhibits 
expression, whereas the lactose induces expression. The E. coli preferentially consume the 
glucose first, then the lactose. This leads to a gentle gradual induction of expression.  
The induction temperature in the standard expression protocol, (Section 7.3) was 19 °C to slow 
down protein production and improve solubility. The temperature after induction was also 
decreased from 19 °C to 16 °C in order further decrease the rate of protein production and 
reduce the chance of misfolded insoluble protein forming. 
 
Figure 44 - SDS page gel showing the levels of soluble and insoluble protein expressed by BL21(DE3) 
codon plus  in different media under induced and non-induced conditions, 
Protein was produced in 2TY under induced and non-induced conditions, although it was 
predominantly insoluble in both conditions. A lower amount was expressed by 2TY 
non-induced as expected. There was no expression in 2TYE and terrific broth enhanced media 
under induced and non –induced expression conditions.  Terrific broth enhanced media gave a 
large amount of insoluble protein under induced conditions. Under non-induced conditions, 
terrific broth enhanced had a reasonable amount of soluble expression. Auto induction media 
was by far the most suitable for over expression of the DH protein; giving a reasonable amount 
of soluble protein.  
The Auto induction medium conditions were taken forward and trialled on a larger scale to 
assess their suitability for large scale production. A total production culture of 2 litres was 
grown, all cultures grew well, and the cells were harvested and purified giving a total of 5 mg of 
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protein. While 2.5 mg of protein per litre is lower than desired, it can be scaled to provide the 
required amount of protein for assay. 
3.3.3  Degradation of protein 
During the scale up of Auto induction conditions, four protein bands of substantial size were 
observed (Figure 45). Two corresponding to the expected weight of the DH protein, 
approximately 38 kDa, and two approximately 25 kDa in size. Typically, with over expressed 
proteins, only one band corresponding to the appropriate molecular weight is observed on the 
SDS page gel in addition to the weaker E. coli protein bands. MALDI protein mass 
spectrometry was carried out on the protein bands in order to identify the origins of the bands 
(Figure 46, Figure 47, Figure 48 and Figure 49). 
 
Figure 45 - SDS page gel showing protein bands expression by BL21(DE3) codon plus cells after Ni 











Figure 46 - DH band 1 MALDI Result: DH-7615 pOPIN-F Amino Acid Sequence, found peptide 
fragments shown in red. 







Figure 47 - DH band 2 MALDI Result: DH-7615 pOPIN-F Amino Acid Sequence, found peptide 
fragments shown in red. 







Figure 48 - DH band 3 MALDI Result:  DH-7615 pOPIN-F Amino Acid Sequence, found peptide 
fragments shown in red. 





Figure 49 - DH band 4 MALDI Result: catabolite activator [Escherichia coli] 23.77 kDa, found peptide 




Analysis of MALDI spectra for each band allowed the identification of each protein. Fragments 
of peptide corresponding to the DH domain were found in three of the four bands. The above 
figures (Figure 46, Figure 47, Figure 48, Figure 49) show the amino acid sequence and the 
peptide fragments found for each protein band identified.  
As three of the four bands of peptide fragments correspond to the DH protein, the DH protein 
must have been undergoing degradation at some point during the growth and purification 
process. The DH band 1(Figure 46) appears to be the full length protein; whereas DH band 2 
(Figure 47) appears to be truncated at the N-terminus as the end sequence fragment is present. It 
is unclear whether the DH band 3 is truncated at the N or C terminus due to the fragmentation 
pattern (Figure 48). DH band 4 is an unrelated E. coli band (Figure 49).  
The degradation of protein was most likely to be occurring during purification. Although the 
BL21 (DE3) codon plus cells are deficient in lon and ompT proteases, when the cells are lysed 
the protein can come into contact with other proteases present within the cell. If the degradation 
was being caused by additional proteases present within the cell, the use of a protease inhibitor 
cocktail during purification would prevent this degradation from occurring.  
 
Figure 50 – SDS page gel of protein expressed and isolated from BL21(DE3) codon plus without the 
presence  of a protease inhibitor cocktail and  SDS page gel of protein expressed and isolated from 




Although the use of a protease inhibitor cocktail decreased the level of degradation in the 
expressed protein (Figure 51), it did not fully eliminate it and two bands of DH protein were 
still observed. Alternative cell strains  (BL21 (DE3), BL21 (DE3) codon plus, KRX) were 
investigated (Figure 51). BL21 (DE3) and BL21 (DE3) codon plus are both deficient in lon and 
ompT proteases whereas KRX single step cells are deficient in ompP and ompT proteases.
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Over expression of protein in KRX is induced by the addition of rhamnose as the strain 
processes a chromosomal copy T7 RNA polymerase gene which is driven by a rhamnose 
promoter. 
Protein was over expressed by all three strains, BL21 (DE3) and BL21 (DE3) codon plus strains 
had higher levels of expression but the degradation of protein persisted in these strains. 
Although the level of expression by the KRX cells was very low, there appeared to only be one 
band of DH protein present in the soluble and insoluble fraction.  
 
 
Figure 51 – A, SDS page gel showing the levels of soluble and insoluble protein expressed by protease 
deficient cell strains: BL21(DE3), BL21(DE3 codon plus and KRX ; B, SDS page gel showing the levels 
of soluble and insoluble protein expressed by KRX during optimisation of growth conditions. 
 
As degradation of the protein occurred in the BL21 (DE3) and BL21 (DE3) codon plus strains, 
further optimisation of the KRX growth conditions was undertaken investigating  the effect of 
media and induction conditions  (Figure 51, B). IPTG was also added to all growth cultures as 
recommended by the technical literature supplied by Promega. The DH expression vector uses a 
lac operator which is adjacent to the T7 promoter, therefore IPTG may be required to achieve 
maximal expression. KRX cell expressed well in all media conditions, however the majority 
was insoluble, and degradation of the protein had occurred in both the soluble and insoluble 
phase. Subsequent trials utilising lower concentration of rhamnose were carried out to slow 
down the rate of protein production and therefore aid solubility. However, it was found upon 
induction that the protein expressed was toxic to the cells. 
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A time course was carried out using the BL21 (DE3) strain to give more information as to when 
the protein degradation was occurring. Samples of the culture were taken at regular time points 
and the crude, soluble and insoluble fractions analysed by SDS page gel.  
After 4 hours, over expression of the DH protein starts to occur in the soluble fractions although 
there are greater amounts of protein in the insoluble phase, which had undergone degradation 
(Figure 53). Degradation was observed in the soluble fraction after nine hours of incubation.  
In a final attempt to overcome the degradation of protein during expression, a trial using the 
E. coli BL21 Gold (DE3) strain was carried out. BL21 (DE3) was also used as a comparison. 
This was grown to stationary phase overnight at 30 °C with shaking. As the BL21 Gold (DE3) 
strain had not been grown before, different media (auto inductions, LB) and growth conditions 
(induced and non-induced) were used (Figure 52). It was found that protein was expressed by 
BL21 Gold (DE3) cells under all conditions. It was observed that protein degradation was less 
apparent in the BL21 Gold (DE3) strain when grown in LB media. A large scale production 
culture of 4.8 litres was carried out using BL21 Gold (DE3). The production culture grew well, 
and the cells were harvested and purified. A total of 44 mg of pure, soluble DH protein was 
isolated, while 9 mg/L is not an ideal quantity, the production is scalable to allow adequate 
amounts of protein to be produced for the required analysis. 
 










3.3.4  Optimisation of buffers and purification protocol 
The plasmid #7615 designed by David Ivision included a vector coding for N-terminal 
hexahistidine tags (His-Tag).
95
 The presence of the His-Tag allows the over expressed protein to 
be easily purified from the bulk of the  E. coli proteins.
140
 This is achieved due to the high 
affinity of the His-Tags for Ni
2+
. The protein is purified by passing the lysed cells through a 
nickel-sepharose high performance column, the His-Tag of the over expressed protein of 
interest interacts with the metal ions in the column matrix causing it to bind. The bulk bacterial 
proteins do not bind and are not retained on the column. Once the unwanted protein has been 
washed though the column using a binding buffer, the protein of interest can be eluted by a 
solution of imidazole in an elution buffer. Further purification can be carried out using a FPLC 
S300 size exclusion column to separate the proteins by size. 
A number of issues were encountered during the optimisation of protein purification. The 
degradation of protein during purification required the addition of a protease inhibitor cocktail 
to the loading buffer to limit the extent of the degradation (Section 3.3.3).  
Achieving the desired level of purity from the Ni
2+
 column required some alterations in protocol 
from that used by David Ivision.
95
 Initially a ready to use 5 mL HisTrap Fast Flow column from 
GE was being used. Although the column was reported to have a high binding capacity, large 
amounts of soluble protein were lost from the Ni
2+
 column. A larger Ni
2+
 sepharose fast flow 
column of 25 mL was prepared using Ni
2+
 sepharose 6 fast flow BioProcess medium. This 
increase in size allowed greater volumes of lysed cell to be passed though the column without 
losing the desired over expressed protein due to overloading.    
While increasing the loading capacity of the Ni
2+
 column reduced the amount of over expressed 
protein from being lost, it also increased the amount of unwanted bacterial protein retained on 
the column. Increasing the concentration of imidazole present in the binding buffer from 5 mM 
to 20 mM dramatically increased the level of purity obtained. A high enough level of purity was 




Figure 54 – Purification factions using 25 mL Ni
2+
 sepharose fast flow column 
Once pure protein has been produced in a soluble form, concentrating it to the desired level 
without causing precipitation or aggregation can be highly problematic and a common 
stumbling block.
134
 It is estimated that 33 – 55 % of all expressed non-membrane proteins are 
not soluble and up to 50 % of the remaining soluble proteins aggregate or precipitate during 
concentration.  During purification of the DH protein, the problem of precipitation was 
encountered. It was found that after elution from the Ni column, the protein tended to precipitate 
immediately or soon after.  
It was noticed that the protein had a low tolerance for high concentration of imidazole. This 
issue was overcome by eluting the His-Tag protein slowly using a gradient change in the 
concentration of imidazole, thus eluting the protein at lower imidazole concentrations. After the 
protein had been eluted from the Ni column, it was concentrated and passed through a desalting 
column to remove the imidazole and reduce the risk of precipitation caused by high salt levels.  
Alongside the change in elution method, the buffer conditions were screened to establish which 
afforded the best solubility.
134
 Previously the buffers were composed as follows; Binding buffer 
contained 20 mM Tris-HCl pH 8, 150 mM NaCl, 5 mM imidazole, 10 % glycerol; Elution 
buffer contained 20 mM Tris-HCl pH 8, 150 mM NaCl, 400 mM imidazole, 10 % glycerol; 
Desalting buffer contained 20 mM Tris-HCl pH 8, 150 mM NaCl, 10 % glycerol. 
It is widely accepted that addition of additives, such as ionic compounds, salts detergents etc. 
can increase the solubility and stability of protein.
141
 A simple screening of buffers and additives 
was carried out using a hanging drop experiment using a 16 well plate. The buffer and additives 
detailed in the JBS solubility kit available from Jana bioscience were used as guide for selecting 





pH buffers ranging from pH 4-10, salt concentrations, buffer type and some additives were 
screened (Table 1). The DH protein has a predicted isoelectric point of 6.93, therefore buffers 
with a pH close to pH 7 should be avoided. The wells were inspected regularly over a 24-hour 
period.  
Buffer Additive 
Sodium acetate pH 4.7 40 % Glycerol 
Sodium phosphate pH 5 10 mM DTT 
Potassium phosphate pH 6 1 M NaCl 
Tris  HCl pH 8.5 100 mM L-Arg & L-Glu 
CHES pH 9  
CHES pH 10  
Table 1 -  Buffers and additives used in initial screen. 
After 24 hours high level of precipitation was observed across all buffers in wells containing 
40% glycerol and 1M NaCl, making these two additives the least suitable.  
At pH 8.5 and pH 10 DTT was not suitable with precipitation occurring very quickly, within the 
first hour. However, at pH 4 and 5, protein precipitation was much slower with visible 
quantities of protein forming after 4 hours. 100 mM L-Arginine and L-Glutamic acid was found 
to be the most suitable additive, improving the proteins solubility and stability at pH 4, 5 and 
8.5, with no precipitate forming after 24 hours. It was decided that the most suitable buffer 
composition for protein storage were as follows: binding buffer:10% glycerol, 50 mM Tris  HCl 
pH 8, 150 mM NaCl and 100 mM L-Arginine and L-Glutamic acid per L.  
3.4  Crystallisation 
David Ivision attempted to crystallize the DH protein using four commercial crystallisation 
screens: Structure screen 1 + 2HT-96, JCSG+ HT96, PACT premier HT-96 and Morpheus HT-
96 (all from Molecular Dimensions).
95
 Sitting drop crystallisation trays were set up using an Art 
Robbins Pheonix crystallisation robot and incubated at 20 °C for several days. Inspection of the 
trays showed heavy precipitate but no defined crystals.  
The four commercial crystallisation screens were repeated using DH protein stored in the 
optimised buffer. Sitting drop crystallisation trays containing 50 µl well solution and 0.1 µl well 
solution + 0.1 µl protein solution were set up using an Art Robbins Pheonix crystallisation robot 
and incubated at 20 °C. After 7 days the trays were inspected and showed precipitation in most 
drops. No further attempts to crystallise the DH domain were undertaken. 
3.5  Conclusion 
After optimisation of the expression conditions, it was possible to isolate approximately 10 
mg/L of soluble active SQTKS DH protein. The optimisation of the purification and storage 
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buffers allowed the purified DH protein to be stored at 4 °C for up to 2 months without 
precipitation.  
The optimised protocol was as follows: E. coli BL21 Gold (DE3) was used as a host for protein 
expression. Following transformation with the appropriate expression plasmid using LB-
Glu/Car agar plates, a single colony was used to inoculate a 50 mL sterile LB starter culture 
medium containing 0.2 mM carbenicillin. This was grown to stationary phase overnight at 30 
°C with shaking.  This starter culture was used to inoculate LB medium supplemented with 
carbenicillin at 1:100 dilution in 500 mL flasks each containing 200 mL of LB medium. The 
flasks were incubated at 37 °C with shaking till an OD600 of 0.4 was reached. The temperature 
of the culture was then adjusted to the expression temperature of 16 °C. Induction when needed 
was induced with 0.4 mM IPTG. The cultures were incubated with shaking for a further 6 hours 
and cells were harvested by centrifugation. The cell pellets suspended in binding buffer 
containing protease inhibitor cocktail and were refrigerated overnight before being purified the 






Chapter 4 - Investigating the Selectivity and Kinetics 
of the Isolated SQTKS DH Domain 
4.1  Introduction  
While it is possible to carry out assays using acyl-ACP species as substrates for PKS enzymes, 
there are many problems associated with their use.
104
 One such difficulty is producing a 
sufficient quantity of ACP to carry out a kinetic assay.
104
 Also assays involving ACP bound 
substrate mimics typically require a TE domain or complex time consuming procedure to 
release the enzymatic product.
104
 As there is no release activity observed for the SQTKS system 
stoichiometric amounts of ACP would be required. For example, carrying out kinetic assays 
utilizing the SQTKS ACP would require 150 - 200 mg of protein per substrate. This amount is 
calculated assuming the KM is 1 mM and the assay volume is 50 µL. The SQTKS ACP is 10 
KDa, and assuming the KM is 1 mM, results in the need to test concentrations of substrate up to 
10 mM, and would result in a maximum of 5 mg of protein per assay. Typically kinetic assays 
are repeated in triplicate to ensure accuracy and repeatability. Previous attempts to produce the 
SQTKS ACP by David Ivision resulted in no soluble protein.
95
  
While the substrate specificity of many PKS DH domains has been interrogated using ACP 





 utilised ACP bound mimics as well as simple diffusible substrates. 
The investigation into Pikromycin DH (Pik2DH) carried by Wu et al. utilised only diffusible 
substrates.
65
 N-Acetylcysteamine (SNAC) or pantetheine based substrate mimics have also been 
used in multiple studies of other PKS enzymes.
13, 65, 67
 These simple mimics are able to diffuse 
into the active site of the domain.
67, 104, 142
 While using diffusible substrate mimics has its 
advantages, there are also some disadvantages; for example the protein-protein interaction 
between the ACP and the catalytic domain might be vital to achieving substrate fidelity.
65
  
Work by Keating-Clay and co-workers investigating the stereoselectivity of the rifamycin DH, 
Rif10DH, highlighted the impact protein-protein interactions have on substrate fidelity (fully 
discussed in Chapter 1, Section 1.5.7).
13
 The stereoselectivity of Rif10DH altered depending on 
whether the substrate was diffusible or attached to the native or a non-native ACP. When 
diffusible SNAC or pantetheine (Pant) based substrates were incubated with the Rif10DH the 
DH domain exhibited high selectivity towards substrates with 2R,3R stereochemistry 73 and 74. 
When the substrate was bound to the native ACP, Rif10ACP selectivity favoured the 2S,3S-2-
methyl-3-hydroxypentanoyl stereoisomer 83. When bound to the non-native ACP, Ery6ACP, 
the stereoselectivity again reversed and only the 2R,3R-2-methyl-3-hydroxypenanoyl-Ery6ACP 
88 substrate was accepted. 
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While diffusible substrate mimics have been successfully used to interrogate the substrate 
specificity of excised DH domains,
13, 65, 67
 very little work has been carried out using these 
mimics to investigate the steady state kinetics of isolated DH domains.
67
 Typically isolated DH 
domains have low activity and therefore require long assay incubation times in order to generate 
sufficient product for detection.
13, 67, 104
   
Li et al. utilised liquid chromatography-tandem mass spectrometry (LC-MS/MS) to carry out 
steady state kinetics on the pikromycin DH domain, Pik2DH.
67
 Their previous work carried out 
on the Pik2KR domain showed that LC-MS/MS was highly selective and sensitive to DH 
substrates and products and therefore was deemed suitable for the analysis of DH substrate 
turnover.
67, 104
 A multi-domain construct was built, (Pik2KR-DH) in order to achieve a more 
native environment for the assay. After overexpression and purification of the protein a range of 
assays were carried out in order to probe the selectivity of the active site.  
 
Scheme 55 – A, Natural PikDH2 substrate 179 and product 180; B, rational design of PikDH2 substrate 
181 mimics to inhibit lactonisation and product 182. 
The simple diffusible SNAC based substrate 181 was used for the assay (Scheme 55, B). The 
substrate mimic was based on the natural product triketide 179 with two differences. First, the 
native ACP-phosphopantetheine arm was replaced by SNAC; second, either a one or two 
carbon methylene spacer was introduced between the carbonyl and the sulfur group to inhibit 
lactonisation.  
Work carried out by Wu et al. examining the kinetic characterisation of dehydratase containing 
pikromycin module 2 (Pik2) utilised TLC phosphor-imaging to quantitatively measure substrate 
turnover.
65
 The aim of the study was to investigate the kinetic selectivity of Pik2DH when part 
of a complete module rather than as an isolated domain. The diketide substrate 183 was 
incubated in the presence of malonyl-CoA, and the module was able to carry out chain 






Scheme 56 – Enzymatic conversion of diketide 183 to triketide 184 by Pik module 2 + TE 
The kinetic characterisation assay required diketide substrate 183 to be incubated at 30 °C for 
40 minutes in the presence of 
14
C-malonyl-CoA, NADPH and Pik2 + a TE domain. The reaction 
was quenched by adding 1 M HCl and subsequently extracted using ethyl acetate (3 x 180 µl). 
The extract was dried and redissolved in ethyl acetate (30 µl), spotted on to TLC plates and 
developed using dichloromethane, 5% methanol and 0.1% acetic acid. The samples were 
analysed by phosphor-imaging, using a known concentration of 
14
C-malonyl-CoA as a standard. 
The use of phosphor-imaging is ideal for monitoring this type of reaction where a whole module 
is being investigated, as chain extension allows the installation of 
14
C. Phosphor-imaging is not 
suitable for studying a DH domain in isolation, as the dehydration reaction only results in the 
loss of water, so radio-labels cannot be incorporated. 
4.2 Michaelis-Menten kinetics   
The model which describes the rate of enzyme catalysed reactions was developed by Michaelis 
and Menten in 1913.
143
 Their work on invertase showed that the rate of an enzyme catalysed 
reaction is proportional to the concentration of the enzyme-substrate complex. The model 
developed by Michaelis et al. makes two assumptions: first the enzyme (E) and substrate (S) 
make a reversible complex (ES); and, second, that the reversible complex (ES) irreversibly 
yields the product (P, Scheme 57) 
 
Scheme 57 – The progress of a Michaelis-Menton enzyme catalysed reaction.  
The rate at which a substrate associates and binds to an active site is described by k1. The 
dissociation rate is described by k-1. Together these two rate constants describe how well a 
substrate binds to the active site. Substrates with a larger k1/k-1 value will bind more strongly to 
the active site.  
kcat is usually the rate limiting step, by which the enzyme transforms the substrate into the  
product (P). The efficiency of an enzymatic reaction is defined by the two parameters k1/k-1 and 
kcat.  The Michaelis-Menten equation (Eq. 1) is derived from this simple model by extrapolating 
the equations. In order to do this the steady state approximation is applied, this approximation 
assumes that the concentration of the ES complex is constant.   
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 Eq. 1 
 
Where ν0 is the initial rate of reaction, obtained when there has been no appreciable decrease in 
substrate or formation of product.  Vmax is the maximum rate of reaction the enzyme can 
achieve. This is where the concentration of substrate is so great that all the enzyme is in the ES 
state. The final term KM is the Michealis Constant, which represents the substrate concentration 
when the rate of reaction is half the rate of Vmax (Figure 55).  
When the enzyme concentration is kept constant and the concentration of the substrate 
increases, the overall rate ν0 will increase in a near linear fashion as long as the substrate 
concentration is well below KM. As more substrate is added, there is more substrate available to 
bind to the active site of the enzyme and therefore the concentration of the enzyme-substrate 
complex (ES) increases.  
 
Figure 55 – Plot of initial rate against substrate concentration in a theoretical enzyme reaction 
demonstrating Michaelis-Menton kinetics. 
At very high concentrations of substrate, much greater than KM, there is less free enzyme in 
solution due to the substrate binding to the enzyme to form the ES complex and the increase in 
the rate is no longer linear. As previously stated, when the rate of reaction is at Vmax, the 
substrate concentration [S] is so high there is no free enzyme, as all the enzyme is occupied in a 
ES complex. It is therefore possible to describe Vmax as follows in Eq. 2. Substrates which bind 
strongly to the active site will have a higher concentration in solution, therefore they will 







              Eq. 2 
It is possible to define the concentration of substrate and ES as follows: 
              
         
  
 Eq. 3 
 
The Michealis constant, KM, is the substrate concentration at which the rate is half of Vmax. It is 
therefore possible to define KM in a way which is directly relatable to k1 and k-1  (Eq. 4). 
    
         
  
 Eq. 4 
 
KM describes the affinity a substrate has for binding to an enzyme. A substrate with poor 
binding affinity would result in a higher KM value. A substrate with a high binding affinity 
would have a low KM value. While KM describes the binding affinity of a substrate, kcat 
describes, the second stage of the enzyme reaction, how quickly the substrate is converted to the 
product. Using these two parameters it is possible to describe how efficiently a particular 
substrate is processed by a particular enzyme. 
                       
    
  
 Eq. 5 
 
The enzymatic efficiency had been investigated in a number of DH domains.  In order to 
investigate the stereoselecity of the SQTKS DH a set of assays were undertaken to measure kcat 
and Vmax for each of the possible four substrates.  
4.3  Results 
4.3.1  Assay development  
4.3.1.1 Previous work on SQTKS DH domain 
Initial work by David Ivison, (Section 1.6.2), produced SQTKS DH as a standalone protein.
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The newly isolated DH domain (132 µM) was incubated with a racemic mixture of 
stereoisomers 2-methyl-3-hydroxybutanoyl-SNAC 111 (0.5 mM) in tris buffer (pH 7) 
overnight. The control assay contained only substrate and buffer. The reactions were quenched 
and analysed by LCMS. The resulting LCMS trace showed an additional peak at 5.2 mins, the 







Figure 56 – Assay carried out by David Ivision: 
95
 A, DH assay ESI
+
 – TIC chromatogram; B, DH assay 
ESI
+
 EIC (tigloyl-SNAC 112); C, DH assay ESI
+
 EIC (3-hydroxy-2-methylbutyryl-SNAC 111); D, 
control ESI + TIC chromatogram; E, control ESI + EIC (tigloyl-SNAC 112); F, control ESI + EIC 
(3-hydroxy-2-methylbutyryl-SNAC 111). EIC = extracted ion chromatogram 
4.3.1.2 Substrates synthesised  
Work carried out by David Ivison on the SQTKS DH proved that the product of the dehydration 
is tigloyl-SNAC 112.
95
 However the stereoselectivity of the DH was still unknown, as racemic 
2-methyl-3-hydroxybutanoyl-SNAC 111 was used in the assay.  
In order to probe the stereoselectivity of the DH a range of diastereomeric and enantiomeric 
diketide-SNAC substrate were synthesised (Chapter 2). In total there were 4 natural substrate 
mimics 114, 115, 116 and 117 (Figure 57). Two non-natural substrate mimics were also 




Figure 57 – diketide substrates synthesised in order to probe the DH active site. 
4.3.1.3 Substrate retention time on LCMS  
In order to monitor the dehydration reaction carried out by the DH domain, standards of the 
substrate and product mimics were analysed using LCMS. This allowed the suitability of LCMS 
assay monitoring to be assessed and the specific retention time and fragmentation patterns to be 
observed. All substrate mimics 114, 115, 116 and 117 were found to have similar retention 
times ranging from 3.9 – 4.1 minutes. The standard of the enzymatic product 112 was found to 
have a retention time of 5.5 minutes  (Figure 58). 
 
Figure 58 – A. UV trace of 2R, 3R-114; B, ESI+ Mass trace of 2R, 3R-114; C, UV trace of 112; D. ESI+ 




4.3.1.4 Initial assay 
After the protein expression process was optimised, (Chapter 3) the assay carried out by David 
Ivison was repeated. The freshly prepared DH (100 µL, 132 µM) was incubated with substrate 
2R,3R-114 (1.7 mM, 10 µL) and protein storage buffer pH 8 (1 M Tris-HCl pH 8 (10 µL), 50 % 
Glycerol (40 µL)) overnight at 30 °C. The reaction was quenched with MeCN:H2O (60:20 µl) 
and the precipitated protein was removed via centrifugation. The supernatant was then analysed  
directly by LCMS. 
 
Figure 59 – A, DH assay, single ion EIC
 +
 trace, 112 [M]Na
+





= 242; C, DH assay, UV trace of initial assay, D, Control assay, single ion EIC
 +
 trace, 112 [M]Na
+
 =  
224, E, Control assay EIC
 +
 trace of 114 [M]Na
+
 = 242, F. Control assay, UV trace of initial assay.  
103 
 
LCMS analysis of the DH assay (Figure 59, C) shows the enzyme is active and the substrate has 
been dehydrated to form the expected product. In the DH assay (Figure 59,C) there is one peak 
with a retention time of 5.0 minutes. This peak was confirmed to be the product 112 by 
interrogation of the mass spectrum (Figure 60, A, m/z 224 [M]Na
+
) and comparison to the 
standard. Traces of the substrate 114 were shown to be present in the EIC with a mass of m/z 
242 [M]Na
+
, retention time 3.0 mins (Figure 59,B).  
 
Figure 60 – A, ESI+ of substrate 114 [M]Na
+
 = 242; B, ESI+ of product 112 [M] Na
+
 = 224. 
Control assays used identical conditions, and this ensured the concentration of all other 
components stayed the same. Ideally, control assays would have been carried out using inactive 
or denatured protein. Although it was possible to denature the DH protein with heat, it was not 
possible to keep the denatured protein in solution. As soon as heat was applied, the protein 
precipitated. Therefore, in control assays the protein was replaced with protein storage buffer. 
LCMS analysis of the control assay did not show the formation of new peaks (Figure 59, E). A 
peak at 3.0 minutes with a mass spectrum of m/z 242 [M] Na
+
 was visible.  
4.3.1.5 Optimization of kinetic assay 
It is possible to monitor the progression of the dehydration by monitoring the consumption of 
substrate or the formation of product. Typically, the formation of the product is used to track the 
reaction. Monitoring the formation of the product is more accurate as there is a larger relative 
change in concentration. The formation of the product can be tracked using the UV peak or the 
ion mass peak. It was decided that ion mass monitoring would be the most sensitive way to 
monitor the reaction progression. Monitoring the UV response of the product was unsuitable as 
the response did not have a linear relationship to concentration, especially at low concentrations 




Figure 61- A, UV dose response to 186; B, SIM peak area response to 186. 
It was decided that rather than monitoring the formation of product using a total ion count 
method (TIC), selected ion monitoring (SIM) method would be used. A SIM method was set up 
to detect the mass of 112, m/z 224 [M]Na
+
. Optimisation of mass monitoring method from TIC 
to SIM allows maximum mass sensitivity. 
4.3.1.6 Initial time course  
To assess the suitability of LCMS as a way of monitoring the kinetics of the DH domain an 
initial time course was performed. This allowed an understanding of the assay time frame to be 
developed. The assay protocol used by David Ivison was used. Assays were performed in a 
volume of 160 µL and contained the following: 
Component Volume (µL) Final concentration 
1 M Tris-HCl pH8 10 62.5 mM 
50 % Glycerol 40 12.5 % 
Substrate mimic 10 ~10 mM 
DH (10 mg.mL
-1
) 100 164 µM 
Table 2 – SQTKS DH assay conditions, as carried out by David Ivison. 
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The DH (164 µM) was incubated with 2R,3R-114 (1.7 mM), and protein storage buffer pH 8 at 
30 °C. Samples of 20 µl were taken after 0.5, 1.0, 2.0, 4.0 and 6.0 hour time points. The aliquots 
were quenched with MeCN:H2O (60:20 µl). The precipitated protein was removed via 
centrifugation and the supernatant was then analysed by LCMS (Figure 62). The UV peak of the 
substrate (2R,3R)-SNAC 114 decreased over the course of the reaction, while the UV peak 




Figure 62 – A. Overlay of LCMS UV spectra during time course assay, the increase in the 112 UV peak 
can clearly be seen over time; B. SIM
+
 trace of 112, m/z 224 [M] Na
+
; C. Graph showing change in SIM
+
 
peak area of 112 m/z 224 [M] Na
+
 over time in the presence of DH enzyme. 
The peak of area of single ion mass monitoring (SIM) of both the substrate and the product were 
used to track the progress of the reaction  accurately (Figure 62, B).  Over time the peak area of 
2R,3R-SNAC 114 decreased and the peak area of tigloyl-SNAC 112 increased. During the 
initial hour the rate of reaction is linear, after this time the rate of reaction begins to slow. After 
3 to 4 hours the change in peak area plateaus and appears to progress no further.  The reaching 
of a plateau is in keeping with findings of other DH assays. It has been found in other DH 
domains that the dehydration is a reversible reaction and after a certain length of time an 
equilibrium is reached.
12, 13
 A plateau is reached in assays of isolated DH domains due the lack 
of downstream PKS domains or modules. In the biosynthetic pathway the downstream modules 
in the PKS are responsible for driving the equilibrium towards to formation of the dehydrated 
product.
67
    
From this it was decided that all subsequent assays would be carried out on a 1 hour time scale 
as the formation of the product tigloyl-SNAC 112 is linear during this time frame. The effect of 
protein concentration on the rate of conversion was investigated in another series of time course 
assays. The initial protocol for the DH assay utilised a high concentration of enzyme (132 µM). 
Continued use of this concentration of protein is unsustainable due to the time consuming nature 
of protein production. Therefore it was a priority to find the minimum amount of protein needed 
to measure the substrate turnover in a realistic time frame. Assays were carried out with various 
enzyme concentrations in order to establish the limit of detection of the product by SIM-LCMS 
analysis.   
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The turnover of substrate 2R,3R-114 was measured by SIM LCMS analysis of samples taken at 
various time points over 6 hours. Assay protein concentrations ranged from 76.9 µM to 60 nM. 
For assays with a protein concentration less than 5.0 µM, it was not possible to accurately 
measure substrate turnover within the first hour by LCMS due to the detection limits. 
 
Figure 63 – A, Example graph of rate determination at a protein concentration of 9.38 µM; B, Rate of 
reaction plotted against enzyme concentration. 
4.3.1.7 Optimization of assay procedure 
The results from the enzyme dilution assays showed it was possible to use lower concentration 
of protein and still measure substrate turnover. It was also decided to modify the assay mixture 
composition to limit the volume of protein used. As assays were performed over an hour with a 
maximum of 5 time points, the volume could be reduced from 160 µL to 100 µL. Therefore the 
assay protein concentration was reduced from 132 µM to 64 µM.  
Literature procedures typically required the assay to be quenched, and extracted.
60, 67
 The 
extracts were then dried and redissolved in the correct solvent for MS analysis.  
 In an effort to simplify the sample processing even further the following protocol was 
developed. At a certain time point, 20 µL of the assay mixture was taken and the reaction was 
quenched with MeCN:H2O (60 µL):(20 µL). The precipitated protein was removed via 
centrifugation and the supernatant transferred to a fresh LCMS vial. The protocol allows 
samples to be processed with minimal manipulation and also minimizes interfering compounds 
while allowing protein to be removed. 
4.3.2  DH substrate selectivity 
4.3.2.1 DH domain substrate specificity 
In order to ascertain which of the natural substrate mimics 114, 115, 116 and 117 SQTKS DH 
would be able to act upon, the following assays were undertaken. SQTKS DH (124 µM) was 
incubated with substrate mimics 114, 115, 116 or 117 (0.91 mM) in Tris-HCl buffer (20 mM, 
pH 8) for 2 hours. Samples of 20 µl were taken every 10 minutes for an hour and then every 30 
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minutes up to 2 hours. The reaction samples were quenched with MeCN:H2O (60:20 µl) and the 
precipitated protein was removed via centrifugation and the supernatant was then analysed by 
SIM LCMS. 
The reactions of 115, 116 and 117 did not show any appreciable increase in the peak associated 
with the product 112, m/z 224 [M] Na
+
, nor did there appear to be any consumption of the 
substrate  ion peak m/z 242 [M] Na
+
, (Figure 64). In contrast, 2R,3R-114 showed substantial 
turnover of the substrate with a large increase in the 224
+
 = [M] Na
+
, peak associated with  
formation of the tigloyl-112 product (Figure 65). These results indicate that the SQTKS DH 
domain is highly selective towards substrate with the 2R,3R-114 stereochemistry, and is unable 
to tolerate and turn over any other enantiomer or diastereomer. 
Figure 65
 
Figure 64 – A, Incubation of 2S,3S-115 (0.91 mM) with SQTKS DH (132 µM), measuring the integrated 
peak area of 112 m/z 224 [M] Na
+
; B, Incubation of 2S,3R-117 (0.91 mM) with SQTKS DH, measuring 
the integrated peak area of 112 m/z 224 [M] Na
+
; C, Incubation of 2R,3S-116 (0.91 mM)  with SQTKS 







Figure 65 – Incubation of various substrates 114, 115, 116 and 117 (0.91 mM) with SQTKS DH (132 
µM),peak area of product tigloyl-SNAC 112 , ion mass 224 [M] Na+. 
In order to probe the DH active site further, the isolated DH protein (132 µM) was incubated 
with non-natural substrates 124 and 125 (0.97 mM) in Tris-HCl buffer (20 mM, pH 8) for 2 
hours. Samples of 20 µl were taken every 10 minutes for an hour and then every 30 minutes up 
to 2 hours. The reaction samples were quenched with MeCN:H2O (60:20 µl), the precipitated 
protein was removed via centrifugation and the supernatant analysed by SIM LCMS. 
The non-natural diastereomeric substrate mimics 124 and 125 were designed to assess the 
importance of the α-methyl group for correct positioning in the active site. Both substrates 
lacked the α-methyl group but retained the β-hydroxyl group. The reaction of (3S)-125 did not 
show any significant increase in the size of the peak associated with the product crotonoyl-
SNAC 185 m/z 210 [M] Na
+
, (Figure 66). The reaction of (3R)-124 showed the substrate 
underwent dehydration with a significant increase in the SIM peak associated with the product 
185 m/z 210 [M] Na
+




Figure 66 - Incubation of substrates 124 and 125 (0.97 mM) with SQTKS DH (132 µM), peak area of 





Figure 67 - A. ESI+ SIM trace of 3R-124; B. ESI+ SIM trace of 185; C. UV trace of 3R-124 assay; 
D. ESI+ of substrate 124 [M]Na
+
 = 228; E, ESI+ of product 186 [M] Na
+




4.3.3  Inhibition studies 
The investigation into the stereoselectivity of the DH domain found that the DH is highly 
selective with only 2 of the substrate mimics tested being competent, these are 2R,3R-114 and 
3R-124. In order to gain more insight into the programming of the active site, inhibition assays 
were undertaken.  
The aim of these assays was to assess why the DH domain is unable to turn over the non-
competent substrates. There are two possibilities as to why the DH domain is unable to catalyse 
the dehydration of the non-competent substrates. It is possible that the non-active substrate are 
able to enter the active site but the catalytic dyad is unable to recognise the key 2-hydrogen and 
3-hydroxy groups to facilitate the reaction. If this is the case it would be expected the 
compounds could act as inhibitors. It is also possible the non-active substrates were not able to 
enter the active site at all. In this case the compounds should not be inhibitors of the DH. 
The SQTKS DH (52.5 µM) was incubated with mixtures of 2R,3R-114 (2.28 mM) and either 
115, 116 or 117 (2.2 mM) in Tris-HCl buffer (20 mM, pH 8) at 30 °C for 40 minutes. Samples 
of 20 µl were taken at 5, 10, 20, 30 and 40 minute time points. The reactions were quenched 
with MeCN:H2O (60:20 µl), the precipitated protein was removed via centrifugation and the 
supernatant analysed by SIM LCMS. Control assays were carried out in which the conditions 
were not altered apart from 115, 116 and 117 being replaced by distilled water, this allowed the 
uninhibited rate of substrate turnover to be monitored in parallel and the two rates compared.  
The rate of turnover of 2R,3R-114 to the tigloyl-product was not inhibited in any of the non-
competent substrates 115, 116 or 117 (Figure 68). The findings indicate that the non-active 
substrates do not enter the active site of the DH domain as the rate of turnover of 2R,3R-114 is 
not inhibited at all. If the non-competent substrates were able to occupy the active site for any 
length of time, the active substrate 2R,3R-114 would be unable to enter the active site and the 









Figure 68 – A, Inhibition studies of active substrate 2R,3R-114 vs 2S,3R-117 (2.28 mM) with SQTKS 
DH (132 µM), peak area of product 112, ion mass 224 [M] Na+; B, Inhibition studies of active substrate 
2R,3R-114  vs 2R,3S-116 (2.28 mM) with SQTKS DH (132 µM), peak area of product 112, ion mass 224 
[M] Na
+
; C, Inhibition studies of active substrate 2R,3R-114 vs 2S,3S-115 (2.28 mM) with SQTKS DH 
(132 µM),peak area of product 112, ion mass 224 [M] Na+. 
y = 1010.6x - 942.99 
R² = 0.9988 
y = -5.8822x2 + 1314.2x - 1686.8 







































2.28 mM 2R,3R, 0.00 mM 2S,3R 
2.28 mM 2R,3R, 2.28 mM 2S,3R 
y = -13.868x2 + 2227.1x + 10908 
R² = 0.9945 
y = -17.838x2 + 2377.9x + 5472 






































2.28 mM 2R,3R, 0.00 mM 2R,3S 
2.28 mM 2R,3R, 2.28 mM 2R,3S 
y = 5211.1x + 40013 
R² = 0.9506 
y = 3899.4x + 65979 


































2.28 mM 2R,3R, 0.00 mM 2S,3S 






4.3.4  Kinetic studies of SQTKS DH  
4.3.4.1 Kinetic studies of substrate 2R,3R -114 
In order to assess the binding affinity of the 2R,3R-114 substrate towards the SQTKS DH and 
how effective the DH is at catalysing the dehydration reaction, efforts were made to measure the 
Michaelis-Menton parameters. The initial rate at which the isolated DH domain catalysed the 
dehydration of 2R,3R-114 was measured at various concentrations ranging from 0.23 mM to 
4.5 mM. The SQTKS DH (60 µM) was incubated with 2R,3R-114 in Tris-HCl buffer (20 mM, 
pH 8) at 30 °C for 40 minutes. Samples of 20 µl were taken at 5, 10, 20, 30 and 40 minute time 
points. The reactions were quenched with MeCN :H2O (60:20 µl), the precipitated protein was 
removed via centrifugation and the supernatant analysed by SIM LCMS. The assays were 
repeated in triplicate. Control assays were also carried out in tandem, using identical conditions 
where the protein was replaced with purification buffer. The initial rate of dehydration plots for 
114 are shown in Appendix 2.  
As the concentration of the substrate 114 decreased, the initial rate of dehydration also 
decreased as expected  ( 
Table 3). The initial rate for each concentration was calculated and plotted into a Michaelis-
Menton plot (Figure 69). In Michaelis-Menton kinetics, the initial rate ν0 increases linearly with 
concentration till Vmax is approached, where ν0 plateaus. The data shows a linear increase in ν0 
with increasing concentration. The data from the two highest concentrations (3.0 mM and 4.5 
mM) may indicate the initial stages of ν0 plateauing, without additional data for higher 
concentrations this remains unclear.  











Table 3  - Velocity of SQTKS DH enzyme catalysed dehydration reaction at various concentrations of 
substrate 2R,3R-114. 
While it is not possible to calculate the Vmax,  and therefore calculate the kcat or KM the from the 
data obtained, it is possible to calculate the substrate efficiency, kcat/KM by measuring the 
gradient at the origin of the Michaelis-Menton plot (Figure 69). The gradient at the origin is 
calculated by differentiating the equation of the curve fitted on the Michaelis-Menton plot 
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(Figure 69 and Eq6 - 8). This results in a general expression of the gradient. The kcat/KM for the 






Figure 69 – Velocity of SQTKS DH enzyme catalysed dehydration reaction as a function of substrate 
concentration of 2R,3R-114. 
            
  
  
       
            
  
  








4.3.4.2 Kinetic studies of substrate 3R -124 
An investigation to assess the binding affinity of the non-natural substrate 3R-124 was also 
undertaken. The initial rate of dehydration of 3R-124 was measured over a range of 
concentrations (0.2 mm – 3.99 mM), initial rate plots are shown in Appendix 3. The assay 
conditions used were identical to those used in previous kinetic studies. The data showed that 
the initial rate of dehydration increased as the concentration of 3R-124 increased (Table 4). The 
initial rates appeared to  plateau, the calculated initial rates were plotted into a Michaelis-
Menton plot (Figure 70).  









y = -0.1709x2 + 1.9027x 































Table 4  - Velocity of SQTKS DH enzyme catalysed dehydration reaction at various concentrations of 
substrate 3R-124. 
The Michaelis-Menton plot showed a linear relationship between the initial rate and 
concentration of 3R-124. At higher concentrations, 2.6 mM to 3.5 mM the initial rate appears to 
plateau although without additional data this can not be confirmed. It is therefore, as with the 
2R,3R-114 substrate, not possible to calculate Vmax,  kcat or KM the from the data obtained. The 
substrate efficiency, kcat/KM, was calculated in the same way as the 2R,3R-114 in Section 






Figure 70 - Velocity of SQTKS DH enzyme catalysed dehydration reaction as a function of substrate 
concentration of 3R-124. 
4.4  Conclusion 
The isolated SQTKS DH domain was found to be highly selective, only catalysing the 
dehydration of two substrates, one natural substrate mimic, 2R,3R-114 and one non-natural, 3R-
124. This finding indicates that the DH domain active site is highly programmed to only 
recognise a substrate with a 3R-hydroxyl group. The active site also only tolerates a non-
methylated substrate or substrate with a 2R-methyl group. Inhibition studies were carried out to 
assess the effect of non-active substrates  115, 116 and 117 on the initial rate of dehydration of 
2R,3R-114. All three substrates were found to not inhibit the rate of dehydration of 2R,3R-114. 
This indicates that the SQTKS DH domain is programmed to only allow certain substrates into 
the active site. 
The stereochemistry of the non-natural substrates shows that the 3-hydroxy position is key to 
active turnover. Without the correct stereochemistry at the hydroxyl position, dehydration is 
unable to occur. It is likely that the programming selectivity is the result of the positioning of 
the catalytic amino acids within the active site. This will be discussed further in chapter 5. 
y = -0.0729x2 + 0.5451x 




























Assay concentration [S]/ mM 
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Kinetic studies were undertaken to gain more insight into the bind affinity and efficiency of 
both substrates. The data obtained was not ideal, as it was not possible to calculate Vmax,  kcat or 
KM  for either substrate due to slow and inefficiency substrate turn over. It was possible to 
calculate the substrate efficiency kcat/KM, although these values must be treated with caution as 
the errors on the initial rate of dehydration kinetic data are large.  









. kcat/KM describes how effectively a substrate is turned over by the active site, 
with the smaller kcat/KM, indicating a substrate is turned over less efficiently. The much lower 
kcat/KM for 3R-124 indicates the presence of a methyl group is key to efficient substrate 
turnover. The impact of stereochemistry and the presence of the methyl group will be examined 
and discussed in more detail in chapter 5.  
The first PKS DH domain to undergo steady-state kinetic characterisation was the pikromycin 
DH domain, Pik2DH.
67
 Aldrich et al. utilized LC-MS/MS to monitor the reaction and found the 
PikDH2 domain to be highly selective. Substrates 179a-b were designed to test the 
stereospecificity of the PikDH2 domain exhibited towards the β-stereocenter. Substrates 180a-e 
were designed to assess how sensitive PikDH2 was towards changes in stereochemistry at the γ 
and δ positions. Of the 7 substrates tested, only the substrate with the native stereocenters 179a 
and 180a were accepted and processed by the enzymes active site. The kcat/KM of 179a  was 











kcat/KM  of the SQTKS substrate 3R-124 is similar to that of 179a  and 180a. All three substrates 
are non-methylated at the β-positions.  
 
Figure 71 – Structures of substrates used to study the steady-state kinetics of PikDH2. 
As the stereochemistry of the final SQTKS polyketide is known, it is therefore known that the 
SQTKS ER catalyses the reduction of the α,β-unsaturated thiolester giving the methyl group S 
stereochemistry. The stereochemical outcome of the earlier β-keto processing reactions is 
unknown. The uncovering of the SQTKS DH domains stereoselectivity allows the elucidation 
of stereochemical outcome of the KR reduction. The stereoselectivity of the DH domain may 
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also indicate the selectivity of the CMet methylation, although it is likely the product of the 
CMet methylation will racemise easily.   
The DH diketide substrate 2R,3R-114 possesses a 2R methyl group. Therefore the CMet domain 
must catalyse the methylation of the α-position so an R stereocenter is formed. Assuming there 
is no racemisation of the CMet product, it can be assumed that the programming of the CMet 
domain causes the methylation to occur so the methyl group is added to the Re face of the 
alkene ester, as (Scheme 58,A).  
It is also possible to predict the stereochemical outcome of the reduction reaction. The DH 
domain substrate has been found to be 2R,3R-114, therefore the KR domain must catalyse the 
reduction of the β-keto to form the 3R-hydroxyl group at the β-position. Therefore the reduction 
must occur with the addition of a hydrogen to the Si face of the β-ketone (Scheme 58,B).  
 
Scheme 58 – A, CMet catalysed methylation of SQTKS diketide with the methylation occurring on the 
Re face of the alkene; B, KR catalysed reduction of SQTKS diketide, with the addition of a hydride to the 
Si face the β-keto group.  
4.5  Future work 
Once the triketide substrate mimic 168 has been successfully synthesised it should be assayed 





Chapter 5 – Modelling the DH domain 
5.1  Introduction  
To date it has not been possible to obtain a crystal structure of the SQTKS DH domain (Section 
3.4). As a crystal structure is unavailable, efforts were made to create a model which would 
assist in the explanation of stereo selectivity exhibited by the DH domain. The course of the DH 
mechanism was discussed in Chapter 1, Section 1.5.1. The structure of crystallised DH domains 
from FAS (FabA, FabZ, mFAS) and PKS (CurDH F, H, J, K, Ery4DH and Rif10DH) were 
discussed in detail in chapter 1, Section 1.5.3. The findings from investigations into substrate 
selectivity of the aforementioned DH domains are also discussed in this section.  
5.1.1  Available crystal structures  
In order to build a suitable model of the SQTKS DH domain, homologous dehydratases with 
available crystal structures had to be identified. The RSCB protein data bank (PDB) is a 
searchable repository of experimentally-derived biological molecules.
144
 It is possible to search 




A search of the PDB database for protein sequences similar to the SQTKS DH domain found 
eight homologous sequences: four PKS DH domains, (CurF, CurK, CurJ and CurH)
17
 from the 
curacin pathway; the terminal DH, (Rif10DH),
13
 from the rifamycin pathway, Ery4DH
6
 from 
the erythromycin pathway and mycocerosic acid DH domain (MASDH)
145
. The DH domain 
from the PKS PpsC (PBD: 4OOC) from mycobacterium tuberculosis was also available but was 
awaiting full publication.
146




5.1.2  Composition of DH domain  
The DH crystal structures from mFAS, curacin, rifamycin, erythromycin and mycocerosic acid 
were discussed in Sections, 1.5.4, 1.5.5, 1.5.6, 1.5.7 and 1.5.8. Five key structural features were 
observed in all the available crystal structures: a double hotdog fold; an active site comprised of 
a histidine and an aspartic acid; a conserved proline situated near the catalytic histidine; a 
hydrogen bonding network; and a substrate tunnel (Figure 72).  
The double hotdog fold, where parallel β-sheets wrap around two hydrophobic α-helices, is a 
highly conserved structural feature in all DH domains. It is key in shaping the internal structure 
and contributing to the formation of the substrate tunnel. The substrate tunnel opening forms 




Figure 72 – A, Key Sections of sequence alignment, showing catalytic amino acids histidine and aspartic 
acid shown in red. Amino acids involved in the hydrogen bonding network are labelled in blue; B-E, 
Overlay of crystal structures of CurFDH (Green), EryDH4 (Blue) and RifDH10 (purple); B, overall 
structure of the three DH domains; C, hotdog folds in all three DH domains; D, catalytic amino acids of 
all three domains; E, hydrogen bonding network in all three DH domains. 
The substrate tunnel is hydrophobic, generally lacking in hydrogen bonding groups and with a 
shape which is largely untailored to the exact shape of the substrate.
6
 The catalytic amino acids 
are positioned with the histidine on the N-terminal hotdog fold and the aspartic acid residue 
residing on the C-terminal hotdog fold.
6, 17
 In addition to the catalytic amino acids, a number of 
other amino acid residues are conserved and form a hydrogen bonding network within the active 
site.
6
 The purpose of this hydrogen bonding network is to ensure the correct positioning of the 
catalytic amino acids. The proline in the HXXXGXXXXP motif is highly conserved in both 
FAS and PKS DH domains (Figure 72, A). The proline helps orientate the catalytic histidine 
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through Van der Waals interactions. Hydrogen bonding from the backbone carbonyl of a nearly 
invariant leucine (sometimes valine, Figure 72, A) also contributes to the correct orientation of 
the histidine.  It is also thought that the hydrogen bonding network contributes to the pKa of the 
aspartic acid residue ensuring that it is able to donate a proton to the substrate, facilitating the 
subsequent loss of water.
6, 13
   
5.2 Model building  
5.2.1  Identifying a suitable candidate 
It is possible to create a model of the DH domain by threading the sequence of the SQTKS DH 
domain on to the structures of proteins which are available and then minimising the side chain 
steric and electronic clashes. By selecting protein structures which catalyse a similar reaction 
and are homologous in sequence, the model formed should reflect the true structure of the DH 
domain.  
A search of the PDB identified published crystal structures was carried out, in order to assess 
their sequence identity to SQTKS DH and therefore their suitability to take forward to build a 
model. Sequence alignment was carried out using Clustal Omega (Appendix 1).
76, 77, 147
 In 
addition to aligning the sequences of all the available DH domains, Clustal Omega was able to 
calculate their sequence identity to the SQTKS DH domain (Table 5).  
 % sequence identity 
to SQTKS 
SQTKS 100.0 
4LN9 Rif10 18.0 
3EL6 Ery4 16.9 
3KG7 CurH 17.3 
3KG8 CurJ 18.1 
3KG6 CurF 19.4 
3KG9 CurK 18.2 
5BP2 MASDH 25.5 
Table 5 – Crystallised DH domains % sequence identity to SQTKS DH domain. 
Rif10DH, Ery4DH, CurJ, CurK and CurH all had similar identities ranging from 16.9% to 
18.2%.  Curacin CurF DH had the greatest sequence identity of all the curacin DH structures at 
19.4%. MASDH had a sequence identity of 25.5%, the highest identity of all the available 
crystal structures.  Although the sequence identity for all the DH domains is low, it had been 
found that despite this, they have a high degree of structural similarity. Akey et al. compared the 
structural and sequence identity of CurFDH with the other CurDH domains, Ery4DH.
17
 While 
CurK had a sequence identity to CurFDH of 68%, the other domains had a much lower 
sequence identity, ranging from 20-32%. The root-mean-square deviation of atomic positions 
(RMSD) measures the average distances between the atoms of two superimposed proteins. 
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When the structures were aligned and the RMSD of the α-Carbon was compared, they were 
found to have a high structural identity with RMSD ranging from 1.0-2.0Å.  
5.2.2  Modelling programs 
Typically computational modelling programs produce a 3D protein model in one of three ways.  
The programs can construct the model using comparative modelling (CM), where the sequence 
or sequence profile comparison identifies evolutionarily related homologous templates.
148, 149
 
The model is then generated by simply copying the framework from the template. This strategy 
results in the generation of a high resolution model.  
Modelling programs which use a threading method match the query sequence directly onto 
solved 3D protein structures by recognising similar folds in the query sequence. This method 
identifies proteins which have similar structures but  have different evolutionary origins. For 
protein sequences which have no structurally related proteins in the PBD, ab initio (or de novo)  
modelling must be carried out.  This technique predicts the tertiary structure on the amino acid 
sequence of the query protein. The success of this type of modelling is limited to small proteins 
only.  









 Ideally, in order to get an accurate model of SQTKS,  solved 
crystal structures of proteins with a high sequence homology would be available. Unfortunately, 
there are only eight published crystal structures of isolated PKS DH domains, all with low 
sequence identity to SQTKS, ranging from 16.9% to 25.5% In order to try and overcome this 
issue, a number of models were produced using different modelling programs. Different 
modelling programs will create the models using different algorithms and databases. The 
following modelling programs were used: SWISS-MODEL, Robetta, Phyre 2, Raptor X, HH 
pred and Itasser. 




I-TASSER uses a composite approach to building protein models, utilising CM, threading and 
de novo modelling. From the submitted amino acid sequence, I-TASSER generates three-
dimensional models from multiple threading alignments and structural assembly simulations. 
The output consists of a predicted secondary structure and five 3D models (Figure 73). Each 
model is assigned a C-score, which estimates the quality of the predicted model. C-score values 
typically range from -5 to 2, a higher C-score, indicates a higher quality of model. Models with 
a C-score of -1.5 or greater are generally thought to have a correct fold.  Of the five models 
created by the I-TASSER modelling server only two had C-scores higher than -1.5, those were 
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models 1 and 4. I-TASSER model 1 had the highest C-score of 0.56, therefore only model 1 
was taken forward to compare with models produced by other modelling programs.  
 




The Phyre2 server offers a simple and intuitive portal for protein modelling.
155
 It is possible to 
submit your model to be processed in two modes, normal and intensive. The intensive mode 
creates a full length model using multiple template modelling and simplified ab initio folding 
simulations for sections of the sequence not covered by the template. The SQTKS DH domain 
sequence was submitted to the intensive modelling server. Phyre2 selected 6 templates, Rif2DH 
and the 4 Curacin DH domains; CurF, CurH, CurJ and CurK. It also selected the dehydratase 
domain of rzxb from Pseudomonas Fluorescens. Phyre2 modelled 95% of the SQTKS protein at 
a confidence of >95%. The server was not able to model 16 residues using the selected 
templates and had to model them ab initio. It must be noted that ab initio modelling is highly 
unreliable. Overall the templates selected by the server covered the majority of the SQTKS 
sequence. 
 








RaptorX uses template based modelling (TBM) to generate a protein model.
150, 156
 RaptorX is 
able to carry out three different modelling tasks, tertiary structure modelling, secondary 
structure modelling and custom alignment modelling. The amino acid sequence for  SQTKS DH 
was submitted to the RaptorX for secondary structure modelling and resulted in one protein 
model (Figure 75). RaptorX used the curacin DH domain CurJ (3Kg8) as a template to thread 
the SQTKS-DH sequence. The protein model produced by RaptorX is given an unnormalized 
global distance test (uGDT) score, which measures the absolute model quality. For proteins of 
more than 100 residues a uGDT score of 50 or more is an indicator of a good model. The 
SQTKSDH model contains 324 residues and was given a uGDT of 183, indicating the SQTKS-
DH model generated by RaptorX is acceptable. The model also gave a global distance test 
(GDT) score. A poor GDT score is defined as a score less than 50. A good uGDT score but a 
poor GDT score is indicative of a model in which only a small portion of the model is accurate. 
The GDT score given to the RaptorX SQTKS DH model was 56 which is lower than desired 
and may indicate that errors are present in this model.   
 




Robetta provides an automated structure prediction service which aims to create a protein model 
from genomics data. The initial step of the modelling process uses a domain prediction method 
called ‘ginzu’. Ginzu is a hierarchical screening process which finds regions in the query 
sequence which are homologous to experimentally determined structures. Regions which are 
homologous to solved structures undergo comparative modelling. Any regions which are not 
covered undergo de novo modelling. The amino acid sequence for SQTKS was submitted to 
Robetta for structure prediction and resulted in 5 models. Models 1 and 4 were produced by 
comparative modelling, the DH from mycocerosic acid synthase-like (MASDH) PKS was used 
as the template for these models. Models 2, 3 and 5 were produced by de novo modelling. This 
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form of modelling is known to be inaccurate and is typically only used for small proteins (less 
than 150 amino acids). Therefore models 2, 3 and 5 were discounted and no further analysis was 
undertaken using these models. Models 1 and 4 were aligned in PyMol and found to be  similar, 
although there were some differences in the predicted positioning of some α-helices and β-
sheets (Figure 76, F).   
 
Figure 76 – A-E; Robetta models of the SQTKS DH domain, A, model ; B, model 2; C, model 3; D, 




HHPred is a remote server which can be used to quickly assess protein homology and carry out 
structure prediction. The SQTKS sequence was submitted to the server as a single query and 
searched against the PDB database. HHPred returns multiple alignments of the query in the 
form of a “hit list” of similar sequences and ranks them according to probability. The results 
also contain details of the alignment of each result against the query sequence with annotations 
on secondary structure. The highest scoring sequences were MASDH (99.75), CurJ (99.44), 
CurH (99.39) and CurK (99.32). HHPred uses the alignment results to automatically select the 
most suitable proteins and the automatic selection tool chose the following protein structures to 
produce the template, MASDH, CurJDH, CurK, CurF. The template was subsequently 







Figure 77  - HHPred model of the SQTKS DH 
domain 




SWISS-MODEL is a fully automated server with a user friendly web interface which allows the 
user to generate a protein structure homology model without the use of complex software 
packages.
153
 The SQTKS DH protein sequence was searched against the SWISS-MODEL 
database to identify possible model templates.
153
  The CurFDH domain was returned as the top 
template match, with the highest sequence identity and coverage. A further model (Figure 78) 
was subsequently built using SWISS-MODEL’s automated modelling server using CurFDH as 
a template. SWISS-MODEL evaluates the accuracy of a model using a range of parameters. The 
global model quality estimation (GMQE) score quantifies how accurate a model is and assigns a 
value between 0-1, the closer to one the more accurate the model. The model was given a 
GMQE score of 0.53 calculated by SWISS-MODEL. 
5.2.4 Comparison of SQTKS DH models 
Once all the models had been produced, they were compared in order to identify the most 
suitable model. Initially the models were overlaid and examined in PyMol. The core structure of 
the active site in all 6 models was highly similar. The α-helix and β-sheets which make up the 
double hotdog fold in the DH domain closely overlap in all six models (Figure 79, A-C). In 
addition the active site amino acids, histidine and aspartic acid,  also overlay well in all six 
models (Figure 79, A).  While the active site of all six models are highly similar, the structure of 
α-helices which are not directly involved in the active site vary between models. In some 
models the length of the α-helix differs slightly (Robetta model, Figure 79, E), while in others it 





Figure 79 – Overlay for all six models: Swiss Model, green; Itasser model, orange; Phyre, yellow; 
Raptor X, magenta; Robetta, pink; HHPred, blue; A-B, Overlay of protein models showing active site α-
helix and active site amino acids; C, Overlay of protein models showing β-sheets from different model 
map onto one another; D, Overlay of protein models showing variation in α-helix orientation;  E, Overlay 
of protein models showing variation in α-helix length. 
As all six models were very similar visually, further analysis was undertaken in order to 
investigate the accuracy of the models and identify the most suitable one. SWISS-MODEL 
possesses a number of model assessment tools which are designed to assess  the accuracy of the 
model. QMEAN is a combined scoring function which estimates the quality of each residue in 
the model, was well as the quality of the entire model.
162-164
 QMEAN4 evaluates the accuracy of 
the model by scoring four structural functions including the torsion angle over three amino 
acids; residue level secondary structure interactions, assessment of the long range interactions; 
and the solvation potentials.
163
 QMEAN6 evaluates the accuracy of the model using the four 





agreement prediction of secondary structure (from the sequence) compared with the calculated 
secondary structure and predicted solvent accessibility.   
All the models were submitted the QMEAN server, the QMEAN4 and QMEAN6 scores are 
summarised in Table 6. A higher QMEAN score indicates a better agreement between the 
model structure and experimental structures of a similar size. QMEAN scores of -4.0 or below 
indicate a poor quality model.
164, 165
  Itasser was the worst performing of all the models with a 
QMEAN4 score of -11.25, indicating it is a poor quality model. SWISS-MODEL, RaptorX, 
HHPred and Phyre2 all scored higher then Itasser but still had QMEAN4 scores below -4.0. The 
only model to score above -4.0 was the model produced by the Robetta server.  
Model QMEAN4 Score QMEAN6 Score 
Swiss Model -6.59 -6.01 
Itasser -11.25 -8.73 
Phyre2 -6.61 -4.85 
RaptorX -4.66 -3.56 
Robetta -0.75 -0.77 
HHPred -5.55 -4.05 
Table 6 - QMEAN4 and QMEAN6 of all six protein models. 
In addition to the QMEAN4 and QMEAN6 scores, SWISS-MODEL’s evaluation QMEAN 
server also provides QMEAN Z-scores which allow the models to be compared to high 
resolution crystal structures in the PDB. The results are reported as comparison plots showing 
how the protein SQTKS DH model compares to known crystal structures (Figure 80). The 
comparison plots for all but the Robetta model show the models are dissimilar to high resolution 
crystal structures in the PDB.  
The Robetta model performed the best in the QMEAN testing, the model used the MASDH as a 
template. The MASDH has the highest sequence homology of all the crystallised DH domains 
currently available. The Robetta model was therefore taken forward as the model suitable 





Figure 80 – Comparison plots of protein models, showing QMEAN scores expressed as Z-Scores. Each 
dot represents a protein structure, the darkest dots are structures with QMEAN Z-scores between 1 and -1.  
grey dots are structures with QMEAN Z-scores between 1 and 2. Light grey dots represent structures with 
QMEAN scores greater than 2. The red star represents the model. A, HHpred model; B, Swiss Model; C, 




5.3 Docking studies 
5.3.1  Diketide Substrate docking  
There are four possible natural diketide substrates for the SQTKS, 114, 115, 116 and 117 
(Figure 81). Investigations into the selectivity of the SQTKS DH domain (Chapter 4) revealed 
the DH domain was highly selective, with only 2R, 3R-114 substrate undergoing dehydration to 
form 112. Inhibition studies which were carried out (0) found that the substrate 115, 116, and 
117, which had not turned over, were unable to enter the active site of the DH domain. 
Therefore, only the docking of 114 was studied.   
The substrate 114 was initially drawn in ChemDraw
166
 and subsequently imported into 
ChemDraw 3D pro,
166
 which allowed the structures to be transformed from 2D image to a 3D 
representation of the molecules and be saved as a 3D coordinate (PBD) file. Once the substrate 
was converted into a 3D model, it was imported into PyMol and manually docked into the 
active site of the Robetta SQTKS DH model. The substrate was roughly aligned with the 
catalytic amino acids H44 and D235. Once this had been done the PDB files were submitted for 
energy minimization using YASARA.
167
 YASARA force field server carries out molecular 
dynamic simulations in order to minimize the energy functions of the docked substrate and the 
protein model, therefore increasing the accuracy of the model.  
 
Figure 81 – The four possible diketide substrate mimics. 
After undergoing energy minimisation the position of the substrate in the active site was 
examined (Figure 82). The orientation of the substrate in relation to the active site amino acids 
was examined and the distances between the α-hydrogen and the catalytic histidine’s nitrogen 
and the β-hydroxyl group and the catalytic aspartic acid were measured (Figure 84).  
Figure 82 – A. Substrate tunnel from the side; B. Substrate tunnel viewed from the top 
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The substrate tunnel is formed by the large central α-helices within the protein, the tunnel runs 
along the length of the C-terminal α-helix and curves towards end where the active site is 
situated. One side of the substrate tunnel, the side nearest the catalytic aspartic acid, is restricted 
making it unable to accommodate large bulky groups (Figure 82). The opposite side is much 
more open and widens around the active site, so it can accommodate the growing polyketide 
chain.  
The substrate 2R,3R-114 is shown docked into the active site of the DH in Figure 84 A and B. 
2R,3R-114 comfortably fits into the active site, with the α-methyl and β-methyl groups 
occupying a large open pocket within the active site. The positioning of the methyl groups in 
this way allows the α-hydrogen to be close enough for the catalytic histidine’s nitrogen to 
abstract the α-hydrogen, therefore facilitating the elimination reaction (3.5 Å, Table 7). The β-
hydroxyl group is at a similar distance, where a proton from the catalytic aspartic acids 
hydroxyl group can hydrogen bond to the oxygen of the β-hydroxyl group (2.6 Å, Table 7). 
 
Figure 83 – Key modelled interactions between the substrate 3R, 3R-114 (magenta) and key amino acids 
with in the SQTKS DH active site (orange). 
The docked 2R, 3R-114 substrate is able to interact with other amino acids with in the active 
site. The thioester carbonyl is able to hydrogen bond to the NH of a nearby glycine (G54, 3.4 Å, 
Figure 83), helping to stabilise the positive charge which will form on the carbonyl during the 
course of the reaction. The SNAC NH can hydrogen bond to the backbone carbonyl of a nearby 
tyrosine (Y52, 4.1 Å). The SNAC carbonyl is situated close to a nearby alanine (A92, 2.8 Å). 
The interactions of these amino acids help position the SNAC correctly in the active site. It can 
be presumed that the amino acids would interact in a similar fashion with a pantetheinyl-ACP 
bound substrate.  The positioning of the α-hydrogen and β-hydroxyl group within hydrogen 
130 
 
bonding distance of the catalytic residues indicates that the substrate will be able to undergo 
dehydration in the presence of the SQTKS DH enzyme. This finding is supported 
experimentally, the assay of 2R,3R-114 underwent dehydration when in the presence of the DH 
enzyme.  
Substrate α/Å β/Å 
2R,3R-114 3.5 2.6 
3R-124 2.6 2.6 
3R intermediate - 1.6 
Table 7 - Measured distances between α-proton and histidine nitrogen and between β-hydroxyl group and 
aspartic acid hydroxyl proton 
The active non-methylated substrate 124 was also docked into the active site (Figure 84). The 
substrate 124 fitted well within the active site and was able to interact with catalytic amino acids 
within hydrogen bonding distance, (α-hydrogen, 2.6 Å, β-hydroxyl, 2.6 Å, Table 7).  
 
Figure 84 – Docking of the active substrate mimics within the active site of the Robetta SQTKS model 
A-B, docking of the methylated substrate 2R,3R-114; A, side view, B, top view; nonmethylated substrate 
mimic with in the active site of the CurF-SQTKS model. C-D, docking of the nonmethylated 3R-124; C, 




5.3.2 Diketide intermediate docking  
To complement the diketide substrate docking experiments, the diketide enolate 179 and enol 
180 intermediates were also docked into the active site. Both the enol and enolate were placed 
into the active site using PyMol and roughly aligned with the catalytic amino acids H44 and 
D235. These structures were then subsequently submitted for energy minimization using 
YASARA.
167
 During the energy minimization process YASARA transformed the enolate into 
the enol, as it was deemed the most stable form, it was not possible to prevent this 
transformation, and therefore only the enol will be discussed further. 
 
The positioning of the enol diketide substrate 180 within the active site is comparable to the 
positioning of the 2R,3R-114.  The distance between the β-hydroxyl and D235 is reduced from 
2.7Å to 1.6Å in this docking simulation (Figure 85). The proposed mechanism is discussed in 
chapter 1, Section 1.5, Scheme 13. The α-methyl group is now in a planar position, allowing the 
methyl group to comfortably fill the open side of the active site tunnel. The planar positioning 
of the methyl group appears to allow the β-hydroxyl group to be positioned closer to D235, it is 
possible that this helps facilitate the loss of water needed to complete the dehydration reaction.  
Once the dehydration has occurred the substrate is released from the active site, as it no longer 
possesses a hydroxyl group and therefore is unable to hydrogen bond to D235.  
 
Figure 85 – Docking of diketide enol intermediate 
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5.3.3  Triketide docking  
The triketide substrate mimic 168, was hypothesised to be an active substrate and was docked 
using the same process used to dock diketide substrates in Section 5.3.1. The substrate was 
docked into the active site of the Robetta SQTKS model and the α-proton and β-hydroxyl 
groups were roughly aligned with H44 and D235. The docking model was then subjected to 
energy minimization, carried out by the YASARA server. 
167
 The conformation of the substrates 
within the active site was then examined and the distance from the catalytic amino acids, H44 
and D235 to the α-proton and β-hydroxyl group was noted.  
 
Figure 86 – Triketide substrate mimic. 
As with the diketide substrate mimics, the stereochemistry of the substrate dictates how the 
substrate fills the active site and interacts with the catalytic amino acids. The 2R,3R,4S substrate 
168 (Figure 87, A) docks into the active site with the α-methyl group positioned away from the 
restricted side of the substrate tunnel, towards the more open face of the tunnel. This allows the 
α-proton and β-hydroxyl group to locate within hydrogen bonding distance. The α-proton is 
2.7 Å away from H44 and β-hydroxyl is 2.7Å away from D235. The long alkyl chain is 
threaded through the substrate tunnel and curves down into the open pocket at the end of the 
tunnel.  
The α-proton and β-hydroxyl and catalytic amino acids interact at a distance which indicates 
that abstraction of the α-proton by H44 and protonation of the β-hydroxyl group is possible. The 
docking of the 2R3R4S-168 indicates that it is likely be an active substrate and will undergo 
dehydration.  
 




In the absence of an available crystal structure six SQTKS DH protein models were produced 
using a range of modelling programs which were tested using SWISS-MODEL QMEAN server.  
The model produced by the Robetta program was deemed the most suitable and used MASDH 
as a template with which to build the model. Although the sequence identity between MASDH 
and SQTKS was lower than desired (25.5%), of all the crystallised DH domains, MASDH has 
the highest sequence identity. The Robetta model was also the only model to have an QMEAN 
score above -4.  
Studies of crystal structures of other DH domains indicate that the difference in substrate size 
should not affect the modelling outcomes to any great degree. The substrate tunnels of other DH 
domains appear to lack amino acids which are able to carry out hydrogen bonding for explicit 
substrate recognition, as the substrate is always delivered by the ACP.
6
 The structural 
similarities observed in these structures indicate that SQTKS DH will also possess a substrate 
tunnel lacking in hydrogen bonding amino acids. The active site contains two amino acids 
which are able to hydrogen bond to the substrate in such a way as to facilitate the dehydration 
reaction, which are a histidine and an aspartic acid residue. Additional amino acids are able to 
hydrogen bonding to the substrate, it is though that these amino acids help stabilise the substrate 
with in the active site during the dehydration reaction. A number of other amino acids in the 
active site is involved in hydrogen bonding to the catalytic amino acids in order to stabilise and 
increase their activity.  
The docking studies indicate that the programming in the DH domain arises from the 
positioning of the catalytic amino acids and the shape of the substrate tunnel. The mechanism of 
dehydration is reliant on the abstraction of proton from the α-position and protonation of the β-
hydroxyl group, and subsequent loss of water. This results in strict requirements for the 
dehydration to occur. The substrate must be able to interact with the catalytic amino acids 
within hydrogen bonding distance. The shape of the tunnel and the positioning of the amino 
acids dictates which stereoisomer substrate is tolerated and turned over.  
Incorrect stereochemistry results in the substrate being unable to interact with the catalytic 







Chapter 6 - Conclusion and future work 
The focus of the work described in this project was to investigate the selectivity and kinetic 
characteristic of the SQTKS DH domain. 
In order to probe the programming of the SQTKS active site a range of diastereometic and 
enantiomerically pure substrates were synthesised. Four natural diketide substrates 115 - 117 
were synthesised, the syn diastereomers were synthesised utilising Evans auxiliaries to control 
the stereocenters formed during the aldol reaction. The anti diastereomers stereocenters were 
installed using Fráter-Seebach alkylation. In addition to the natural diketide substrates two non-
natural substrates were also synthesised, they were designed to assess the importance of the β-
methyl group to substrate turn over.  
 
Figure 88 – synthesis diketide mimics.  
While it was possible to produce the SQTKS DH as soluble protein, the enzyme was found to 
be unstable.  The optimisation of purification and storage buffers allowed the DH domain to be 
stabilised in solution by L-Arginine and L-Glutamic acids. Despite additives to help stabilise the 
protein, precipitation still occurred over time, but it was possible to store the enzyme at 4 °C for 
up to 2 months and carry out the required assays.  
The assays were designed to test the selectivity and kinetic characteristics of the isolated DH 
towards diketide substrates mimics. The assays progress was monitored by measuring the 
formation of the tigloyl-SNAC product via SIM LCMS. The assays demonstrated the DH 
domain was highly selective, only catalysing the dehydration of one natural substrate mimic 114 
out of the possible four stereoisomers. The DH domain was also able to act on one non-natural 
substrate 124. The investigation found that substrate 2R,3R-114 was processed more efficiently 
than by the isolated DH 3R-124. 
Inhibition studies showed no significant reduction in the rate 114 is processed by the DH when 
incubated in the presence of an additional substrate (115, 116 and 117). These results indicated 




Scheme 59– Selective exhibited by the SQTKS DH domain towards methylated and non-methylated 
substrate mimics. 
Attempts at crystallizing the DH domain were unsuccessful. In the absence of a crystal 
structure, a model was created to gain insight into how the active substrate sit within the active 
site. PKS DH domains share limited sequence identity but when the crystal structures are 
compared, they share a high degree of structural similarity. To limit the inaccuracies which 
could arise due to the low sequence identity between the SQTKS DH domain and the available 
PKS crystal structures a range of models were created. The models were assessed using SWISS-
MODEL QMEAN software and the most suitable model was produced by the Robetta server. 
This model DH structure was then used in docking studies with various possible substrates. 
Only the active substrates were docked into the active site of the model as the inhibition studies 
had shown the non-substrate did not enter the active site.  
The results from the docking study fit well with the results observed in the chemical assay, 
rationalising the observed stereoselectivity of the DH domain. The assays showed the DH 
domain programming controls which stereoisomer is accepted and subsequently dehydrated 
(Scheme 59). The mechanism for DH requires the substrate to interact with two catalytic amino 
acids, histidine and aspartic acid. The model of SQTKS DH rationalised the hypothesis that the 
programming of the DH arises from the positioning of the amino acids within the active site 
(Scheme 60). The positioning in turn dictates which stereoisomer is tolerated. For a substrate to 
be dehydrated it must contain a 3R-hydroxyl group. The DH domain can act on non-methylated 
137 
 
substrate, but if a methyl group is present in the α-position then it must also have R 
stereochemistry. 
The modelling also showed additional amino acids within the active site tunnel can interact with 
key sections of the substrate. These amino acids help position and stabilise the substrate, so the 
dehydration reaction can occur. The nearby glycine which interacts with thioester carbonyl, can 
stabilise negative charges which form temporarily during the reaction.   
 
Scheme 60 – Dehydration mechanism of the 2R,3R-114 substrate with in the DH active site. 
The SQTKS DH domains selectivity also fits well with the selectivity observed in other known 
DH enzymes. The crystallised DH domains, Ery4DH and Rif10DH both exhibit the same 
selectivity towards the 2R,3R-2-methyl-3-hydroxyacyl-SNAC substrates.
12, 13
 The selectivity 




 bacterial FabA and 
FabZ.
70, 71
 All of the aforementioned DH domains catalyse the dehydration to give the Z 
geometry α,β-unsaturated thiolester. Docking also showed how the syn elimination geometry is 
controlled which agrees with the observation that the 2R,3R-114 substrate gives the E product.  
Further work on the SQTKS DH will focus on the interactions between the DH and the ER 
domain. The investigations will examine how interactions between the DH and ER domain 
affect the selectivity’s and kinetic characteristic of both domains. Also, a larger fragment of the 
SQTKS, from the DH to KR has successfully been cloned and isolated. Work will be carried out 
on the larger fragment to assess its selectivity.   
The interaction between the “non-substrates” and the DH and ER domain will also be studied 
using surface plasmon resonance (SPR). The aim of the investigation is to find out if the alcohol 
substrates can enter the active site of the ER and if the alkene substrates are able to enter the DH 
active site. If the substrates do enter the active site, the use of SPR will also allow the time 







Chapter 7 – Experimental 
7.1  General Microbiological techniques 
7.1.1  Media 
All growth media were sterilised by autoclaving at 121 °C for 10 minutes prior to use.  
For solid medium, E. coli was grown on LB-agar containing 10 g/L tryptone, 5 g/L NaCl and 
15 g/L agar. Sterile agar was melted in a microwave and allowed to cool slightly. Appropriate 
antibiotics were added, and the molten agar poured into sterile petri dishes either in a laminar 
flow hood or under sterile conditions.  
SOC recovery medium used during E. coli transformation, contained 0.5 % (w/v) yeast extract, 
2 % (w/v) tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM 
glucose.   
LB Glu/Carb agar containing 10 g/L tryptone, 5 g/L NaCl and 15 g/L agar. Sterile agar was 
melted in a microwave and allowed to cool slightly. 2 mL of 20 % glucose stock and 200 µL of 
100 mg/mL carbenicillin stock per 200 mL were added and the molten agar poured into sterile 
petri dishes either in a laminar flow hood or under sterile conditions. 
LB liquid medium was used for starter cultures of E. coli. It contained 10 g/L tryptone, 10 g/L 
yeast extract and 5 g/L NaCl. 
2TY medium used for growth of E. coli for protein expression contained 16 g/L tryptone, 10 
g/L yeast extract and 5 g/L NaCl. 
2TY-glucose medium used for growth of E. coli for protein expression contained 16 g/L 
tryptone, 10 g/L yeast extract and 5 g/L NaCl. After sterilisation,5 % glucose w/v was added.   
2TY Enhanced (2TYE) medium for growth of E. coli used for protein expression contained 16 
g/L tryptone, 10 g/L yeast extract and 5 g/L NaCl dissolved in 900 mL of H2O. After 
sterilisation 1 mL/L 2 M MgSO4, 1 mL/L metal mix A, 100 mL/L 100 mM phosphate buffer 
and 0.5 % glucose w/v were added.   
Terrific Broth (TB) medium used for growth of E. coli for protein expression contained 12 g/L 
Bacto-tryptone, 24 g/L Bacto-yeast extract, 4 mL/L glycerol dissolved in 900 mL of H2O. After 
sterilisation 100 mL 100 mM phosphate buffer was added. 
Terrific Broth Enhanced (TBE) used for growth of E. coli for protein expression contained 12 
g/L Bacto-tryptone, 24 g/L Bacto-yeast extract, 4 mL/L glycerol dissolved in 900 mL of H2O. 
After sterilisation 100 mL/L 100 mM phosphate buffer, 1 mL/L metal mix A and 0.5 % glucose 
w/v were added.   
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Rich media was used for growth of E. coli for protein expression. It contained 2TY medium, 
which contained 16 g/L tryptone, 10 g/L yeast extract and 5 g/L NaCl. After autoclave 
sterilisation the following autoclave sterilised components were added; 50 ml/L 20xNPS, 1 
mL/L metal mix B. The following filter sterilised components were also added; 25 ml/L 
glucose, glycerol, MgSO4 stock solution. 
Auto induction medium used for growth of E. coli for protein expression contained phosphate 
buffer (pH 7.2) consisting of 6 g/L Na2HPO4 and 3 g/L KH2PO4. 20 g/L tryptone, 5 g/L yeast 
extract, 5 g/L NaCl. After autoclave sterilisation the following filter sterilised components were 
added; 10 mL/L 60 % v/v glycerol, 5 mL/L 10 % w/v glucose and 25 mL/L 8% w/v lactose. 
Auto induction-LB5052 medium used for growth of E. coli for protein expression contained 5 
g/L yeast, 10 g/L tryptone, 5 g/L glycerol, 0.7 g/L Na2SO4, 2.5 g/L NH4Cl dissolved in 900 mL 
H2O. After sterilisation 0.5 g/L glucose, 2 g/L lactose, 1 mL/L 2 M MgSO4, 1 mL/L metal mix 
A, 100 mL/L 50 mM phosphate buffer and 0.5 % glucose w/v were added.   
20xNPS contained 6.6 g/L NH4SO4, 13.6 g/L KH2PO4, 14.2 g/L Na2HPO4. glucose, glycerol, 
MgSO4 stock solution contained 5 g/100 mL glucose, 25 g/100 mL glycerol and 8 mL 1M 
MgSO4 
Metal mix A stock solution was made as follows: solutions of the metal compounds, tabled 
below were made in water at their defined volume and concentrations. FeCl3.6H2O was made up 
in 50 mL 0.1 M HCl instead of distilled water. All metals dissolved in distilled water were 
added to 46 mL of distilled water and filter sterilised. The FeCl3.6H2O in 50 mL 0.1 M HCl was 
then added to the filter sterilised solution. 
Reagent Mass (g) Volume (mL) Concentration (M) 
FeCl3.6H2O 1.35 50 (0.1 M HCl) 0.1 
MnCl.4H2O 0.91 1 1 
ZnSO4.7H2O 0.28 1 1 
CoCl.2H2O 0.23 1 0.1 
NiCl2.6H2O 0.23 1 0.2 
 
Metal Mix B stock solution was made as follows: solutions of the metal compounds, tabled 
below were made in water at their defined volume and concentration. FeCl3.6H2O was made up 
in 50 mL 0.1 M HCl instead of distilled water. The solutions were added to distilled water (36 





Reagent Mass (g) Volume (mL) Concentration (M) 
FeCl3.6H2O 1.35 50 (0.1 M HCl) 0.1 
CaCl2 0.22 2 1 
MnCl.4H2O 0.20 1 1 
ZnSO4.7H2O 0.29 1 1 
CoCl.2H2O 0.05 1 0.2 
CuCl.2H2O 0.03 2 0.1 
NiCl2.6H2O 0.05 1 0.2 
NaMoO4.2H2O 0.05 2 0.1 
NaSeO3.5H2O 0.05 2 0.1 
H3BO3 0.012 2 0.1 
 
Phosphate buffers were made as follows using distilled water and filter sterilised before use. 100 
mM phosphate buffer consisted of 200 mL/L 1M KH2PO4 and 800 mL/L 1M K2HPO4. 50 mM 
phosphate buffer consisted of 100 mL/L 1M KH2PO4 and 400 mL/L 1M K2HPO4 and 500 mL/L 
distilled water. 
7.1.2 Stock solutions 
7.1.2.1 Antibiotic stock 
0.2 M carbenicillin stock contained 1 g/ 10 mL of carbenicillin in H2O, which was filter 
sterilised using a 0.2 µL filter, divided into aliquot and stored at -20 °C. 
7.1.2.2 Induction stock solutions 
20 % (w/v) rhamnose solution contained 2 g/ 10 mL of rhamnose in H2O, which was filter 
sterilised using a 0.2 µL filter, aliquot and stored at room temperature. 
1 M IPTG stock contained 2.3 / 10 mL of IPTG in in H2O, which was filter sterilised using a 0.2 
µL filter, aliquot and stored at -20 °C. 
20 % (w/v) glucose stock contained 2 g/ 10 mL of glucose in H2O, which was filter sterilised 
using a 0.2 µL filter, aliquot and stored at room temperature. 
7.2  Transformation protocol 
Frozen 25 µL aliquots of the appropriate E. coli strain were defrosted on ice. 0.5 µL of plasmid 
DNA was added and incubated on ice for 30 minutes. The cells were heat-shocked at 42 °C for 
30 seconds and immediately placed onto ice. After resting on ice for 2 minutes, 200 µL SOC 
medium was added and the tubes were incubated in a water bath at 37 °C for 1 hour. 100 µL 
portions of the transformation mixture were spread into LB agar plate containing the appropriate 
antibiotic(s) and the plates incubated at 37 °C. Agar plates for transformation of E. coli BL21 
142 
 
(DE3) contain (1 mL/L) carbenicillin. Agar plates for transformations of E. coli Rosetta strain 
contain (1 mL/L) carbenicillin and (1 mL/L) chloramphenicol.  
7.3  Standard expression protocol 
Following transformation with the appropriate expression plasmid, a single transformed E. coli 
colony was used to inoculate a 50 mL sterile LB starter culture medium containing appropriate 
antibiotic(s). This was grown to stationary phase overnight at 37 °C with shaking.  This starter 
culture was used to inoculate auto induction medium supplemented with the appropriate 
antibiotic(s) at 1:100 dilution in 500mL flasks each containing 200 mL medium. The flasks 
were incubated at 37 °C with shaking until the OD600 reached 0.6. 
The temperature of the culture was then adjusted to the expression temperature of 19 °C and 
induced with the appropriate inducer (1 M IPTG or rhamnose) solution which was added with 
the appropriate final concentration. The cultures were incubated with shaking overnight and 
cells were harvested by centrifugation. The cell pellets were suspended in binding buffer.  
7.4  Optimised expression protocol  
E. coli BL21 gold (DE3) was used as a host for protein expression. Following transformation 
with the appropriate expression plasmid using LB-Glu/Car agar plates, a single colony was used 
to inoculate a 50 mL sterile LB starter culture medium containing appropriate antibiotic(s). This 
was grown to stationary phase overnight at 30 °C with shaking.  This starter culture was used to 
inoculate auto induction medium supplemented with the appropriate antibiotic(s) at 1:100 
dilution in 500mL flasks each containing 200 mL of LB medium. The flasks were incubated at 
37 °C with shaking for 4 hours. The temperature of the culture was then adjusted to the 
expression temperature of 16 °C. Induction when needed was induced with 0.4 mM IPTG. The 
cultures were incubated with shaking for a further 4 hours and cells were harvested by 
centrifugation. The cell pellets suspended in binding buffer containing protease inhibitor 
cocktail and were refrigerated overnight before being purified the following day. 
7.5  Protein purification 
7.5.1  SDS-Page analysis of protein 
Proteins were analysed on 12.5 % tris-glycine polyacrylamide gels using a Bio-Rad Mini-
Protean
TM
gel casting and electrophoresis system. A separating gel was poured between glass 
plates, overlaid with water-saturated butanol to create a flat surface. Once the gel had set, the 
butanol was removed, and the stacking gel solution was poured to the top of the gel and a 15 






Component Volume (mL) Final concentration 
Stacking gel 
1 M tris-HCl pH 6.8 0.25 0.125 M 
10 % SDS 0.02 0.1 % 
40 % acrylamide/bisacrylamide 37.5:1 0.25 5 % 
H2O 1.46 - 
10 % ammonium persulphate 0.02 0.1 % 
TEMED 0.002 6.6 mM 
Separating Gel 
1.5 M tris-HCl pH 8.8 1 0.375 M 
10 % SDS 0.04 0.1 % 
40 % acrylamide/bisacrylamide 37.5:1 1.25 12.5 % 
H2O 1.67 - 
10 % ammonium persulphate 0.04 0.1 % 
TEMED 0.002 13 mM 
 
Gels were placed in the electrophoresis tank and SDS-PAGE running buffer was poured around 
the gels. For Tris-glycine gels, a single running buffer was prepared from a 10x concentrate. 
The running buffer contained tris base 68 g/L, glycine 144 g/L, SDS 10 g/L. 
Samples from electrophoresis were mixed with 5x SDS-PAGE loading buffer and heated at 
95 °C for 5 minutes.  
Component Concentration 
Tris-HCl pH 6.8 50 mM 
Glycerol 40 % 
SDS 1 % 
β-mercaptoethanol 10 mM 
Bromophenol blue % 
 
7.5.2 Purification buffers 
Binding buffer contained 20 mM Tris-HCl pH8, 150 mM NaCl, 5 mM imidazole, 10 % 
glycerol, 100 mM L-Arginine and L-Glutamic acid. 
Elution buffer contained 20 mM Tris-HCl pH8, 150 mM NaCl, 400 mM imidazole, 10 % 
glycerol 100 mM L-Arginine and L-Glutamic acid. 
Desalting buffer contained 20 mM Tris-HCl pH8, 150 mM NaCl, 10 % glycerol 100 mM L-





 affinity purification protocol 
The cell pellet from E. coli cultures was suspended in elution buffer (35-50 mL for each L of 
culture). The cell suspension was sonicated in a glass beaker on ice at full power for 30 second 
bursts with 30 seconds rest between bursts for a total of 6 minutes. The lysate was clarified by 
centrifugation (17,000 RPM for 15 minutes). 
A 25 mL his-trap (GE healthcare) column was attached to  FPLC instrument and charged with 
100 mM NiSO4 and equilibrated with 200 mL binding buffer. The clarified lysate was then 
loaded onto the column using an FPLC super loop. The column was then washed with enough 
of binding buffer for the UV trace to settle. The bound protein was eluted over a gradient of 0-
100 % elution buffer in 100 mL. 5 mL fractions were collected. Fractions for which a peak in 
the UV280 absorbance trace was observed were analysed by SDS-PAGE to determine the purity 
and size of the eluted protein.  
Binding buffer contained 20 mM Tris-HCl pH8, 150 mM NaCl, 5 mM imidazole and 10 % 
glycerol. Elution buffer contained 20 mM Tris-HCl pH8, 150 mM NaCl, 400 mM imidazole and 
10 % glycerol. 
7.5.4  Desalt purification protocol  
After Ni
2+
 affinity purification the protein was concentrated using a Vivaspin 20 centrifugal 
concentrator with a 10 kDa cutoff. A HiPrep
TM
 26/10 desalting column was equilibrated with 
1.5 column volumes of desalting buffer (20 mM Tris-HCl pH8, 150 mM NaCl, 10 % glycerol 
100 mM L-Arginine and L-Glutamic acid). Up to 10 mL of protein (for 100 mL HiPrep
TM
 26/10 
column) was injected and eluted over one column volume. When the beginning of a peak in 
UV280 absorbance trace was observed one fraction was collected. 
7.5.5  Size exclusion purification protocol 
Protein for size exclusion chromatography was concentrated using a Vivaspin 20 centrifugal 
concentrator with a 10 kDa cutoff. A supersex S300 column was equilibrated with 1.5 column 
volumes of desalting buffer (20 mM Tris-HCl pH8, 150 mM NaCl, 10 % glycerol 100 mM L-
Arginine and L-Glutamic acid). Up to 2 mL of protein (for 120 mL S200 column) was injected 
and eluted over one column volume. 5 mL fractions were collected and those for which a peak 




7.6  DH enzyme assay 
7.6.1  DH protein production 
E. coli BL21 (DE3) were transformed using the expression plasmid #7615 pOpinF as detailed in 
section 7.2 and expressed as detailed in section 7.4 DH protein was prepared by Ni
2+
 affinity 
and size exclusion chromatography as described in section 7.7.1.  
7.6.2  DH substrate specificity enzyme assay 
DH substrate specificity enzyme assays were performed in a volume of 100 µL and contained 
the following: 
Component Volume (µL) concentration 
1 M Tris-HCl pH8 10 50 mM 
50 % Glycerol 40 33 % 
Substrate mimic 10 ~10 mM 
DH (10 mg.mL) 50 132 µM 
 
The mixture was incubated at 30 °C for 8 hours. For analysis, at set time points, 20 µL aliquots 
were taken and mixed with 60 µL of acetonitrile, 20 µl H2O, then centrifuged in a 
microcentrifuge to remove the precipitated protein. The supernatant was removed analysed by 
LC-MS as described in section 7.7.1.. 
7.6.3  DH inhibition assays 
DH substrate specificity enzyme assays were performed in a volume of 100 µL and contained 
the following: 
Component Volume (µL) concentration 
1 M Tris-HCl pH8 10 50 mM 
50 % Glycerol 40 33 % 
Substrate (2R,3R) 5 2.00 mM 
Substrate (2S,3S) or (2R,3S) or (2S,3R) 5 2.00 mM 
DH (5 mg.mL) 50 66 µM 
 
The mixture was incubated at 30 °C for 1 hour. For analysis, at set time points, 20 µL aliquots 
were taken and mixed with 60 µL of acetonitrile, 20 µl H2O, then centrifuged in a 
microcentrifuge to remove the precipitated protein. The supernatant was removed and analysed 
by LC-MS as described in section 7.7.1.  
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7.6.4  DH Kinetic enzyme assay 
DH substrate specificity enzyme assays were performed in a volume of 100 µL and contained 
the following: 
Component Volume (µL) concentration 
1 M Tris-HCl pH8 10 50 mM 
50 % Glycerol 40 33 % 
Substrate mimic 10 0.2-3.99 mM 
DH ( mg.mL) 50 132 µM 
 
The mixture was incubated at 30 °C for 1 hours. For analysis, at set time points, 20 µL aliquots 
were taken and mixed with 60 µL of acetonitrile, 20 µl H2O, then centrifuged in a 
microcentrifuge to remove the precipitated protein. The supernatant was removed and analysed 




7.7  General synthetic techniques 
7.7.1  Synthetic methods 
All reagents were purchased from commercial suppliers and used without further purification, 
unless otherwise stated. Common anhydrous solvents were obtained by passing through a 
modified Grubbs system of alumina columns, manufactured by Anhydrous Engineering.
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DMF was purchased as an anhydrous solvent. Triethylamine and diisopropylamine were 
distilled over calcium hydride and stored under an inert nitrogen atmosphere.  
All moisture or air sensitive reactions were carried out in flame dried glassware under a positive 
pressure of nitrogen using standard Schlenk-line techniques. After aqueous work of reaction 
mixtures, organic solutions were routinely dried with anhydrous magnesium sulphate. 
Column Chromatography 
Column chromatography was performed using Merck Kieselgel 60 silica gel, eluting with the 
solvent system stated. Columns were eluted under pressure and the fractions analysed by TLC. 
Fractions with the same Rf were pooled and concentrated in vacuo.  
NMR 
NMR spectra were recorded at 25 °C using Varian 400-MR or Jeol ECP (Eclipse) 400 




C spectra as stated. Proton spectra are referenced to 
CDCl3 at 7.26 ppm for proton and 77.4 ppm for carbon. Coupling constants are given to 1 
decimal place and are in Hertz (Hz). The abbreviations used to denote 
1
H NMR are as follows; 
s, singlet; d doublet; dd, doublet of doublets; dq, doublet of quartets; t, triplet; q,  quartet; qd, 
quartet of doublets; pent., pentet; m, multiplet; br, broad. Abbreviations used to describe 
1
H 
NMR assignment are as follows; Ar, aryl. Signal assignment was aided by analysis of COSY, 
HMBC and HMQC where necessary.  
TLC 
Thin layer chromatography was carried out on Merck glass backed TLC plates coated with 0.2 
mm silica gel or Merck DC-Alufolien Kieselgel 60 F254 aluminium-backed silica plates TLC 
plates. Plates were visualised with 254 nm UV light and developed with either a KMnO4 or 
p-anisaldehyde solution and developed with a heat gun, where appropriate.    
IR 
Infrared (IR) spectroscopy was recorded on a Perkin Elmer Spectrum 100 FT-IR spectrometer 
with an ATR diamond cell irradiating between 4000 cm
−1







Melting points were determined using an electrothermal melting point apparatus and are 
uncorrected. 
Optical rotation  
Optical rotations were determined with the sodium D line (λ= 589 nm) using a Perkin Elmer 
241 MC polarimeter.     








Mass spectra (both high and low resolution) were recorded on a Bruker Daltonics Apek 4e 7.0T 
FT-MS mass spectrometer mass and were obtained by electrospray ionisation (ESI) or chemical 
ionisation (CI). 
LCMS  
Chromatography was performed using a Water 2695 HPLC system and phenomenex KineticTM 
C18 reverse-phase column (150 x 2.5 mm, 100 Å with a flow rate of 1 mL min
-1
. Solvents were 
A: H2O + 0.05% formic acid and B: CH3CN + 0.05% formic acid. A gradient elution was 
performed as follows over 10 minutes: 
 
Single Ion Response (SIR) of certain mass ions was monitored over different time points as 
follows: 
Event Mass ion Time (minutes) 
MS Scan 100-600 ES- 0.00-10.00 
SIR (internal standard) 196.40 1.40-3.40 
SIR (Substrate) 242.20 2.00-4.00 
SIR (dehydrated product) 224.20 4.00-6.00 
 
Typically, 20 µL of sample was injected and detection was by Waters 2998 PDA and Waters 
Quatro micro API MS. MS was performed in ESI+ and ESI- modes. Typical MS conditions 
were as follows: capillary voltage (kV) 3.3; cone voltage (V): 30, desolvation gas flow (L min -
1): 600; cone gas flow (L min-1): 50. 









7.8  Synthesis of diketide substrates 





A solution of poly-3-(R)-hydroxybutyrate (10 g) in ethanol (70 mL), 1,2-dichloroethane (60 
mL) and concentrated sulfuric acid (4 mL) was heated to reflux for 96 hours. The mixture was 
allowed to cool to room temperature and filtered through celite. The celite was washed with 
dichloromethane (100 mL) and the filtrate washed with NaHCO3 (100 mL), brine (100 mL), 
dried (MgSO4) and concentrated in vacuo. The crude material was distilled (72 °C at 11 mmHg) 
to give the title compound 141 (colourless oil, 8.40 g, 63 mmol, 55%).     
   -38.0 (c 1.0, 
CHCl3), [lit [    -44 (c 1.0, CHCl3)]
109
; δH (400 MHz, CDCl3): 1.12 (3H, d, J = 6.3 Hz, 3-CH3), 
1.26 (3H, t, J = 7.2 Hz, OCH2CH3), 2.44 (2H, qd, J = 8.7, 3.6 Hz, 2-CH2), 3.05 (1H, br s, OH), 
4.16 (3H, m, OCH2 & 3-CH); δC (400 MHz, CDCl3); 14.2 (OCH2CH3), 22.5 (3-CH3), 42.9 (2-















Diisopropylamine (12.2 mL, 87.1 mmol) was dissolved in anhydrous THF (80 mL) under 
nitrogen and cooled to -78 °C. n-Butyl lithium (2.36 M, 27.1 mL, 87.1 mmol) was added 
dropwise and the mixture stirred at -78 °C for 1 hour. A solution of ethyl (3R)-3-
hydroxybutyrate 141 (5.01 g, 37.9 mmol) in anhydrous THF (20 mL) was added dropwise. The 
cold bath was removed and the mixture stirred at room temperature for 20 minutes, after which 
it was cooled back to -78 °C and methyl iodide (1.4 eq, 3.30 mL, 53.0 mmol) was added 
dropwise. The reaction was stirred at 0 °C for 3 hours, then quenched with 6 M aq. HCl (60 
mL). The layers were separated and the aqueous layer was extracted with Et2O (4 x 40 mL). The 
organic phases were combined, dried (MgSO4), filtered and concentrated in vacuo. 
The resulting residue was dissolved in anhydrous CH2Cl2 (100 mL) under nitrogen. Pyridine 
(6.40 mL, 78.5 mmol) was added. The mixture was cooled to 0 °C and tert-butyldimethylsilyl 
triflate (10.4 mL, 45.4 mmol) was added dropwise. The reaction was stirred at room temperature 
for 1 hour, after which it was quenched with sat. aq. NaHCO3, (20 mL). The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (2 x 100 mL). The organic phases 
were combined, dried (MgSO4), filtered and concentrated in vacuo. Purification of the crude 
residue by flash chromatography (5% EtOAc, in PE) gave the title compound 143 (4.8 g, 32.9 
mmol, 86% over two steps) as a colourless oil.     
     - 36.0 (c 1.0, CHCl3), [lit      -31.5 (c 
1.9, CHCl3)]
116
;   δH (400 MHz, CDCl3); 0.02 (3H, s, SiCH3), 0.05 (3H, s, SiCH3), 0.85 (9H, s, 3 
x CH3), 1.07 (3H, d, J = 7.1 Hz, 2-CH3), 1.10 (3H, d, J = 6.2 Hz, 3-CH3), 1.25 (3H, t, J = 6.9 
Hz, OCH2CH3), 2.47 (1H, pent.. J = 7.3 Hz, 2-H), 4.01 (1H, dq, J = 6.4, 6.2 Hz, 3-H), 4.10 (2H, 
q, J = 7.1 Hz, OCH2);  δC (400 MHz, CDCl3); -4.9 (Si-CH3), -4.23 (Si-CH3), 12.8 (2-CH3), 14.3 
(OCH2CH3), 18.1 (Si-C(CH3)3) 20.7 (3-CH3), 25.9 (Si-C(CH3), 48.3 (2-CH), 60.3 (OCH2), 70.3 













MeOH (12 mL) and lithium hydroxide (414 mg, 17.2 mmol) in water (2 mL) were added to 
ester 143 (1.50 g, 5.76 mmol) dissolved in THF (5 mL). The reaction mixture was heated to 60 
°C overnight. The reaction was diluted with water (8 mL) and extracted with Et2O (2 x 15 mL). 
The aqueous layer was acidified to pH 3 with H2SO4 (6 M) and further extracted with EtOAc (3 
x 15 mL), the pH was adjusted to pH 3 as required. The organic layers were combined, dried 
(MgSO4), filtered and concentrated in vacuo to give a yellow oil. Purification by flash 
chromatography (SiO2, 10% EtOAc/ Petrol/ 0.5% acetic acid, visualised with KMnO4) afforded 
the title compound 144 (550 g, 2.37 mmol, 41%) as a colourless oil.     
     -7.0 (c 1.0, CHCl3), 
[lit      -12.5 (c 1.0, CHCl3)]
170
; δH (400 MHz, CDCl3); 0.11 (3H, s, SiCH3), 0.13 (3H, s, 
SiCH3), 0.91 (9H, s, SiC(CH3)3), 1.23 (3H, d, J = 7.0 Hz, 2-CH3), 1.25 (3H, d, J = 6.1 Hz, 
3-CH), 2.52 (1H, dq, J = 7.5, 4.5 Hz, 2-CH) 3.97 (1H, q, J = 7.2 Hz, 3-CH); δC (400 MHz, 
CDCl3); 5.0 (SiCH3), 4.2 (SiCH3), 13.3 (2-CH3), 18.0 (SiC(CH3)3) 21.0 (3-CH3), 25.8 
(SiC(CH3)3), 48.0 (2-CH), 70.4 (3-CH), 175.4 (CO).  νmax(neat) / cm
-1
:2930 (OH), 2887 (CH), 
1708 (C=O), 1115 (CO), 831 (Si-CH3). 
1











Potassium hydroxide (6M) was added to a solution of cysteamine hydrochloride (30.8 mmol, 
3.60 g) in water (20 mL) at 0 °C until pH 8 was reached. Acetic anhydride (92.4 mmol, 5.82 
mL) was added dropwise keeping the reaction at pH 8 using potassium hydroxide (6 M). After 
the addition of acetic anhydride the pH was adjusted to 7 with hydrochloric acid (2 M) and 
stirred at 0 °C for 1.5 hours. The mixture was extracted with CH2Cl2 (5 x 25 mL), dried 
(MgSO4), filtered and concentrated in vacuo to give the title compound 181 as a colourless oil, 
(2.70 g, 54% yield). δH (400 MHz, CDCl3): 1.96 (3H, s, CH3), 2.34 (3H, s, CH3), 3.00 (2H, t, J = 
6.5 Hz, S-CH2), 3.41 (2H, dt, J = 6.5 Hz, N-CH2), 6.06 (1H, br s, NH); δc (400 MHz, CDCl3): 
23.3 (4-CH3), 28.9 (1-CH3), 30.8 (S-CH2), 39.7 (N-CH2), 170.6 (1-CO), 196.4 (4-CO); νmax 
(oil)/cm-
1












Potassium hydroxide (9.07 g, 155 mmol) was added to a solution of N,S-diacetylcysteamine  
151 (5.28 g, 31.0 mmol) dissolved in water (30 mL) at 0 °C. The reaction was warmed to room 
temperature and stirred for 1 hour before being cooled to 0 °C and acidified to pH 5. The  
aqueous layer extracted with CH2Cl2 (3 x 30 mL). The organic extracts were combined, dried 
(MgSO4) and concentrated in vacuo to give the title compound 151 as a colourless oil (3.01 g, 
26.0 mmol, 82% yield). δH (400 MHz, CDCl3): 1.36 (1H, t, J = 8.1 Hz, SH), 1.83 (3H, s, 1-
CH3), 2.48 (2H, q, J = 7.0 Hz, CH2S), 3.21 (2H, q, J = 6.6 Hz, CH2N); δC (400 MHz, CDCl3)
173
: 











7.8.1.6 (2R, 3R)-3-Tert-butyldimethylsilyloxy-2-methylbutanoyl-N-actylcysteamine 
145 
 
EDCI (405 mg, 2.60 mmol) and DMAP (23.0 mg, 0.20 mmol) were added to a solution of acid 
144 (402 mg, 1.80 mmol) in anhydrous CH2Cl2 (25 mL) at 0 °C under nitrogen . After stirring at 
0 °C for 15 minutes, HSNAC 151 was added in anhydrous CH2Cl2 (10 mL). The mixture was 
allowed to warm to room temperature and stirred overnight. The reaction was quenched with 
water (15 mL) and the layers separated. The aqueous phase was extracted with CH2Cl2 (3 x 25 
mL). The organic layers were combined, dried (MgSO4), filtered and concentrated in vacuo. 
Purification by flash chromatography gave the title compound 145 (360 mg, 1.10 mmol, 59%) 
as a pale yellow oil.     
     -69.4 (c 1.0, CHCl3); δH (400 MHz, CDCl3); 0.00 (3H, s, Si-CH3), 
0.04 (3H, s, Si-CH3), 0.85 (9H, s, Si-C(CH3)3), 1.10 (3H, d, J = 7.0 Hz, 2-CH3), 1.12 (3H, d, J = 
6.1 Hz, 3-CH3), 2.70 (1H, dt. J = 7.4 Hz, 2-CH), 2.99 (2H, m, S-CH2), 3.42 (2H, m, N-CH2), 
4.04 (1H, dq, J = 7.2 Hz , 3-CH), 5.85 (1H, br s, NH); δC (400 MHz, CDCl3); -5.1 (Si-CH3), -4.2 
(Si-CH3), 13.6 (2-CH3), 18.1 (Si-C(CH3)3), 20.9 (3-CH3), 23.4 (CH3), 25.9 (Si-C(CH3)3), 28.6 
(S-CH2), 38.9 (N-CH2), 56.9 (2-CH), 70.3 (3-CH), 170.3 (N-CO), 203.2 (S-CO); νmax (neat) / 
cm
-1
: 3284 (NH), 2955 (CH), 2929 (CH),2856 (CO-CH3), 1688 (S-CO), 1654 (N-CO), 836 (Si-
CH3); m/z (ESI) 356.17 [M+Na
+














7.8.1.7 (2R,3R)-3-Hydroxy-2-methylbutanoyl-N-acetylcysteamine 114 
 
TBDMS-ether 145 (150 mg, 0,45 mmol) was dissolved in THF (1.3 mL), water (1.3 mL) and 
acetic acid (4 mL) and stirred at room temperature for 5 days. The reaction was diluted with 
water (25 mL) and the aqueous layer washed with CH2Cl2 (25 mL). The aqueous layer was 
concentrated to give the title compound 114 (78.0 mg, 0.35 mmol, 79%) as a colourless oil. 
    
     -32.8 (c 0.33, CHCl3); δH (400 MHz, CDCl3);1.19, (3H, d, J = 7.1 Hz, 2-CH3), 1.23 (3H, 
d, J = 6.3 Hz, 3-CH3), 1.96 (3H, s, CO-CH3),2.69 (1H, dt, J = 7.2 Hz, 2-CH), 3.05 (2H, m, S-
CH2), 3.45 (2H, m, N-CH2), 3.94 (1H, dt, J = 6.2 Hz, 3-CH), 5.88 (1H, br s, NH); δC (400 MHz, 
CDCl3); 14.9 (2-CH2), 21.2 (3-CH3), 23.3 (CO-CH3), 28.7 (S-CH2) 39.5 (N-CH2), 56.1 (2-CH), 
70.1 (3-CH), 170.7 (N-C=O), 204.0 (S-C=O); ); νmax (neat) / cm
-1
: 3287 (NH), 3134 (OH), 2973 
(CH), 2932 (CH), 1654 (NC=O), 1548 (SC=O); 1438 (NH); m/z (ESI) 242.08 [M+Na
+
]; Found 
(ESI) 242.0822 (C9H17NaNO3S requires 242.0821). 
1












400 MHz and 
13
C NMR, 100 MHz, of (3R, 2R) 114 in CDCl3. 
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7.8.2  (2S,3S)-3-Hydroxy-2-methylbutanoyl-N-acetylcysteamine 115 




Diisopropylamine (5.0 mL, 35.5 mmol) was dissolved in anhydrous THF (30 mL) under 
nitrogen and cooled to -78 °C. n-Butyl lithium (2.15 M, 16.5 mL, 35.5 mmol) was added 
dropwise and the mixture stirred at -78 °C for 1 hour. A solution of methyl (3S)-3-
hydroxybutyrate (2.00 g, 16.5 mmol) in anhydrous THF (12 mL) was added dropwise. The cold 
bath was removed and the mixture stirred at room temperature for 20 minutes, after which it 
was cooled back to -78 °C and methyl iodide (1.30 mL, 21.1 mmol) was added dropwise. The 
reaction was stirred at 0 °C for 3 hours, then quenched with 6 M aq. HCl (20 mL). The layers 
were separated and the aqueous layer was extracted with Et2O (4 x 20 mL). The organic layers 
were combined, dried (MgSO4), filtered and concentrated in vacuo. 
The resulting residue was dissolved in anhydrous CH2Cl2 (40 mL) under nitrogen. Pyridine 
(2.90 mL, 35.5 mmol) was added. The mixture was cooled to 0 °C and tert-butyldimethylsilyl 
triflate (4.70 mL, 20.3 mmol) was added dropwise. The reaction was stirred at room temperature 
for 1 hour, after which it was quenched with sat. aq. NaHCO3, (20 mL). The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (2 x 40 mL). The organic layers 
were combined, dried (MgSO4), filtered and concentrated in vacuo. Purification of the crude 
residue by flash chromatography (5% EtOAc, in petroleum ether) gave the title compound 154 
(2.50 g, 10.3 mmol, 63% over two steps) as a pale yellow oil.     
     +37.3 (c 1.0, CHCl3), [lit 
     +37.1 (c 1.43, CH,Cl3)]
118
 δH (400 MHz, CDCl3); 0.01 (3H, s, Si-CH3), 0.04 (3H, s, Si-
CH3), 0.85 (9H, s, Si-C(CH3)3), 1.06 (3H, d, J = 7.1 Hz, 2-CH3), 1.10 (3H, d, J = 6.2 Hz, 3-
CH3), 2.49 (1H, dq., J = 7.2 Hz, 2-CH), 3.65 (3H, s, CO-CH3), 3.99 (1H, dq. J = 6.2, 7.4 Hz, 3-
CH). δC (400 MHz, CDCl3); -5.0 (Si-CH3), -4.2 (Si-CH3), 12.9 (2-CH3), 18.0 (Si-C(CH3)), 20.7 
(3-CH3), 25.8 (Si-C(CH3)3), 48.3 (2-CH), 51.5 (O-CH3), 70.3 (3-CH), 175.3 (CO);  νmax(neat) / 
cm
-1















Ester 154 (1.00 g, 4.1 mmol) was dissolved in THF (5 mL) and MeOH (8 mL) and lithium 
hydroxide (291 mg, 12.2 mmol) in water (1.5 mL) was added. The reaction mixture was heated 
to 60 C overnight. The reaction was cooled and diluted with water (7 mL) and extracted with 
Et2O (2 x 10 mL). The aqueous layer was acidified to pH 3 with H2SO4 (6 M) and further 
extracted with EtOAc (3 x 15 mL), the pH was adjusted to pH 3 as required. The organic layers 
were combined, dried (MgSO4), filtered and concentrated in vacuo to give a yellow oil. 
Purification by flash chromatography (SiO2, 10% EtOAc/ petroleum ether, 0.5% acetic acid 
visualised with KMnO4) afforded the title compound 155 (416 g, 1.79 mmol, 44%) as a pale 
yellow oil.     
     +7.9 (c 1.0, CHCl3), [lit      +5.7 (c 0.88, CH,Cl3)]
174
; δH (400 MHz, 
CDCl3); 0.07 (3H, s, Si-CH3), 0.08 (3H, s, Si-CH3), 0.88 (Si-C(CH3)3), 1.16 (3H, d, J = 7.1 Hz, 
2-CH3), 1.18 (3H, d, J = 6.2 Hz, 3-CH3), 2.51 (1H, dq., J = 6.1 Hz, 2-CH), 4.00 (1H,dq , J = 6.2 
Hz, 3-CH); νmax (neat) / cm
-1
: 2953 (CH), 2930 (CH), 2886 (CH), 2857 (CH), 1740 (CO). 
1
H 








Acid 155 (225 mg, 0.92 mmol) was dissolved in anhydrous CH2Cl2 (10 mL) at 0 °C  under 
nitrogen. EDCI (245 mg, 1.28 mmol) and DMAP (1.0 mg, 0.10 mmol) were added. After 
stirring at 0 °C for 15 minutes, HSNAC 151 (152 mg, 1.28 mmol) was added in dry CH2Cl2 (10 
mL). The mixture was allowed to warm to room temperature and stirred overnight. The reaction 
was quenched with water (5 mL) and the layers separated. The aqueous phase was extracted 
with CH2Cl2 (3 x 15 mL). The organics were combined, dried (MgSO4), filtered and 
concentrated in vacuo. Purification by flash chromatography (SiO2, 3% MeOH/ CH2Cl2 
visualised with KMnO4) gave the title compound 156 (169 mg, 0.51 mmol, 55%) as a pale 
yellow oil.     
      +56.9 (c 1.0, CHCl3); δH (400 MHz, CDCl3); 0.01 (3H, s, Si-CH3), 0.05 (3H, 
s, Si-CH3), 0.85 (9H, s, Si-C(CH3)3), 1.10 (3H, d, J = 7.0 Hz, 2-CH3), 1.12 (3H, d, J = 6.1 Hz, 3-
CH3), 1.96 (3H, s, CO-CH3), 2.71 (1H, dq J = 7.2 Hz, 2-CH), 3.00 (2H, m, S-CH2), 3.43 (2H, m, 
N-CH2), 4.03 (1H, dq. J = 6.8 Hz, 3-CH); δc (400 MHz, CDCl3); -5.1 (Si-CH3), -4.2 (Si-CH3), 
13.6 (2-CH3), 18.1 (SiC(CH3)3), 20.9 (3-CH3), 23.4 (CO-CH3), 25.9 (SiC(CH3)3), 28.5 (S-CH2), 
39.9 (N-CH2), 56.9 (2-CH), 70.3 (3-CH), 170.0 (N-CO), 203.2 (S-CO);  νmax (neat) / cm
-1
: 3285 
(NH), 2955 (CH), 2929 (CH), 2884 (CH), 2586 (CH), 1687 (CO), 1653 (CO); ); m/z (ESI) 
356.17 [M+Na
+








400 HHz, and 
13




7.8.2.4 (3S, 2S)-3-Hydroxy-2-methylbutanoyl-N-acetylcysteamine 115 
 
TBDMS-ether 156 (100 mg, 0.30 mmol) was dissolved in THF (0.9 mL), water (0.9 mL) and 
acetic acid (2.6 mL) and stirred at room temperature for 5 days. The reaction was diluted with 
water (25 mL) and the aqueous layer washed with CH2Cl2 (25 mL). The aqueous layer was 
concentrated to give the title compound 115 (37 mg, 0.16 mmol, 56%) as a colourless oil. 
    
     +36.8 (c 0.64, CHCl3); δH (400 MHz, CDCl3); 1.17 (3H, d, J = 7.1 Hz, 2-CH2), 1.23 (3H, 
d, J = 6.3 Hz, 3-CH3), 1.95 (3H, s, CO-CH3), 2.68 (1H, pent. J = 7.2 Hz, 2-CH), 3.02 (2H, m, S-
CH2), 3.43 (2H, m, N-CH2), 3.94 (1H, pent., J = 6.8 Hz, 3-CH), 6.15 (1H, br s, NH); (400 MHz, 
CDCl3); 15.0 (2-CH3), 21.2 (3-CH3), 23.3 (NCO-CH3), 28.7 (S-CH2), 39.5 (N-CH2), 56.1 (2-
CH), 70.1 (3-CH), 170.8 (NC=O), 204.1 (SC=O); νmax(neat) / cm
-1
:3287 (NH), 3134 (OH), 2973 
(CH), 2931 (CH), 1653 (NC=O), 1549 (SC=O), 1449 (NH); ); m/z (ESI) 242.08 [M+Na
+
]; 





















(S)-4-Benzyl-2-oxazolidinone  127 (1.01 g, 5.60 mmol) was dissolved in dry THF (20 mL) 
under N2 and cooled to -78 °C, n-BuLi (1.95 M in hexane) (2.80 mL, 5.60 mmol) was added 
dropwise and the solution stirred for 20 minutes. Propionyl chloride (0.60 mL, 6.20 mmol) was 
added and stirred for 3 hours before being warmed to room temperature. The reaction was 
quenched with NH4Cl aq.  (5 mL) and the majority of the THF was removed in vacuo. CH2Cl2 
(10 mL) was added and the solution washed with 10% aq NaOH. The aqueous layer was 
extracted with CH2Cl2 (2 x 20 ml). The organic layers were combined, washed (brine), dried 
(MgSO4), filtered and concentrated in vacuo to give the title compound 129 (0.93 g, 3.98 mmol, 
72% yield) as a white solid. mp 41.5-43 °C (from CH2Cl2),     
     +82.5 (c 0.3, CHCl3), [lit 
[α]D +90.4 (c = 0.95, CHCl3)]
176
;  δH (400 MHz, CDCl3); 1.21 (3H, t, J = 7.4 Hz, 7-CH3), 2.77 
(1H, dd, J = 13.4, 9.6 Hz, 8-CH2), 2.96 (2H, q, J = 7.3 Hz, 7-CH2), 3.31 (1H, dd, J = 13.4, 3.4 
Hz, 8-CH2), 4.19 (2H, m, 5-CH2O), 4.67 (1H, m, 4-CHN), 7.29 (5H, m, Ar-H); νmax (neat) / cm
-
1
: 2983 (CH), 2940 (CH), 2919 (CH), 1780 (CO), 1699 (CO). 
1












(S)-4-benzyl-3-propionyloxazolidin-2-one 129 (1 eq, 207 mg, 0.858 mmol) was dissolved in dry 
CHCl2 (2 mL) under N2, cooled to 0 °C and gently deoxygenated. Dibutyl boron triflate (1.2 eq, 
1.03 mL, 1.03 mmol) was added slowly dropwise. Triethylamine (1.2 eq, 0.14 mL, 1.03 mmol) 
was then added slowly dropwise before the solution was cooled to -78 °C and acetaldehyde (10 
eq, 0.5 mL 8.89 mmol) added. The solution was stirred at -78 °C for 20 minutes, before being 
allowed to warm slowly to 0 °C over 3.5 hours. The reaction was quenched with MeOH/1M 
phosphate buffer (8 mL:3:1). MeOH/30 % aq. hydrogen peroxide (6 mL, 2:1) was then added 
slowly, keeping the temperature below 10 °C and stirred for 1 hour. The volatiles were removed 
and the resulting slurry extracted with ether (3 x 10 mL). The ether layers were combined and 
washed with 5 % 2NaHCO3 (6 mL, 0.3 g) and brine (6 mL). Sodium sulfite solution (2M) (6 
mL) was then added to the ether layer and stirred for 1 hour before being extracted with ether (2 
x 10 mL). The organic layers were combined, dried (MgSO4) and concentrated in vacuo. The 
crude product was purified using column chromatography (solvent system 50:50 ethyl acetate: 
petrol (40-60 °C) to give the title compound Figure 40) 163 (clear colourless oil, 149 mg, 0.594 
mmol, 59 %). [α]D
22
 +47.5 (c 1.0, CHCl3), [lit [α]D + 70.4 (c 1.04, CHCl3)]
102
; δH (400 MHz, 
CDCl3); 1.23 (3H, d, J = 6.9 Hz, 2-CH3), 2.77 (1H, dd, J = 13.4, 9.5 Hz, CH2Ph), 3.05 (1H, br s, 
OH), 3.25 (1H, dd, J = 13.5, 3.4 Hz, CH2Ph), 4.10 (3H, m, CH2O & CHN), 4.60 (1H, m, 2-CH), 
5.10 (1H, d, J = 3.7 Hz, 3-CH), 7.32 (10H, m, Ar-H). δc (400 MHz, CDCl3); 11.1 (2-CH3), 38.0 
(CH2Ph), 55.68 (CHN), 66.43 (CH2O), 55.1 (2-CH), 73.83 (3-CH), 126.3 (Ar-C), 127.6 (Ar-C), 









(S)-4-Benzyl-3-propionyloxazolidin-2-one 129 (850 mg, 3.65 mmol) was dissolved in 
anhydrous CH2Cl2 (10 mL) and cooled to -78 °C under N2. Dibutyl boron triflate (1 M in 
CH2Cl2, 7.30 mL, 7.30 mmol) was added dropwise over 1 hour. After 10 minutes triethylamine 
(1.27 mL, 9.13 mmol) was added dropwise and the solution stirred for 1 hour at -78 °C, then 
100 minutes at 0 °C. The solution was cooled to -78 °C and a solution of acetaldehyde (10 eq, 
2.05 mL, 36.5 mmol) in anhydrous CH2Cl2 (1.0 mL) also at -78 °C was added slowly. After 
stirring for 2 hours at -78 °C and then 100 minutes at 0 °C, phosphate buffer (pH 7.1 M, 28 mL) 
and MeOH (28 mL) were added, the resulting mixture was stirred vigorously in an ice bath as 
30% H2O2 (14 mL) was added dropwise. After 30 minutes at 10-15 °C, the solvent was removed 
in vacuo and the resulting residue was partitioned between saturated NaCO3 aq. and CH2Cl2 (8 
mL). The aqueous layer was extracted with CH2Cl2 (2 x 8 mL) and the combined organic layers 
were washed with saturated NaCO3 aq. (8 mL), dried (MgSO4), filtered, and concentrated in 
vacuo to give a crude pale yellow oil. The crude material was purified by flash chromatography 
(SiO2, 20% to 40% EtOAc /petroleum ether. visualized with KMnO4) to give the aldol adduct 
138 as a colourless oil (602 mg, 2.10 mmol, 69% yield).     
     +48.8 (c = 1.0, CHCl3), [lit. 
[α]D +51.1 (c = 1.0, CHCl3)]
121
;δH (400 MHz, CDCl3); 1.19 (3H, d, J = 6.4 Hz, 2-CH3), 1.27 
(3H, d, J = 7.0 Hz, 3-CH3), 2.79 (1H, dd, J = 13.4, 9.4 Hz, CH2Ph), 2.89 (1H, br s, OH), 3.26 
(1H, dd, J = 13.5, 3.4 Hz, CH2Ph), 3.75 (1H, dq, J = 7.1, 2.9 Hz, 2-CH), 4.21 (3H, m, 3’-CH2 & 
3-CH), 4.71 (1H, m, 4’-CH), 7.32, (5H, m, Ar-H); δC (400 MHz, CDCl3) 10.6 (3-CH3), 19.8 (2-
CH3), 38.0 (5’-CH2), 43.3 (2-CH), 55.2 (4’-CH), 66.3 (3’-CH), 67.8 (3-CH), 127.3 (Ar-C), 
129.1 (Ar-C), 129.6 (Ar-C), 135.1 (Ar-C), 153.3 (1’-CO), 177.5 (1-CO); νmax (neat) / cm
-1
: 3439 
(OH), 2987 (CH), 1775 (CO), 1688 (CO), 889 (Ar-CH).
1











Aldol adduct 138 (1.00 g, 3.61 mmol) was dissolved in anhydrous CH2Cl2 (30 mL) under N2. 
TBDMSCl (1.10 g, 7.20 mmol), imidazole (0.98 g, 14.4 mmol) and DMAP (3 crystals) were 
added and stirred overnight. The reaction was quenched with NaHCO3 (34 mL), extracted with 
CH2Cl2. The organic extracts were dried (MgSO4), filtered and concentrated.  Purification by 
flash chromatography (SiO2, 10% EtOAc in petroleum ether visualised with KMnO4) gave 160 
(532 mg, 1.36 mmol, 37%) as a colourless crystalline solid.     
     +51.8 (c = 1.0, CHCl3), 
[lit.       +49.2 (c = 1.0, CHCl3)]
121
 δH (400 MHz, CDCl3): 0.02 (3H, s, SiCH3), 0.05 (3H, s, 
SiCH3), 0.87 (9H, s, SiC(CH3)3), 1.18 (3H, m, J = 6.1 Hz, 2-CH3), 1.22 (3H, d, J = 6.8 Hz, 3-
CH3), 2.77 (1H, dd, J = 13.3, 9.7 Hz, CH2Ph), 3.29 (1H, dd, J = 13.3, 3.3 Hz, CH2Ph), 3.83 (1H, 
qd, J = 6.9, 5.7 Hz, 2-H), 4.08 (1H, m, J = 6.0 Hz, N-CH), 4.16 (2H, m, OCH2), 4.63 (1H, m, 3-
CH), 7.21-7.36 (5H, m, Ar-H); νmax (neat)/cm
-1
: 2955 (CH), 2929 (CH), 2885 (CH), 2856 (CH), 
1778 (CO), 1694 (CO), 809 (Ar C);
 1










A solution of the protected aldol 160 (377 mg, 1.27 mmol) dissolved in THF/H2O (20 mL/6 
mL) was cooled to 0 °C. Hydrogen peroxide (6.35 mmol, 0.70 mL 30% w/v H2O2) and LiOH 
(61.0 mg 2.54 mmol) were added. The reaction was warmed to room temperature. After 4 hours 
the excess peroxide was quenched using 1.5 M sodium sulfate (Na2SO3) aq. and the THF 
removed in vacuo. The resulting slurry was acidified to pH 2 using 2M HCl and extracted with 
CH2Cl2 (3 x 20 mL). The organic extracts were combined, washed with brine (10 mL), dried, 
filtered and concentrated in vacuo. Purification of the crude by flash chromatography (SiO2, 10 
EtOAc/ petroleum ether/ 0.1% Acetic acid, visualised with KMnO4) afforded the title compound 
161 (181 mg, 0.78 mmol, 61%) as a colourless oil.     
     +20.6 (c 1.0, CHCl3), [lit      +25 (c 
= 0.51, CHCl3)]
174
; δH (400 MHz, CDCl3); 0.11 (3H, s, SiCH3), 0.12 (3H, s, SiCH3), 0.90 (9H, s, 
SiC(CH3)3, 1.14 (3H, d, J = 7.1 Hz, 2-CH2), 1.18 (3H, d, J = 6.3 Hz, 3-CH3), 2.58 (1H, qd, J = 
4.9, 7.2 Hz, 2-CH), 4.10 (1H, m, 3-CH); νmax (neat) / cm
-1
: 2955 (CH), 2929 (CH), 2887 (CH), 
2857 (CH), 1705 (CO).
 1






7.8.3.6 (2S,3R)- 3-tert-Butyldimethylsilyloxy-2-methylbutanoyl-N-acetylcysteamine 
162 
 
EDCI (93.0 mg, 0.60 mmol) and DMAP (5.00 mg, 0.04 mmol) were added to a solution of acid 
161 (100 mg, 0.43 mmol) in anhydrous CH2Cl2 (6 mL) at 0 C under nitrogen . After stirring at 
0 C for 15 minutes, HSNAC 151 (71.0 mg, 0.60 mmol) was added in anhydrous CH2Cl2 (2.5 
mL). The mixture was allowed to warm to room temperature and stirred overnight. The reaction 
was quenched with water (7 mL) and the layers separated. The aqueous phase was extracted 
with CH2Cl2 (3 x 15 mL). The organics were combined, dried (MgSO4), filtered and 
concentrated in vacuo. Purification by flash chromatography (SiO2, 3% MeOH/ CH2Cl2 
visualised with KMnO4) gave the title compound 162 (67.0 mg, 0.20 mmol, 46%) as a 
colourless oil.     
     +15.6 (c 1.0, CHCl3), δH (400 MHz, CDCl3); 0.04 (3H, s, Si-CH3), 0.05 
(3H, s, Si-CH3), 0.87 (9H, s, SiC(CH3), 1.15 (3H, d, J = 6.1 Hz, 2-CH3), 1.18 (3H, d, J = 6.9 Hz, 
3-CH3), 1.95 (3H, s, CO-CH3), 2.65 (1H, dq, J = 6.8 Hz, 2-CH), 3.0 (2H, m, S-CH2), 3.42 (2H, 
m, N-CH2), 4.01 (1H, dq, J = 6.1 Hz, 3-CH), 5.86 (1H, br s, NH); δC (400 MHz, CDCl3); -4.9 
(Si-CH3), -4.3 (Si-CH3), 13.4 (2-CH3),  18.0 (3-CH3), 21.8 (CO-CH3), 23.2 (Si-C), 25.7 
(SiC(CH3)3), 28.3 (S-CH2), 39.8 (NH-CH2), 56.4 (2-CH), 69.9 (3-CH), 170.2 (6-CO), 202.8 
(CO); νmax (neat) / cm-1: 3279 (NH), 2955 (CH), 2929 (CH), 2886 (CH), 2856 (CH), 1682 
(CO), 1654 (CO), 1550 (NH), 1374 (CH), 1360 (CH); m/z (ESI) 356.17 [M+Na
+
]; Found (ESI) 















7.8.3.7 (2S,3R)-3-Hydroxy-2-methylbutanoyl-N-acetylcysteamine 117 
 
TBDMS-ether 162 (119 mg, 0.35 mmol) was dissolved in THF (0.9 mL), water (0.9 mL) and 
acetic acid (2.6 mL) and stirred at room temperature for 5 days. The reaction was diluted with 
water (25 mL) and the aqueous layer washed with CH2Cl2 (25 mL). The aqueous layer was 
concentrated to give the title compound 117 (37 mg, 0.16 mmol, 47%) as a colourless oil. 
    
    +3.0 (c 1.0, CHCl3); δH (400 MHz, CDCl3): 1.19 (3H, d, J = 6.4 Hz, 2-CH3), 1.22 (3H, d, 
J = 7.1 Hz, 3-CH3), 1.95 (3H, s, CO-CH3), 2.69 (1H, qd, J = 7.0, 4.0 Hz, 2-CH), 3.04 (2H, m, S-
CH2), 3.43 (2H, m, NH-CH2), 4.09 (1H, qd, J = 6.3, 4.1 Hz, 3-CH), 5.96 (1H, br s, NH);   δC 
(400 MHz, CDCl3): 11.7 (2-CH3), 20.3 (3-CH3), 23.3 (CO-CH3), 28.7 (S-CH2), 39.5 (N-CH2), 
54.7 (2-CH), 68.5 (3-CH), 170.7 (N-CO), 204.1 (S-CO);  νmax (neat) / cm
-1
: 3288 (NH), 3135 
(OH), 2930 (CH), 1655 (NCO), 1548 (SCO); m/z (ESI) 242.08 [M+Na
+
]; Found (ESI) 242.0816 










400 MHz and 
13









(R)-4-benzyl-2-oxazolidinone (4.0 g, 22.6 mmol) was dissolved in dry THF (80 mL) under N2 
and cooled to -78 °C, n-BuLi (1.5 M in hexane) (14.9 mL, 22.6 mmol) was added dropwise and 
the solution stirred for 20 minutes. Propionyl chloride (2.20 mL, 24.8 mmol) was added and 
stirred for 3 hours before being warmed to room temperature. The reaction was quenched with 
NH4Cl aq. (20 mL) and the majority of the THF was removed in vacuo. CH2Cl2 (40 mL) was 
added and the solution washed with 10% aq NaOH. (20 mL) The aqueous layer was extracted 
with CH2Cl2 (2 x 20 ml). The organic layers were combined, washed (brine), dried (MgSO4), 
filtered and concentrated in vacuo to give the title compound 130 (5.22 g, 22.4 mmol, 99% 
yield) as a white solid.     
    -62.8 (c 1.0, CHCl3), [lit      -65.1 (c = 1.01, CHCl3)]
178
; m.p. 
=41.7 - 42.8 °C; δH (400 MHz, CDCl3): 1.20 (3H, t, J = 7.3 Hz, 7-CH3), 2.77 (1H, dd, J = 9.7, 
13.2 Hz, 8-CH2), 2.96 (2H, dq, J = 7.7, 9.6 Hz, 7-CH2), 3.30 (1H, dd, J = 3.3, 13.2 Hz, 8-CH2), 
4.17 (2H, m, 5-CH2), 4.67 (1H, m, 4-CH), 7.19-7.34 (5H, m, Ar-H); νmax (neat) / cm
-1
: 2982 
(CH), 2941 (CH), 1779 (C=O), 1698 (NC=O), 1349 (CN), 1213 (CO). 
1
H NMR data in 











(R)-4-Benzyl-3-propionyloxazolidin-2-one 130 (860 mg, 3.69 mmol) was dissolved in 
anhydrous CH2Cl2 (10 mL) and cooled to -78 °C under N2. Dibutyl boron triflate (1 M in 
CH2Cl2, 7.4 mL, 7.58 mmol) was added dropwise over 1 hour. After 30 minutes triethylamine 
(1.28 mL, 9.23 mmol) was then added dropwise and the solution stirred for 1 hour at -78 °C, 
then 100 minutes at 0 °C. The solution was cooled to -78 °C and a solution of acetaldehyde (2.4 
mL, 42.9 mmol) in dry CH2Cl2 (4 mL) also at -78 °C was added slowly. After stirring for 2 
hours at -78 °C and then 100 minutes at 0 °C, 1 M phosphate buffer (pH 7, 28 mL) and MeOH 
(28 mL) were added, the resulting mixture was stirred vigorously in an ice bath as 30% H2O2 
(14 mL) was added dropwise. After 30 minutes at 10-15 °C, the solvent was removed in vacuo 
and the resulting residue was partitioned between saturated NaCO3 aq. (20 mL) and CH2Cl2 (20 
mL). The aqueous layer was extracted with CH2Cl2 (2 x 8 mL) and the combined organic layers 
were dried (MgSO4), filtered, and concentrated in vacuo to give a crude pale yellow oil. The 
crude material was purified by flash chromatography (SiO2, 20% EtOAc in petroleum ether, 
visualized with KMnO4) to give the aldol adduct 164 as a colourless oil (693 mg, 2.10 mmol, 
68% yield).     
     -47.2 (c 1.0, CHCl3), [lit      -54.8  (c = 0.96, CHCl3)]
122
; δH (400 MHz, 
CDCl3): 1.21 (3H, d, J = 6.4 Hz, 2-CH3), 1.27 (3H, d, J = 7.1 Hz, 3-CH3), 2.79 (1H, dd, J = 
13.4, 9.4 Hz, 6’-CH2), 3.25 (1H, dd, J = 13.4, 3.4 Hz, 6’-CH2), 3.74 (1H, qd, J = 7.1, 3.0 Hz, 2-
CH), 4.21 (3H, m, 5’-CH & 3-CH), 4.69 (1H, m, 4’-CH), 7.20-7.35 (5H, m, Ar-H);  νmax (neat) / 
cm
-1
:3509 (OH), 2977 (CH), 2926 (CH), 1772 (C=O), 1690 (NC=O), 1349 (C-N), 1208 (COC). 
1











Aldol adduct 164 (693 mg, 2.49 mmol) was dissolved in anhydrous CH2Cl2 (20 mL) under N2. 
TBDMSCl (753 mg, 4.99 mmol), imidazole (678 mg, 9.96 mmol) and DMAP (3 crystals) were 
added and the reaction mixture stirred overnight. The reaction was quenched with NaHCO3 
(10 mL) and extracted with CH2Cl2 (3 x 25 mL). The organic extracts were dried (MgSO4), 
filtered and concentrated in vacuo.  Purification by flash chromatography (SiO2, 10% EtOAc in 
petroleum ether, visualised with KMnO4) gave 165 (729 mg, 1.86 mmol, 75%) as a colourless 
crystalline solid.     
    -43.1 (c 1.0, CHCl3), Enantiomer [lit     +49.2 (c = 1.0, CHCl3)]
121
; δH 
(400 MHz, CDCl3); 0.02 (3H, s, Si-CH3), 0.05 (3H, s, Si-CH3), 0.88 (9H, s, SiC-CH3), 1.19 (3H, 
d, J = 6.1 Hz, 2-CH3), 1.22 (3H, d, J = 6.8 Hz, 3-CH3), 2.77 (1H, dd, J = 13.4, 9.6 Hz, 6’-CH2), 
3.29 (1H, dd, J = 13.4, 3.24 Hz, 6’-CH2), 3.83 (1H, dq, J = 6.7, 5.9 Hz, 2-CH), 4.09 (1H, p, J = 
6.0 Hz, 3-CH), 4.17 (2H, m, 5’-CH2), 4.62 (1H, m, 4’-CH), 7.20-7.36 (5H, m, Ar-H); δC (400 
MHz, CDCl3): -4.9 (SiCH3), -4.4 (SiCH3), 12.6 (2-CH3), 21.7 (3-CH3), 25.8 (SiC(CH3)3), 37.8 
(SiC), 45.0 (Ar-CH2), 55.7 (NCH), 66.0 (OCH2), 69.7 (3-CH), 127.4 (Ar-C), 129.0 (Ar-C), 















A solution of protected aldol 165 (718 mg, 1.83 mmol) dissolved in THF/H2O (60 mL/9 mL) 
was cooled to 0 °C. Hydrogen peroxide (9.12 mmol, 1.04 mL, 30% w/v H2O2) and LiOH (153 
mg, 3.66 mmol) were added. The reaction was warmed to room temperature. After 4 hours the 
excess peroxides were quenched using 1.5 M sodium sulfate (Na2SO3) aq. and the THF 
removed in vacuo. The resulting slurry was acidified to pH 2 using 2M HCl and extracted with 
CH2Cl2 (3 x 30 mL). The organic layers were combined, washed with brine (30 mL), dried 
(MgSO4), filtered and concentrated in vacuo. Purification of the crude material by flash 
chromatography (SiO2, 10 EtOAc/petroleum ether / 0.1% Acetic acid, visualised with KMnO4) 
afforded the title compound 166 (230 mg, 0.99 mmol, 54%) as a colourless oil.     
     -35.3 (c 
1.0, CHCl3), [lit     -22.3 (c = 1.07, CHCl3)]
174
; δH (400 MHz, CDCl3); 0.12 (3H, s, Si-CH3), 
0.13 (3H, s, Si-CH3), 0.91 (9H, s, SiC-(CH3)3), 1.14 (3H, d, J = 7.1 Hz, 2-CH3), 1.19 (3H, d, J = 
6.3 Hz, 3-CH3), 2.59 (1H, dq, J = 7.1, 4.8 Hz, 2-CH), 4.07 (1H, dq, J = 6.3, 4.8 Hz, 3-CH); δC 
(400 MHz, CDCl3);-5.0 (Si-CH3), -4.4 (Si-CH3), 12.1 (2-CH3), 18.1 (Si-C), 20.2 (3-CH3), 25.8 
(SiC(CH3)3), 46.5 (2-CH), 70.1 (3-CH), 177.8 (CO); νmax (neat) / cm
-1
: 2956 (CH), 2887 (CH), 
1705 (C=O), 831 (SiCH3). 
1









Acid 166 (185 mg, 0.80 mmol) was dissolved in anhydrous CH2Cl2 (12 mL) at 0 
°
C under 
nitrogen EDCI (eq, 173 mg, 1.11 mmol) and DMAP (1.0 eq, 48 mg, 0.04 mmol) was added. 
After stirring at 0 
°
C for 15 minutes, HSNAC 151 (133 mg, 1.12 mmol) in anhydrous CH2Cl2 
(10 mL) was added. The mixture was allowed to warm to room temperature and stirred 
overnight. The reaction was quenched with water (15 mL) and the layers separated. The 
aqueous phase was extracted with CH2Cl2 (3 x 25 mL). The organics were combined, dried 
(MgSO4), filtered and concentrated in vacuo. Purification by flash chromatography gave the title 
compound 167 (193 mg, 0.58 mmol, 72%) as a colourless oil.     
     -11.0 (c 1.0, CHCl3); δH 
(400 MHz, CDCl3); 0.04 (3H, s, SiCH3), 0.06 (3H, s, SiCH3), 0.88 (9H, s, SiC-(CH3)3), 1.15 
(3H, d, J = 6.2 Hz, 2-CH3), 1.19 (3H, d, J = 6.8 Hz, 3-CH3), 2.65 (1H, m, 2-CH), 3.01 (2H, td, J 
= 6.4, 1.2 Hz, S-CH2), 3.43 (2H, m, N-CH2), 4.02 (1H, p, J = 6.1 Hz, 3-CH), 5.80 (1H,brs,NH); 
δC (400 MHz, CDCl3); -5.1 (Si-CH3),), -4.2 (Si-CH3), 13.6 (2-CH3), 18.1 (Si-C(CH3)3), 20.9 
(3-CH3), 23.4 (CO-CH3), 25.9 (SiC(CH3)3), 28.5 (S-CH2), 39.8 (N-CH2), 56.9 (2-CH), 70.3 
(3-CH), 170.4 (N-CO), 203.2 (S-CO); νmax (neat) / cm-1: 3286 (NH), 2955 (CH), 2930 (CH), 
2857 (CH), 1683 (C=O), 1656 (C=O), 1551 (NH), 836 (SiCH3); m/z (ESI) 356.17 [M+Na
+
]; 









400 MHz and 
13




7.8.4.6 (2R,3S)- 3-Hydroxy-2-methylbutanoyl-N-acetylcysteamine 116 
 
TBDMS-ether 167 (180 mg, 0.54 mmol) was dissolved in THF (1.5 mL), water (1.5 mL) and 
acetic acid (5 mL) and stirred at room temperature for 3 days. The reaction was diluted with 
water (15 mL) and the aqueous layer washed with CH2Cl2 (15 mL). The aqueous layer was 
concentrated to give the title compound 116 (62.0 mg, 0.28 mmol, 52%) as a colourless oil. 
    
     -4.9 (c 1.0, CHCl3); δH (400 MHz, CDCl3); 1.20 (3H, d, J = 6.4 Hz, 2-CH3), 1.23 (3H, d, 
J = 7.1 Hz, 3-CH3), 1.97 (3H, s, CO-CH3), 2.70 (1H, qd, J = 7.1, 4.0 Hz, 2-CH), 3.04 (2H, m, S-
CH2), 3.46 (2H, m, N-CH2), 4.11 (1H, qd, J = 6.4, 4.0 Hz, 3-CH), 5.78 (1H, br s, NH); δC (400 
MHz, CDCl3); 11.4 (2-CH3), 20.1 (3-CH3), 23.0 (CO-CH3), 28.4 (S-CH2), 39.2 (N-CH2), 54.4 
(2-CH), 68.2 (3-CH), 170.3 (N-CO), 203.7 (S-CO); νmax (neat) / cm
-1
:3299 (NH), 3134 (OH), 
2974 (CH), 2934 (CH), 1653 (C=O), 1549 (C=O), 1451 (NH); m/z (ESI) 242.08 [M+Na
+
]; 







H 400 MHz and 
13




7.8.5  (3R)-Hydroxybutanoyl-N-acetylcysteamine 




Pyridine (1.20 mL, 16.0 mmol) was added to ethyl-(3R)-3-hydroxybutyrate 141 (1.0 g, 7.56 
mmol) dissolved in CH2Cl2 (20 mL) and cooled to 0 °C. tert-Butyldimethylsilyl triflate (2.4 mL, 
10.6 mmol) was added dropwise. The mixture was allowed to warm to room temperature, 
stirred overnight and quenched with sat. NaHCO3 aq. (20 mL). The layers were separated and 
the aqueous layer extracted with CH2Cl2 (3 x 20 mL), dried (MgSO4), filtered and concentrated 
in vacuo. Purification by flash chromatography (SiO2, 5% EtOAc/ petroleum ether visualised 
with KMnO4) gave the title compound 157 (1.15 g, 4.96 mmol, 67%) as a colourless oil.     
     
-23.0 (c 1.0, CHCl3), [lit      -27.5 (c = 1.02, CHCl3)].
180
; δH (400 MHz, CDCl3); 0.03 (3H, s, 
Si-CH3), 0.05 (3H, s, Si-CH3), 0.85 (9H, s, Si-C(CH3)3), 1.18 (3H, d, J = 6.1 Hz, 3-CH3), 1.25 
(3H, t, J = 7.1 Hz, CH2CH3), 2.35 (1H, dd, J = 5.4, 14.3 Hz, 2-CH2), 2.46 (1H, dd, J = 7.7, 14.3 
Hz, 2-CH2), 1.44 (2H, dq, J = 4.2, 3.9 Hz, O-CH2), 4.27 (1H, m, 3-CH); νmax (neat) / cm
-1
: 2957 
(CH), 2930 (CH), 2896 (CH), 2857 (CH), 1736 (CO); 
1








Ester 157 (517 mg, 3.78 mmol) was dissolved in THF (2.5 mL), MeOH (4 mL) and lithium 
hydroxide (271 mg, 11.3 mmol) in water (0.75 mL) were added. The reaction mixture was 
heated to 60 °C overnight. The reaction was diluted with water (5 mL) and extracted with Et2O 
(2 x 5 mL). The aqueous layer was acidified to pH 3 with H2SO4 (6 M) and further extracted 
with EtOAc (3 x 7 mL), the pH was adjusted to pH 3 as required. The organic layers were 
combined, dried (MgSO4), filtered and concentrated in vacuo to give a pale yellow oil. 
Purification by flash chromatography (SiO2, 10% EtOAc/ Petroleum ether/ 0.5% acetic acid 
visualised with KMnO4) afforded the title compound 158 (299 mg, 1.37 mmol, 36%) as a 
colourless oil.     
     -12.0 (c 1.0, CHCl3), [lit      -10.8 (c 0.25, CHCl3)]
181
; δH (400 MHz, 
CDCl3); 0.06 (3H, s, Si-CH3), 0.08 (3H, s, Si-CH3), 0.87 (9H, s, Si-C(CH3)3), 2.47 (1H, d, J = 
2.8 Hz, 2-CH2), 2.49 (1H, d, J = 2.7 Hz, 2-CH3), 4.28 (1H, sext., J = 6.1 Hz, 3-CH); νmax (neat) / 
cm
-1
: 2955 (CH), 2929 (CH), 2896 (CH), 2857 (CH), 1710 (CO) 1472 (CH). 
1
H NMR data in 





7.8.5.3 (3R)-3-(tert-Butyldimethylsilyloxy)-butanoyl-N-acetylcysteamine 159 
 
Acid 158 (200 mg, 0.98 mmol) was dissolved in anhydrous CH2Cl2 (12 mL) at 0 C under 
nitrogen. EDCI (213 mg, 1.37 mmol) and DMAP (16 mg, 0.14 mmol) were added. After stirring 
at 0 C for 15 minutes, HSNAC 151 (163 mg, 1.37 mmol) was added in anhydrous CH2Cl2 (5 
mL). The mixture was allowed to warm to room temperature and stirred overnight. The reaction 
was quenched with water (5 mL) and the layers separated. The aqueous phase was extracted 
with CH2Cl2 (3 x 15 mL). The organics were combined, dried (MgSO4), filtered and 
concentrated in vacuo. Purification by flash chromatography (SiO2, 3% MeOH/ CH2Cl2 
visualised with KMnO4) gave the title compound 159 (174 mg, 0.54 mmol, 56%) as a colourless 
oil.     
     -26.8 (c 1.0, CHCl3); δH (400 MHz, CDCl3); 0.02 (3H, s, Si-CH3), 0.05 (3H, s, Si-
CH3), 0.85 (9H, s, Si-C(CH3)3), 1.18 (3H, d, J = 6.1 Hz, 3-CH3), 1.96 (3H, s, CO-CH3), 2.59 
(1H, dd, J = 5.1, 14.7 Hz, 2-CH2), 2.75 (1H, dd, J = 7.8, 14.4 Hz, 2-CH2), 3.01 (2H, m, S-CH2), 
3.43 (2H, m, N-CH2), 4.29 (1H, m, 3-CH), 5.91 (1H, br s, NH); δC (400 MHz, CDCl3): -4.9 
(SiCH3), -4.8 (SiCH3), 18.1 (3-CH3), 23.6 (SiC(CH3), 23.9 (COCH3) 25.9 (SiC(CH3), 28.9 
(NCH3), 39.8 (SCH2), 53.9 (2-CH2), 66.1 (3-CH), 170.5 (NCO), 196.5( SCO);  νmax (neat) / cm
-
1
: 3288 (NH), 2965 (CH), 2929 (CH), 2895 (CH), 2856 (CH), 1688 (CO), 1656; ); m/z (ESI) 
342.15 [M+Na
+
]; Found (ESI) 342.1535 (C14H29NO3SSi requires 342.1530). 
7.8.5.4 (3R)-3-Hydroxy-butanoyl-N-acetylcysteamine 124 
 
Butanoate 159 (100 mg, 0.30 mmol) was dissolved in THF (0.9 mL), water (0.9 mL) and acetic 
acid (2.6 mL) and stirred at room temperature for 5 days. The reaction was diluted with water 
(25 mL) and the aqueous layer washed with CH2Cl2 (25 mL). The aqueous layer was 
concentrated to give the title compound 124 (28.0 mg, 0.17 mmol, 58%) as a colourless oil. 
    
     -23.2 (c 1.0, CHCl3); δH (400 MHz, CDCl3); 1.23 (3H, d, J = 6.3 Hz, 3-CH3), 1.96 (3H, 
s, COCH3), 2.71 (1H, d, J = 3.8 Hz, 2-CH2), 2.72 (1H, d, J = 0.8 Hz, 2-CH2), 3.03 (2H, dq, J = 
3.7, 6.4 Hz, S-CH2), 3.43 (2H, q, J = 6.3 Hz, N-CH2), 4.24 (1H. m, 3-CH), 6.03 (1H, br s, NH); 
δC (400 MHz, CDCl3); 22.9 (3-CH3), 23.7 (CO-CH3), 28.9 (S-CH2), 39.4 ( N-CH2), 52.6 (2-
CH2), 170.8 (NCO). 199.4 (SCO); νmax (neat) / cm
-1
: 3288 (NH), 3074 (OH), 2967 (CH), 2920 
(CH), 1654 (C=O), 1550 NH ; ); m/z (ESI) 228.07 [M+Na
+
]; Found (ESI) 228.0668 
(C8H15NO3S requires 228.0665). 
182 
 
7.8.6  (3S)-Hydroxybutanoyl-N-acetylcysteamine 




Pyridine (4.10 mL, 17.8 mmol) was added to ethyl-(3S)-3-hydroxybutyrate (1.00 g, 8.47 mmol), 
dissolved in CH2Cl2 (20 mL) and cooled to 0 °C. tert-Butyldimethylsilyl triflate (2.4 mL, 10.6 
mmol) was added dropwise. The mixture was allowed to warm to room temperature, stirred for 
1 hour and quenched with sat. NaHCO3 (20 mL). The layers were separated and the aqueous 
layer extracted with CH2Cl2 (3 x 20 mL), dried (MgSO4), filtered and concentrated in vacuo. 
Purification by flash chromatography (SiO2, 5% EtOAc/ petroleum ether visualised with 
KMnO4) gave the title compound 180 (1.38 g, 5.95 mmol, 70%) as a pale yellow oil.      
    
 
+29.6 (c 1.0, CHCl3), [lit      +30.3 (c 1.0, CH,Cl3)]
183
; δH (400 MHz, CDCl3); 0.02 (3H, s, Si-
CH3), 0.04 (3H, s, Si-CH3), 0.84 (9H, s, Si-C(CH3)3), 1.17 (3H, d, J = 6.1 Hz, 3-CH3), 2.35 (
1
H, 
dd, J = 5.8, 14.5 Hz, 2-CH2), 2.45 (1H, dd, J = 7.7, 14.5 Hz, 2-CH3), 3.64 (3H, s, O-CH3), 4.26 
(1H, m, 3-CH); νmax (neat) / cm
-1
: 2956 (CH), 2930 (CH), 2858 (CH). 1710 (C=O), 1001 (CO), 
827 (SiCH3). 1H NMR data in accordance with the literature.
182
 




Ester 180 (1.0 g, 4.31 mmol) was dissolved in THF (5 mL), MeOH (8 mL) and lithium 
hydroxide (542 mg, 12.9 mmol) in water (1.5 mL) was added. The reaction mixture was heated 
to 60 °C overnight. The reaction was diluted with water (7 mL) and extracted with Et2O (2 x 10 
mL). The aqueous layer was acidified to pH 3 with H2SO4 (3 M) and further extracted with 
EtOAc (3 x 15 mL), the pH was adjusted to pH 3 as required. The organic layers were 
combined, dried (MgSO4), filtered and concentrated in vacuo to give a pale yellow oil. 
Purification by flash chromatography (SiO2, 10% EtOAc/ petroleum ether/ 0.5% acetic acid 
visualised with KMnO4) afforded the title compound 179 (299 mg, 1.37 mmol, 36%) as a 
colourless oil.     
     +11.7 (c 1.0, CHCl3), [lit      +11.9 (c 1.29 , CH,Cl3)]
185
; δH (400 MHz, 
CDCl3); 0.06 (3H, s, Si-CH3), 0.08 (3H, s, Si-CH3), 0.87 (9H, s, Si-C(CH3)3), 1.23 (3H, d, J = 
6.2 Hz, 3-CH3), 2.46 (1H, dd, J = 5.5, 13.6 Hz, 2-CH2), 2.51 (1H, dd, J = 6.7, 13.6 Hz, 2-CH2), 
4.27 (1H, septet, J = 6.1 Hz, 3-CH); νmax (neat) / cm
-1
: 3358 (OH), 2925 (CH), 1689 (C=O). 
1
H 







Acid 179 (300 mg, 1.37 mmol) was dissolved in dry CH2Cl2 (19 mL) at 0 C under nitrogen. 
EDCI (376 mg, 1.92 mmol) and DMAP (17.0 mg, 0.14 mmol) were added. After stirring at 0 C 
for 15 minutes, HSNAC 151 (228 mg, 1.92 mmol) was added in anhydrous CH2Cl2 (7.5 mL). 
The mixture was allowed to warm to room temperature and stirred overnight. The reaction was 
quenched with water (15 mL) and the layers separated. The aqueous phase was extracted with 
CH2Cl2 (3 x 25 mL). The organics were combined, dried (MgSO4), filtered and concentrated in 
vacuo. Purification by flash chromatography (SiO2, 3% MeOH/ CH2Cl2 visualised with KMnO4) 
gave the title compound 181 (174 mg, 0.54 mmol, 56%) as a colourless oil.     
     +101.5 (c 
1.0, CHCl3); δH (400 MHz, CDCl3); 0.01 (3H, s, SiCH3), 0.04 (3H, s, SiCH3), 0.84 (9H, s, 
SiC(CH3)3), 1.17 (d, J = 6.1 Hz, 3-CH3), 1.95 (3H, s, COCH3), 2.58 (1H, dd, J = 5.0, 14.4 Hz, 2-
CH2), 2.74 (1H, dd, J = 7.4, 14.4 Hz, 2-CH2), 3.01 (2H, qt, J = 6.4, 13.9 Hz, S-CH2), 3.41 (2H, 
m, N-CH2), 4.28 (1H, m, 3-CH), 5.84 (1H, br s, NH); ); δC (400 MHz, CDCl3): -4.8 (SiCH3), -
4.9 (SiCH3), 18.1 (3-CH3), 23.4 (SiC(CH3), 23.8 (COCH3) 25.9 (SiC(CH3), 28.8 (NCH3), 39.8 
(SCH2), 53.9 (2-CH2), 66.1 (3-CH), 170.5 (NCO), 196.1( SCO);  νmax (neat) / cm
-1
: 3281 (NH), 
2955 (CH), 2929 (CH), 2887 (CH), 2856 (CH), 1689 (CO), 1652 (CO), 1550 (NH), 1375 (CH), 
1361 (CH); m/z (ESI) 342.15 [M+Na
+
]; Found (ESI) 342.1545 (C14H29NO3SSi requires 
342.1530). 
7.8.6.4 (3S)-3-Hydroxy-butanoyl-N-acetylcysteamine 114  
 
Butanoate 181 (119 mg, 0.54 mmol) was dissolved in THF (0.9 mL), water (0.9 mL) and acetic 
acid (2.6 mL) and stirred at room temperature for 3 days. The reaction was diluted with water 
(15 mL) and the aqueous layer washed with CH2Cl2 (15 mL). The aqueous layer was 
concentrated to give the title compound 114 (70 mg, 0.34 mmol, 63%) as a colourless oil. 
    
     +27.9 (c 1.0, CHCl3); δH (400 MHz, CDCl3); 1.24 (3H, d, J = 6.3 Hz, 3-CH3), 1.97 (3H, 
s, COCH3), 2.73 (2H, m, 2-CH2), 3.04 (2H, td, J = 3.5, 6.3 Hz, S-CH2), 3.45 (2H, qd, J = 2.9, 
6.3 Hz, N-CH2), 4.26 (1H, m, 3-CH), 5.81 (1H, br s, NH); δC (400 MHz, CDCl3); 22.8 
(CO=CH3), 23.2 (3-CH3), 28.9 (S-CH2), 39.3 (N-CH2), 52.6 (2-CH2), 65.1 (3-CH), 170.7 
(NHC=O), 199.4 (SC=O); νmax (neat) / cm
-1
: 3290 (OH), 3086 (NH), 2931 (CH), 1652 (CO), 
1548 (NH), 1431 (CH), 1074 (CN); ); m/z (ESI) 228.07 [M+Na
+
]; Found (ESI) 228.0669 
(C8H15NO3S requires 226.0665). 
184 
 
7.9  Synthesis of triketide substrate mimic 





(1R)-(+)-camphorsultam 172 (1 e.q., 5.0 g, 23 mmol) in dry toluene (40 mL) was added 
dropwise to a suspension of sodium hydroxide (60% dispersion in oil, 1.8 e.q., 1.4g, 41.8 mmol) 
in dry toluene (15 mL) under N2. After stirring for 1 hour, propionyl chloride (1.1 e.q., 2.2 mL, 
25.3 mmol) was added dropwise and stirred at room temperature for 2 hours. The reaction was 
quenched with saturated aq. NH4Cl (150 mL) and stirred for 35 minutes. The aqueous layer was 
extracted with ethyl acetate (3 x 50 mL). The organic layers were combined, dried (MgSO4) and 
concentrated in vacuo to give a white solid. The crude solid was recrystallized in methanol and 
the isolated solid was redissolved in CH2Cl2 to remove any residual methanol. (1R,2S)-N-
Propionyl-bornane-10-2-sultam 169 (5.63 g, 20.7 mmol, 90%) was isolated as a colourless 
solid. mp. 142.3-143.5 °C;     
     +114.2 (c 1.0, CHCl3), [lit      +116.5.0 (c 1.00 , 
CH,Cl3)]
186
; δH  400 MHz, CDCl3); 0.97 (3H, s, 8’-CH3), 1.18 (6H, m, 9’-CH3 & 3-CH3), 1.38 
(2H, m, 5’-CH2 & 6-CH2), 1.90 (3H, m, 4’-CH, 5’-CH2, 6’-CH2), 2.09 (2H, m, 3’-CH2), 2.75 
(2H, qd, J = 7.5, 5.7 Hz, 2-CH2), 3.46 (2H, q, J = 13.5 Hz, 10’-CH2), 3.86 (1H, dd,  J = 7.5, 5.0 
Hz, 2’-CH); δc (400 MHz, CDCl3); 8.5 (3-CH3), 20.0 (8’-CH3), 20.9 (9’-CH3), 26.6 (2-CH2), 
29.1 (5’-CH2), 33.0 (6’-CH2), 38.6 (3’CH3), 44.8 (4’-CH), 47.9 (7’-C), 48.6 (1’-CH), 53.7 (10’-
CH2), 65.4 (2’-CH); νmax (neat) / cm
-1
: 2953 (CH), 2922 (CH), 2881 (CH), 1687 (CO), 1327 
(CN), 770 (C-S), 559 (CO).
 1











Triethylamine (freshly distilled over calcium hydride, 3 e.q., 11.524 mmol, 1.61 mL) was added 
to a solution of Propionyl sultam 169 (1 e.q., 3.84 mmol, 1.04 mg) in dry CH2Cl2 (8 mL) under 
N2 at room temperature. After 5 minutes TBDMSOTf was added and the reaction stirred for 20 
hours at room temperature. NaHCO3 (10 mL) was added and the aqueous layer extracted with 
ethyl acetate (4 x 15 mL). The organic layers were combined, dried (MgSO4), filtered and 
concentrated in vacuo. The residue was dissolved in dry CH2Cl2 (8 mL) under N2 and cooled to 
-78 °C. Methylbutaldehyde (2.2 e.q., 8.45 mmol, 0.80 mL) was added slowly. After 10 minutes 
titanium (IV) chloride (1.0 M in CH2CL2, 2.2 e.q., 8.45 mml, 8.45 mL) was added dropwise. 
The reaction was stirred for 2 hours at -78 °C. The reaction was quenched with saturated NH4Cl 
(15 mL) and extracted with CH2CL2 ( 4 x 20 mL). Organic layers were combined, dried (MgSO-
4), filtered and concentrated in vacuo. Purification by flash chromatography (SiO2, 5-15% 
EtOAc/ Petrol visualised with KMnO4) afforded the partially pure compound 174 (0.99g, 2.77 
mmol, 72%) as a white solid. δH (400 MHz, CDCl3); 0.89 (6H, m, 4-CH3 & 6-CH3), 0.97 (3H, s, 
8’CH3), 1.15 (3H, d, J = 6.6 Hz, 2-CH3), 1.19 (3H, s, 9’-CH3), 1.24-1.28 (4H, m, 5-CH2, 6’-
CH2, 5’-CH2), 1.85-1.91 (4H, m, 4-CH, 6’CH2, 5’-CH2, 4’-CH2), 2.05-2.19 (2H, m, 3-CH3), 
3.28 (1H, p, J = 6.6 Hz, 2-CH), 3.50 (2H, q, J = 13.8 Hz, 10’CH2), 3.61 (1H, m, 3-CH), 3.90 
(1H, dd, J = 7.9, 4.7 Hz, 2’-CH). enantiomer
 1
H NMR data in accordance with the literature.
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Aldol 174 (1 e.q., 1.0 g, 2.79 mmol) was dissolved in CH2Cl2 (11 mL) and cooled to 0 °C. 
Pyridine (2 e.q., 0.5 mL, 6.14 mmol) was added, followed by TBDMSOTf (1.5 e.q., 0.86 mL, 
3.75 mmol). After stirring at room temperature for 2 hours, the reaction was quenched with sat. 
ammonium chloride (15 mL). The aqueous layer was extracted with CH2Cl2 (3 x 50 mL), 
organic layers were combined, dried (MgSO4) and concentrated in vacuo to give a colourless 
solid. Purification by flash chromatography (SiO2, 10-15% EtOAc/ Petrol visualised with 
KMnO4) afforded the title compound 175 (761 mg, 1.62 mmol, 58%) as a colourless solid. mp. 
104.7- 105.8  δH (400 MHz, CDCl3); 0.05 (3H, s, Si-CH3), 0.08 (3H, s, Si-CH3), 0.81 (3H, t, J = 
7.3 Hz, 6-CH3), 0.87 (3H, s, 8’-CH3), 0.88 (SiC(CH3), 0.95 (3H, 9’-CH3), 1.15 (3H, d, J = 4.0 
Hz, 4-CH3), 1.18 (3H, d, J = 6.6 Hz, 2-CH3), 1.30-1.43 (4H, m, 5-CH2, 5’-CH2, 6’=CH2), 1.87 
(3H, m, 5’-CH2, 6’-CH2,4’-CH), 2.04 (3H, d, J = 7.4 Hz, 3’-CH2), 3.29-3.49 (3H, m, 10’-CH2 & 
2-CH), 3.88 (1H, m, 3-CH), 4.06 (1H, dd, J = 4.8 Hz, 1.7, 2’-CH); δc (400 MHz, CDCl3); -4.8 
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(SiCH3), 3.9 (SiCH3), 12.3 (6-CH3), 14.4 (4-CH3), 18.4 (2-CH3), 19.9 (9’-CH3) 20.1 (8’CH3), 
26.0 (SiC(CH3)3, 26.1 (4-CH), 27.9 (5-CH2), 33.0 (SiC), 38.6 (6’-CH2), 44.8 (3’CH2), 46.5 (2-
CH), 47.7 (7’-C), 48.1 (4’-CH), 53.2 (10’CH2), 65.7 (2’CH), 75.3 (3-CH), 174.2 (1-CO) ;νmax 
(neat) / cm
-1
; 2959.4 (CH), 2932 (CH), 2881 (CH), 1683 (CO), 1335 (SO), 1129 (SO), 327 (C-
Si), 777 (C-S); m/z (ESI): 472.27 [M+Na
+
]; Found (ESI) 494.2711 (C24H45NNaO5SSi requires 
494.2731). 
7.9.1.3 (3’R,2’R)-4-Methyl-3-(tert-butyldimethylsilanyloxy)-2-methylhexanoic acid 
176 
 
Aldol 175 (1 e.q., 700 mg, 1.48 mmol) was dissolved in THF (11.5 mL) and H2O (4.6.mL). 
LiOH (2 e.q., 71 mg, 2.96 mmol) was added, followed by H2O2 (30% a.q., 7.4 e.q., 1.25 mL, 
10.95 mmol). After 7 hours, the reaction was diluted with H2O (15 mL) and washed with ether 
(8 mL). The aqueous layer was cooled to 0 °C and acidified to pH 5 with HCl (2 M) and 
extracted with ethyl acetate (6 x 15 mL). The organic layers were combined, dried (MgSO4) and 
concentrated in vacuo to give a colourless oil. Purification by flash chromatography (SiO2, 10% 
EtOAc/PE/ 0.1% Acetic acid, visualised with KMnO4) gave the title compound 176 (226 mg, 
0.82 mmol, 56%) as a colourless oil. δH (400 MHz, CDCl3); 0.11 (3H, s, Si-CH3), 0.14 (3, s, Si-
CH3)  0.92 (15H, m, SiC(CH3)3, 4-CH3, 6-CH3), 1.10 (1H, m, 4-CH); 1.23 (3H, d, J = 7.3 Hz, 2-
CH3), 1.55 (2H, m, 5-CH2), 2.66 (1H, m, 2-CH), 3.76 (1H, 3-CH); δc (400 MHz, CDCl3): -4.2 
(SiCH3), -3.7 (SiCH3), 12.5 (6-CH3), 14.3 (2-CH3), 16.7 (4-CH3), 19.7 (5-CH2), 25.1 (SiC), 26.3 
(SiC(CH3)3, 40.1 (3-CH), 43.0 (2-CH), 79.1 (3-CH), 173.5 (CO); νmax (neat) / cm
-1
; 3235 (OH), 
2959 (CH). 2930 (CH), 1706 (CO), 833 (SiC); m/z (ESI): 297.18 [M+Na
+
]; Found (ESI) 







Acid 176 (1 e.g., 215 mg, 1.3 mmol) was dissolved in dry CH2Cl2 (18 mL) and cooled to 0 °C. 
EDCI (1.4 e.q., 295 mg, 1.9 mmol) and DMAP (0.1 e.q., 15 mg, 0.13 mmol) were added. After 
stirring for 15 minutes at 0 °C, HSNAC 151 (1.4 e.q., 226 mg, 1.9 mmol), in dry CH2Cl2 (2 
mL), was added and allowed to warm to room temperature and stirred overnight. The reaction 
was quenched with water (5 mL), the aqueous layer was extracted with CH2Cl2 (3 x 20 mL). 
The organic layers were combined, dried (MgSO4), filtered and concentrated in vacuo to give a 
colourless oil. Purification by flash chromatography (SiO2, 10% EtOAc/PE, visualised with 
KMnO4) gave the title compound 177 (222 mg, 0.59 mmol, 46%) as a colourless oil. δH (400 
MHz, CDCl3); -0.05 (3H, s, SiCH3), -0.03 (3H, s, SiCH3), 0.87 (15H, m, SiC(CH3)3, , 4-CH3 & 
6-CH3), 1.08 (3H, d, J = 7.1 Hz, 2-CH3), 1.17-1.42 (5H, m, 5-CH2, 4-CH), 2.09 (NCH2), 3.09 
(SCH2), 3.42 (3H, q, J = 6.3 Hz, 2-CH), 3.92 (1H, dd, J = 7.9, 2.1 Hz, 3-CH) 5.57 (1H, br s, 
NH); δc (400 MHz, CDCl3); -4.05 (SiCH3), -4.04 (SiCH3), 12.5 (6-CH3), 13.2 (5-CH3), 15.0 (4-
CH3), 15.8 (2-CH3), 18.6 (COCH3), 23.4 (SiC(CH3), 27.3 (SiC(CH3), 26.9 (NCH2), 28.6 
(SCH2), 30.1 (4-CH), 30.2 (2-CH), 170.1 (NCO), 203.5 (SCO); νmax (neat) / cm
-1
; 3285 (NH), 
2959 (Ch), 2857 (CH). 2929 (CH), 1689 (NCO), 1655 (CO), 1251 (CN), 1218 (CN), 1131 (SO), 
770 (SiC), 559 (SCO); m/z (ESI): 398.21 [M+Na
+
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SQTKS_DH          ------------------------------------------NKAHRQRVHPPHDLLGSL 18 
2vz8_mFASDH       PPVEFPAPRGTPLISPHXKWDHSQAWDVPSA-------ADF---PSGS------------ 38 
4LN9_RifDH10      ------------MGSSHHHHHHSSGL-VPRGSHMADTASDAVSLGLAGA---DHPLLGAV 44 
3EL6_EryDH4       -----------EMGSSHHHHHHSSGL-VPRGSHMHRP-ADVSALGVRGA---EHPLLLAA 44 
3KG7_CurHDH       ------------------------------------------SNASGQQ---VHRLLGNK 15 
3KG8_CurJ_DH      ------------------------------------------SNASTTK---LHPLINQK 15 
3KG6_CurF_DH      -----------------------------------------------SN---AHPLLGEK 10 
3KG9_CurK_DH      ------------------------------------------SNATAKN---LHPLLGEK 15 
                                                                               
 
SQTKS_DH          IVG-RDLREPTWRHFIRVQD-IPWIRDHVVQSALVYPGAGFICMAMEAMVQLHELRDSQS 76 
2vz8_mFASDH       ----SCSSVAVYKFDVSPESPDHYLVDHCIDGRVLFPGTGYLWLTWKTLARALSQNL--- 91 
4LN9_RifDH10      VQL-PQSDGLVFTSRLSLRS-HPWLADHAVRDVVIVPGTGLVELAVRAGDEA-------- 94 
3EL6_EryDH4       VDV-PGHGGAVFTGRLSTDE-QPWLAEHVVGGRTLVPGSVLVDLALAAGEDV-------- 94 
3KG7_CurHDH       LELASTGQ-TIYHQDINLNN-HPWIGDHRVYDTPVIPGVSYIAMTLAAV----------- 62 
3KG8_CurJ_DH      FQS-PLSKEIFFESYFSTEN-LPFLADHIVYEQVVVPGASHISLLLAAASLTF------- 66 
3KG6_CurF_DH      INLAGIEDQHRFQSYIGAES-PGYLNHHQVFGKVLFPSTGYLEIAASAGKSLF---T--- 63 
3KG9_CurK_DH      LNLARIENQHHFQSYLTAES-PAYLSQHQVFNKVLFPATGYLEIAAAVGKNLL---T--- 68 
                             :   .   .   :: .* :    : *.   : :   .             
 
SQTKS_DH          RKVAGYRLAEVDILRAMLIPDTSEGLEAHISLRPCSTKLLLTNEWYDFCVSSVGD----- 131 
2vz8_mFASDH       -EETPVVFEDVTLHQATILPKTGTV-SLEVRLLEA---------SHAFEVSDS------- 133 
4LN9_RifDH10      ---GCPVLDELVIEAPLVVPRRGGV-RVQVALGGP-----ADDGSRTVDVFSLRED---- 141 
3EL6_EryDH4       ---GLPVLEELVLQRPLVLAGAG-A-LLRMSVGAP-----DESGRRTIDVHAAEDV---- 140 
3KG7_CurHDH       --GVPAAVEDINFQQPLFLAESNTTRETQLMLHTA------DNVGKQF------------ 102 
3KG8_CurJ_DH      -AATECQIEDILFPQALAIPEQGVR-TVQVVLT-P------QNNSFSFQVISFDDSLESQ 117 
3KG6_CurF_DH      -SQEQVVVSDVDILQSLVIPETEIK-TVQTVVSFA------ENNSYKFEIFSPSEG---- 111 
3KG9_CurK_DH      -TGEQVVVSDVTIVRGLVIPETDIK-TVQTVISTL------ENNSYKLEIFSTSEG---- 116 
                         . :: :     :         .  :               .             
 
SQTKS_DH          ----------DDKFVDHCRGRITIEFDTSGSADTPRTSLRERSRSTGLMRSVDPSNLYSF 181 
2vz8_mFASDH       ------------NGSLIASGKVYQWESPDPKLFDTRAAVD--PADSTAEFRLSQGDVYKD 179 
4LN9_RifDH10      ----------ADSWLRHATGVLVPENRPRGTAAFDFAAW---PPPEAK--PVDLTGAYDV 186 
3EL6_EryDH4       ------ADLADAQWSQHATGTLAQGV---AAGPRDTEQW---PPEDAV--RIPLDDHYDG 186 
3KG7_CurHDH       VEVFSRDGAKQEEWQQHASMSVSENPPPPPTLSVD---I---PALCEQLRPLDTDTLTEI 156 
3KG8_CurJ_DH      INQVSNNGSHISDWAVHATGKLSVAN--AEQSLIPLEEI---QARCSQ--KIDSAEIYQH 170 
3KG6_CurF_DH      ------ENQQTPQWVLHAQGKIYTEPTRNSQAKIDLEKY---QAECSQ--AIEIEEHYRE 160 
3KG9_CurK_DH      ------DNQQANQWTLHAEGKIFLDSTTNTKAKIDLEQY---QRECSQ--VIDIQQHYQQ 165 
                              .    .   :                             :         
 
SQTKS_DH          LRAQGIYHGPIFQNLKTISSRKDHSE----SSFVVANTASVMPNGFQSPHVIHPTTLDSI 237 
2vz8_mFASDH       LRLRGYDYGPFFQLVLESDLEGNRG------RLQ--------------WNDSWVSFLDAM 219 
4LN9_RifDH10      LADVGYGYGPTFRAVRAVWRRGSGNTTETFAEIALPEDARAE----AGRFGIHPALLDAA 242 
3EL6_EryDH4       LAEQGYEYGPSFQALRAAWRKDDSV----YAEVSIA----AD----EEGYAFHPVLLDAV 234 
3KG7_CurHDH       YASISLVYGPMLQAVRQAWIGEETS----LLEIEVPKALAFQ----LAGEPIHPVLIDAC 208 
3KG8_CurJ_DH      LWDRQIHLGQSFRWIEQVWLGEGEV----LCQMKVPKTILN-----TTKYQLHPTLVDSC 221 
3KG6_CurF_DH      YRSKGIDYGSSFQGIKQLWKGQGKA----LGEMAFPEELTAQ----LADYQLHPALLDAA 212 
3KG9_CurK_DH      FKSRGIDYGNSFQGIKQLWKGQGKA----LGKIALPEEIAGQ----ATDYQLHPALLDAA 217 
                          *  :: :                 .                       :*:  
 
SQTKS_DH          FQGAYTALPGAG-LDQNTAMIPRSIQELYLSSALTSDVGQCLVSDTSLIRYDGQSFTVNV 296 
2vz8_mFASDH       LHMSIL-AP-----GQLGLYLPTRFTSIRIDPVTHRQKLYTLQDTTQAAD---VVVDRNL 270 
4LN9_RifDH10      LHSTMVSAAADTESYGDEVRLPFAWNGLRLHAAGASV-LRVRVAKP-------ERDSLSL 294 
3EL6_EryDH4       AQTLSLGALG----EPGGGKLPFAWNTVTLHASGATS-VRVVATPA-------GADAMAL 282 
3KG7_CurHDH       TRLT-PDLFDFS-SDSGVFWAPWRVKEMTLSHPTPSR-FYAYVEEPSRVNEQLQTRSYDI 265 
3KG8_CurJ_DH      FQSIIALVLDQS-GNKNETFVPFSIDKFTFYNSSDNDLLWCYTCG-SKDKQSGEKFKADI 279 
3KG6_CurF_DH      FQIV-SYAIPHT-ET-DKIYLPVGVEKFKLYRQTISQ-VWAIAE------IRQTNLTANI 262 
3KG9_CurK_DH      LQIL-GHAIGNT-ETDDKAYLPVGIDKLKQYRQTITQ-VWAIVE------IPENTLKGSI 268 
                   :                   *     .                               : 
 
SQTKS_DH          DVSSKADSEHTPVLEIKGLRNQSVGQMA-------------------------------- 324 
2vz8_mFASDH       NTVV---AGGALFLGAHSSVAPRRPQEHLKPILEKFCFTPHVESGCLAGNTALQEELQLC 327 
4LN9_RifDH10      EAVD---ESGGLVVTLDSLVGRPVSNDQLTTA---------------------------A 324 
3EL6_EryDH4       RVTD---PAGHLVATVDSLVVRSTGEKWEQPE---------------------------P 312 
3KG7_CurHDH       QLLD---ETGQAFGRINGFTVKRAPSQLFLK----------------------------- 293 
3KG8_CurJ_DH      QLFD---QHGQLVAQVIGFEGRKANPKILLMT---------------------------- 308 
3KG6_CurF_DH      FLVD---NQGTVLVELEGLRVKVTEP---------------------------------- 285 
3KG9_CurK_DH      KLVD---NQGSLLAEIEGLRVTATTADALLK----------------------------- 296 
                              .    .                                           
 
SQTKS_DH          --------------------------- 324 
2vz8_mFASDH       RGLAQALQTKVAQQGLKMVVPGLDGAQ 354 
4LN9_RifDH10      G-------------------------- 325 
3EL6_EryDH4       RG------------------------- 314 
3KG7_CurHDH       --------------------------- 293 
3KG8_CurJ_DH      --------------------------- 308 
3KG6_CurF_DH      --------------------------- 285 
3KG9_CurK_DH      --------------------------- 296 









Appendix 2 – Kinetic data for substrate 2R,3R -114 
Graphs produced using Microsoft excel. Automatic second order polynomial trendlines fitted 
using microsft excel curve fitting tool.  
 
Figure 89 – Initial rate of dehydration of 114 by the isolated DH domain from SQTKS to form 112: A. 
114 concentration 4.5 mM; B.  114 concentration 3.0 mM;  C. 114 concentration 2.3 mM. 
y = -0.0877x2 + 5.3973x 


































y = -0.0788x2 + 3.7816x 



































y = -0.0314x2 + 2.7435x 










































Figure 90 Initial rate of dehydration of 114 by the isolated DH domain from SQTKS to form 
112: A. 114 concentration 1.0 mM; B. 114 concentration 0.8 mM.; C. 114 concentration 0.5mM 
y = -0.0668x2 + 2.9985x 


































y = -0.0207x2 + 1.4602x 



































y = -0.0191x2 + 1.159x 







































Figure 91 Initial rate of dehydration of 114 by the isolated DH domain from SQTKS to form 112: A. 114 
concentration 0.2 mM. 
 
  
y = -0.0161x2 + 0.7947x 











































Appendix 3 - Kinetic data for substrate 3R -114 
Graphs produced using Microsoft excel. Automatic second order polynomial trendlines fitted 
using microsft excel curve fitting tool.  
 
Figure 92 Initial rate of dehydration of 124 by the isolated DH domain from SQTKS to form 185: A. 124 
concentration 3.99 mM;  B. 124 concentration 3.50  mM, C. 124 concentration 2.6  mM. 
y = -0.0157x2 + 1.0558x 


































y = -0.0137x2 + 0.8978x 



































y = -0.0235x2 + 1.1097x 








































Figure 93 Initial rate of dehydration of 124 by the isolated DH domain from SQTKS to form 185: A. X 
concentration 2.0  mM;  B. 124 concentration 0.88  mM, C. 124 concentration 0.64  mM. 
y = -0.0116x2 + 0.6839x 






































y = -0.0071x2 + 0.4305x 







































y = -0.0057x2 + 0.3472x 










































Figure 94 Initial rate of dehydration of 124 by the isolated DH domain from SQTKS to form 185: A. 124 
concentration 0.44 mM;  B. 124 concentration 0.20  mM. 
 
y = -0.0016x2 + 0.1325x 







































y = -0.0026x2 + 0.1805x 
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